US20060014743A1 - Methods of preventing bacterial infections with florfenicol-type antibiotics - Google Patents

Methods of preventing bacterial infections with florfenicol-type antibiotics Download PDF

Info

Publication number
US20060014743A1
US20060014743A1 US11/211,919 US21191905A US2006014743A1 US 20060014743 A1 US20060014743 A1 US 20060014743A1 US 21191905 A US21191905 A US 21191905A US 2006014743 A1 US2006014743 A1 US 2006014743A1
Authority
US
United States
Prior art keywords
compound
group
mmol
mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/211,919
Inventor
Constantine Boojamra
Lee Chong
Scott Hecker
Tomasz Glinka
Dale Shuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet Inc
Original Assignee
Schering Plough Animal Health Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Animal Health Corp filed Critical Schering Plough Animal Health Corp
Priority to US11/211,919 priority Critical patent/US20060014743A1/en
Publication of US20060014743A1 publication Critical patent/US20060014743A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the fields of organic chemistry, pharmaceutical chemistry, biochemistry and medicine.
  • it relates to novel florfenicol-type antibiotics.
  • chloramphenicol resistant strains of organisms such as K. pneumoniae, E. cloacae, S. typhus and E. coli are susceptible to florfenicol.
  • chloramphenicol acetyl transferase CAT
  • CAT chloramphenicol acetyl transferase
  • Ribosomal binding is the primary mechanism of action of the chloramphenicol antibiotics and results in inhibition of peptidyl transferase, which is responsible for the transfer of amino acids to growing peptide chains and subsequent protein formation in bacteria.
  • compounds having the primary hydroxyl group do have utility in the treatment of bacterial infections, as evidenced by the continuing use of chloramphenicol and thiampheniol throughout the world.
  • piscicida (formerly Pasteurella piscicida ) (Kim, E., et al., Microbiol. Immunol., 1996, 40, 665). This resistance has been traced to a highly conserved gene (flo) that produces an antibiotic efflux pump (Flo).
  • the emergence, and threatened spread, of resistance to florfenicol has fostered the need for new antibiotics that retain or exceed the activity of florfenicol, maintain its imperviousness to the CAT enzyme and, in addition, are not substrates for the Flo efflux pump.
  • the compounds of the present invention are such antibiotics.
  • an embodiment of this invention is a compound having the chemical formula: wherein:
  • R 1 is —F.
  • R 2 and R 3 are independently selected from the group consisting of Cl and F.
  • R 8 is hydrogen
  • R 4 is —C( ⁇ R 5 )R 6 wherein R 5 and R 6 are as defined above.
  • R 4 is CH 3 C(O)—.
  • R 4 is wherein:
  • R 4 is selected from the group consisting of:
  • R 4 is as defined above.
  • R 4 is and one of A 2 -A 5 that is carbon is substituted with an —NH 2 group, all other carbon and, if applicable, nitrogen atoms in the ring being unsubstituted.
  • a presently preferred embodiment of this invention is a compound selected from the group consisting of: wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
  • a presently particularly preferred embodiment of this invention is a compound selected from the group consisting of: wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
  • the compound herein is substantially enantiomerically pure and has a 1-(R)-2-(S) absolute configuration.
  • An embodiment of this invention is a method of treating or preventing a bacterial infection, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound hereof.
  • the bacterial infection is caused by a bacteria of the genus Pasteurella, Haemophilus, Fusobacterium, Bacterioides, Aeromonas, Enterobacter, Escherichia, Klebsiella, Salmonella, Shigella, Actinobacillus, Streptococcus, Mycoplasma, Edwardsiella, Staphylococcus, Enterococcus, Bordetella, Proteus, or Mannheimia.
  • the bacterial infection is caused by Mannhemia haemolytica, Pasteurella multocida, Haemophilus somnus, Fusobacterium necrophorum, Bacterioides melaninogenicus, Actinobacillus pleuropneumoniae, Streptococcus suis, Salmonella cholerasuis, Mycoplasma bovis, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Mycoplasma gallisepticum, Edwardsiella ictaluri, Escherichia coli, Enterobacter cloacae, Staphylococcus aureus, Staphylococcus intermedius, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Proteus mirabilis, or Aeromonas salmonicida.
  • Table 2 is a list of the microorganisms against which the compounds of this invention were tested. The list is not intended, nor should it be construed, to limit the scope of this invention in any manner whatsoever.
  • halo refers to fluorine, chlorine, bromine or iodine.
  • alkyl refers to a saturated (containing no multiple bonds) aliphatic (no delocalized ⁇ -electron system), hydrocarbon (containing, if unsubstituted, only carbon and hydrogen).
  • (1C-4C)alkyl refers to CH 3 —, CH 3 CH 2 —, CH 3 CH 2 CH 2 —, CH 3 CH(CH 3 )—, CH 3 CH 2 CH 2 CH 2 —, CH 3 CH 2 CH(CH 3 )— or (CH 3 ) 3 C—.
  • the alkyl group may be unsubstituted or substituted with one or more moieties selected from the group consisting of halo, —OH, OCH 3 , and —C ⁇ N.
  • cycloalkyl refers to an all-carbon cyclic or fused multicyclic ring, which, although it may contain one or more double bonds, maintains an essentially aliphatic character; that is, the double bonds do not interact to form a delocalized ⁇ -electron system around the ring.
  • the ring may contain up to 7 carbon atoms.
  • the designation (3C-6C)cycloalkyl refers to 3, 4, 5, and 6-member all-carbon-atom rings.
  • “fused” means that two cycloalkyl groups share at least one ring atom between them. Thus, such compounds as spiro[4.4]nonane are considered “fused” for the purposes of this invention.
  • fused rings share two adjacent ring carbon atoms.
  • An example of such a fused system is decalin.
  • a cycloalkyl ring may be unsubstituted or substituted with a moiety selected from the group consisting of —OH, —OCH 3 , halo and —C ⁇ N.
  • aryl refers to an all-carbon 6-member ring or two fused six-member rings, the ring or fused rings having a delocalized ⁇ -electron system. By “fused” is meant that each ring of the system shares two adjacent ring carbon atoms with at least one other ring.
  • An aryl ring may be unsubstituted or substituted with one or more moieties selected from the group consisting of —OH, —OCH 3 , halo and —C ⁇ N.
  • heteroaryl refers to a five-member or six-member ring or to two rings, i.e., two 5-member, two six-member or a five- and a six-member ring fused together wherein the ring or fused ring has a delocalized ⁇ -electron system. If a ring is six-membered, it must consist of carbon and nitrogen only and may contain from one to four nitrogen atoms. If a ring is five-membered, it must contain one nitrogen, oxygen or sulfur atom and may contain one, two or three additional nitrogen atoms. A five-member ring with a circle in the center indicates that the ring is heteroaromatic.
  • the circle is used to emphasize the fact that the location of the double bonds that participate in making the ring heteroaromatic is not static, rather it is dependent on the nature of the atoms forming the ring, i.e., whether they are carbon, nitrogen, oxygen or sulfur and what groups, if any, are bonded to them.
  • the actual structure of any five-member heteroaromatic will be immediately apparent to those skilled in the art once the ring atoms are designated.
  • heteroaromatic groups the term fused has the same meaning as in -the case of aryl groups.
  • a heteroaryl group may be unsubstituted or substituted with any of the moieties described above with regard to aryl groups.
  • heteroalicyclic refers to a cyclic or fused cyclic ring system containing atoms selected from the group consisting of carbon, nitrogen, oxygen and sulfur but no delocalized ⁇ -electron system. “Fused” has the same meaning set forth above with regard to cycloalkyl rings. Likewise, a heteroalicyclic ring may be unsubstituted or substituted with the same moieties described above for cycloalkyl rings.
  • ring carbon atom is stated to be “unsubstituted,” it is understood that any unfilled valences are in fact occupied by hydrogen atoms.
  • a ring nitrogen atom is capable of being further substituted and it is stated to be unsubstituted, it means that the nitrogen is bonded to a hydrogen atom.
  • relative stereochemistry refers to the positioning in space of substituents relative to one another.
  • absolute stereochemistry refers to the exact positioning of substitutents in three-dimensional space as determined by the Cahn-Ingold-Prelog rules, the application of which are well-known to those skilled in the art.
  • an “enantiomer” refers to one of the two absolute stereochemical configurations of a molecule that rotates plane polarized light in one direction or the other (i.e.; counterclockwise from its original axis, conventionally called “left,” or clockwise, conventionally referred to as “right”).
  • substantially enantiomerically pure is meant that the compound consists of greater than 90% of the one enantiomer, preferably greater than 95%, and most preferably greater than 99%.
  • Racemate refers to a 1:1 mixture of the two enantiomers of a compound. Racemic mixtures are designated by a ( ⁇ ) indicator. Substantially enantiomerically pure compounds are shown without the indicator.
  • patient refers to birds, reptiles, fish, shellfish, and mammals.
  • birds such as, without limitation, chickens and turkeys, fish such as, without limitation, salmon, trout, catfish and yellowtail, mammals such as, without limitation, cats, dogs, rabbits, sheep, cattle, pigs, horses and goats and to human beings.
  • the compounds of this invention are expected to be useful for the treatment of bacterial infections in patients.
  • ⁇ -bromobenzaldehyde (5) can be converted to (d/l)-threo-p-bromophenylglycine (6, Scheme 1), (Bolhoffer, W. A. J. Am. Chem. Soc. 1954, 76, 1322; Herbert, R. B.; Wilkinson, B.; Ellames, G. J. Can. J. Chem. 1994, 72, 114), which can be protected as N-Boc derivative 7 and then reduced in two-steps: activation with DCC and N-hydroxysuccinimide followed by treatment with NaBH 4 to provide 8.
  • Compound 9 can be isolated as its TFA salt or as the free base.
  • Compound 18 was protected as isopropylidene derivative 19, which was converted to boronic acid 23 (Scheme 3).
  • Compounds 18, 19, 22 and 23 were used in Suzuki cross-coupling reactions.
  • Compound 23 provided the most versatility since it could be cross-coupled with any aryl bromide or iodide and the protecting groups could be easily removed under mild conditions.
  • Compound 22 was attractive as a Suzuki cross-coupling partner in that the coupling reactions yielded the desired florfenicol analogs directly without the need for deprotection and dihaloacetylation. However, cross-coupling yields with 22 were lower than those with 23. Cross-couplings using 21 gave the desired products contaminated with acetate and monochloroacetate analogs.
  • Racemic compound 20 was identical spectroscopically to a sample synthesized from semi-synthetic 11 by hydrolytic cleavage and basic work-up. This provided unequivocal proof that the condensation of phenylserine 6 had proceeded with the appropriate relative threo or syn stereoselectivity.
  • Compound 41 (Scheme 7) was prepared from intermediate 36, the preparation of which from 30 has been described (von Strandtmann, M., et al., J. Med. Chem., 1967, 10, 888).
  • Compound 36 was deprotected with aqueous H 2 SO 4 and then regioselectively protected as phenyloxazoline 38.
  • Compound 39 was obtained on treatment with DAST and then was deprotected and dichloroacetylated to give 41.
  • ⁇ -Acyl derivatives were obtained by Stille coupling reactions of the protected intermediates (Scheme 9, compounds 87 and 88) with acid chlorides. Trimethylstannyl groups were introduced by Pd-mediated reactions using hexamethylditin.
  • the cyclobutyl derivative 73 was prepared from 87 via a Stille coupling reaction that produced intermediate 89 (Scheme 10) which was deprotected and dichloro-acetylated.
  • ⁇ -carboxyphenyl derivatives of protected phenicol intermediates could be prepared in two ways. For example, hydrolysis of the ⁇ -nitrile analog of 17 gives the corresponding carboxylic acid. However, nitrites generally could not be obtained as readily as the bromo derivatives. Thus, the preferred approach to carboxylation was replacement of the bromo group.
  • carboxylic acid derivative 102 (Scheme 11) was prepared by lithiation of 17 followed by treatment with CO 2 and acid work-up. Compound 102 was converted to methyl ester 103, which was reacted with hydrazine to give 104. Cyclization of 104 with triethyl orthoformate gave oxadiazole 105, which was deprotected and dihaloacetylated to give 106 and 107.
  • the carboxylic acid derivative of 102 was also used to prepare compounds such as 109 (Scheme 12), by reduction to alcohol 108 followed by deprotection and dichloroacetylation Biological Evaluation
  • All of the compounds of this invention are expected to demonstrate antimicrobial activity against the same bacteria as the other members of the chloramphenicol family. In addition, they may be expected to be active against species of bacteria that are resistant to current chloramphenicol antibiotics, in particular florfenicol. It is also expected that the present compounds may exhibit activity against genera and species of bacteria against which current chloramphenicol-type antibiotics are not active.
  • one enantiomer of a compound may be more active than the other. In such case, whether expressly stated or not, the more active isomer is considered the preferred embodiment of this invention. Particularly preferred is the most active enantiomer of the 1-(R)-2(S) absolute configuration of any compound herein.
  • NCCLS National Committee for Clinical Laboratory Standards (NCCLS) 2000, Methods for Dilution of Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Fifth Edition, Approved Standard, NCCLS Document M7-A5, Vol 20, No. 2).
  • the minimum inhibitory concentration (MIC) is defined as the lowest concentration of a compound that prevents the growth of the bacteria.
  • CAMHB Cation-Adjusted Mueller-Hinton Broth
  • the bacterial inocula were prepared as follows. For each strain, one isolated colony was used to inoculate a volume of 5 ml of CAMHB. The cultures were incubated overnight (20 hours) at 35° C. in a shaking incubator. They were then diluted in sterile saline to a density equivalent to a 0.5 McFarland suspension (approx. 10 8 CFU/ml). The suspensions were further diluted in CAMHB to approximately 5 ⁇ 10 5 CFU/ml. A volume of 50 ⁇ l of the inoculum was added to each well. Positive and negative growth controls were included on each plate. The original inocula were determined by applying 10 ⁇ l of several 10-fold dilutions on TSA plates.
  • Agar plates were incubated overnight at 35° C. and colony-forming units (CFU) counted.
  • Microtiter plates were incubated for 20 hours at 35° C. and were read using a microtiterplate reader (Molecular Devices) at 650 nm and by visual observation using a microtiterplate reading mirror to determine the MIC.
  • a compound of the present invention, a prodrug thereof or a physiologically acceptable salt of either the compound or its prodrug can be administered as such to a patient or can be administered in pharmaceutical compositions in which the foregoing materials are mixed with suitable excipient(s).
  • suitable excipient(s) suitable excipient(s).
  • Techniques for formulation and administration of drugs may be found in Remington's Pharmacological Sciences, Mack Publishing Co., Easton, Pa., latest edition. The formulations and techniques discussed in Remington relate primarily to use with human patients; however, they may readily modified for use with non-human patients by techniques well-known to those skilled in the veterinary art.
  • administer refers to the delivery of a compound, salt or prodrug of the present invention or of a pharmaceutical composition containing a compound, salt or prodrug of this invention to an organism for the purpose of treating or preventing a microbial infection.
  • Suitable routes of administration may include, without limitation, oral, rectal, transmucosal, intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal, aural or intraocular.
  • the preferred routes of administration are oral and parenteral.
  • a sustained release formulation may be used.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., using a variety of well-known mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • the compositions may be formulated in conjunction with one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, physiological saline buffer or polar solvents including, without limitation, N-methyl-2-pyrrolidone, 2-pyrrolidone, other pyrrolidones, N,N-dimethylacetamide, N,N-dimethylformamide, dimethylsulfoxide, acetone and glycerol formal.
  • physiologically compatible buffers such as Hanks' solution, Ringer's solution, physiological saline buffer or polar solvents including, without limitation, N-methyl-2-pyrrolidone, 2-pyrrolidone, other pyrrolidones, N,N-dimethylacetamide, N,N-dimethylformamide, dimethylsulfoxide, acetone and glycerol formal.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the
  • the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well-known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, pastes, slurries, solutions, suspensions, concentrated solutions and suspensions for diluting in the drinking water of a patient, premixes for dilution in the feed of a patient, and the like, for oral ingestion by a patient.
  • Pharmaceutical preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores.
  • Useful excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, for example, maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydroxypropyl-methylcellulose, sodium carboxy-methylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers may be added in these formulations, also.
  • the compounds of the present invention can conveniently be delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide.
  • a suitable propellant e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide.
  • the dosage unit may be controlled by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the compounds may also be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers.
  • Useful compositions include, without limitation, suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain adjuncts such as suspending, stabilizing and/or dispersing agents.
  • Pharmaceutical compositions for parenteral administration include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle.
  • Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes.
  • Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • a compound of this invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
  • Liposomes and emulsions are well-known examples of delivery vehicles or carriers for hydrophobic drugs.
  • organic solvents such as dimethylsulfoxide may be used, although often at the risk of greater toxicity.
  • the compounds may be delivered using a sustained-release system, such as semi-permeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are well known by those skilled in the art.
  • Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the particular compound, additional stabilization strategies may be employed.
  • compositions useful herein also may comprise solid or gel phase carriers or excipients.
  • carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • a therapeutically effective amount refers to an amount of compound effective to prevent, alleviate or ameliorate symptoms of a microbial infection. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the disclosure herein.
  • the therapeutically effective amount can be estimated initially from cell culture assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the MIC as determined in cell culture. Such information can then be used to more accurately determine dosages useful in patients.
  • Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
  • the MIC and the LD 50 for a particular compound can be determined by methods well-known in the art.
  • the data obtained can be used to formulat a range of dosages useful in patients.
  • the dosage may vary depending upon the dosage form and route of administration.
  • the exact formulation, route of administration and dosage can be selected by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1).
  • the presently preferred dosage range for systemic delivery of a compound of this invention will be from about 1 to about 100 mg/Kg.
  • the presently preferred dosage range for topical use will generally be from about 0.1 mg to about 1 gm.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the compound that are sufficient to maintain a concentration equal to the MIC or any other desired level. Such plasma levels are often referred to as minimum effective concentrations (MECs).
  • MEC minimum effective concentrations
  • the MEC will vary for each compound but can be estimated from in vitro data, e.g., the concentration necessary to achieve 80+% inhibition of a microbe, may be ascertained using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. HPLC assays or bioassays can be used to determine plasma concentrations.
  • Dosage intervals can also be determined using MEC value.
  • Compounds should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
  • the effective local concentration of the drug may not be related to plasma concentration and other procedures known in the art may be employed to determine the correct dosage amount and interval.
  • the amount of a composition administered will, of course, be dependent on the patient being treated, the severity of the infection, the manner of administration, the judgment of the prescribing physician, etc.
  • compositions may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or of human or veterinary administration. Such notice, for example, may be of the labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
  • Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
  • Method A the aryl boronic acid (0.167 mmol) and aryl bromide (0.334 mmol) were combined in a mixture of aqueous Na 2 CO 3 (3 mL of a 10% (w/w) solution) and THF (5 mL). The mixture was purged briefly with N 2 . Pd(PPh 3 ) 4 (10 mol %, 0.0167 mmol) was added, the mixture purged with N 2 , and then refluxed for 16 hours. The reaction mixture was diluted with ethyl acetate (EtOAc), washed with a saturated brine solution, dried over anhydrous Na 2 SO 4 and concentrated. The residue was then purified by chromatography.
  • EtOAc ethyl acetate
  • Method B the aryl boronic acid (0.301 mmol), the aryl bromide (0.602 mmol), and Cs 2 CO 3 (0.903 mmol) were combined in THF (2.0 mL), DMF (2,0 mL), and H 2 O (0.5 mL) at room temperature. The mixture was purged with N 2 for 5 min and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.0301 mmol) was added. The mixture was purged with N 2 for 5 minutes and then stirred at 55° C. for 16 hours. The mixture was concentrated under vacuum, diluted with EtOAc and washed with brine. The EtOAc was dried over anhydrous Na 2 SO 4 and concentrated. The residue was purified by chromatography.
  • Method C the aryl boronic acid (0.934 mmol), the aryl bromide (2.34 mmol), and Cs 2 CO 3 (2.80 mmol) were suspended in a mixture of toluene (4 mL), n-butanol (4 mL), and H 2 O (2 mL). The mixture was purged at room temperature with N 2 after which Pd(PPh 3 ) 4 (0.280 mmol) was added. The mixture was purged with N 2 for an additional 5 minutes and then heated to 75° C. After 12 hours, the mixture was cooled to room temperature and concentrated under vacuum. The residue was partitioned between H 2 O (75 mL) and EtOAc (75 mL). The EtOAc layer was washed with brine (2 ⁇ 50 mL), dried over anhydrous Na 2 SO 4 , and concentrated under vacuum. The residue was purified by chromatography.
  • 1,1′-Carbonyldiimidazole (23.6 g, 0.146 mol) was dissolved in 250 mL of anhydrous 1,2-dichloroethane at room temperature followed by addition of triethylamine (Et 3 N, 12.2 g, 16.8 mL).
  • 13 33.26 g, 0.121 mol was dissolved in 125 mL of anhydrous tetrahydrofuran (THF) and an equivalent of triethylamine.
  • THF tetrahydrofuran
  • B(OMe) 3 (158 ⁇ L, 1.39 mmol), which had been stored over 4 ⁇ activated molecular sieves for at least 48 hours, was added dropwise over one minute using an oven-dried, gas-tight syringe. The mixture was warmed to room temperature and stirred under N 2 for 16 hours. Approximately 20 mL of saturated aqueous NH 4 Cl was added with vigorous stirring, which resulted in a white precipitate dispersed in the two liquid phases. The mixture was stirred for an additional 90 minutes and then diluted with EtOAc and H 2 O until all the precipitate dissolved. The organic layer was separated, washed with brine and dried over anhydrous Na 2 SO 4 .
  • Compound 32 was prepared by the procedure of Pines, et al., supra. In a 250-mL round-bottom flask was placed 1,1′-carbonyldiimidazole (CDI, 5.06 g, 31.2 mmol) and Et 3 N (2.17 mL, 15.6 mmol) in 1,2-dichloroethane (50 mL). Compound 32 (4.00 g, 15.6 mmol) was added to a beaker containing 1,2-dichloroethane (50 mL). Et 3 N (4.34 mL, 31.2 mmol) was added to the beaker upon which a thick suspension formed.
  • CDI 1,1′-carbonyldiimidazole
  • Et 3 N (2.17 mL, 15.6 mmol
  • Compound 32 (4.00 g, 15.6 mmol) was added to a beaker containing 1,2-dichloroethane (50 mL).
  • Et 3 N (4.34 mL, 3
  • the biaryl intermediate was prepared from 18 and the appropriate boronic acid using Suzuki coupling method A. Removal of the Boc group was accomplished by brief treatment with 90/10 (v/v) TFA/H 2 O. Dichloroacetylation was performed as in the synthesis of 29.
  • LRMS (ESI ⁇ ) m/z: 379.0 (M ⁇ H + C 18 H 14 C 12 FN 2 O 2 379.0).
  • the biaryl intermediate was prepared from 18 and the boronic acid using Suzuki coupling method B. Removal of the Boc group was accomplished by brief treatment with 9/1 (v/v) TFA/H 2 O. Dichloroacetylation was performed as in the synthesis of 29.
  • the biaryl intermediate was prepared from boronic acid 23 and compound 24 using Suzuki coupling method B. Removal of the protecting groups was accomplished by brief treatment with 9/1 (v/v) TFANH 2 O. Dichloroacetylation was performed as in the synthesis of 29.
  • the biaryl intermediate was prepared from 18 and the appropriate boronic acid using Suzuki coupling method B. Removal of the protecting group was accomplished by brief treatment with 9/1 (v/v) TFA/H 2 O. Difluoroacetylation was performed as in the synthesis of 48.
  • the biaryl intermediate was prepared from 11 and the appropriate boronic acid using Suzuki coupling method A.
  • the phenyloxazoline protecting group was removed and the dichloroacetate group introduced as in the synthesis of 29.
  • the biaryl intermediate was prepared from 11 and the appropriate boronic acid using Suzuki coupling method A.
  • the phenyl oxazoline protecting group was cleaved and dichloroacetate introduced as in the synthesis of 29.
  • the biaryl intermediate was prepared from bromide 11 and the appropriate boronic acid using Suzuki coupling method A. Removal of the protecting group and dichloroacetylation was performed as in the synthesis of 29.
  • the carboxylic acid intermediate from the synthesis of 72 was dichloroacetylated as in the synthesis of 29.
  • the resulting intermediate (95.8 mg, 0.297 mmol) was dissolved in 2 mL of MeOH, several drops of H 2 O were added and then a 20% (w/v) aqueous Cs 2 CO 3 solution was added dropwise until the solution reached pH 7.
  • the mixture was concentrated under vacuum.
  • One drop of Et 3 N and 10 mL of 2-chloroethanol were added and the mixture stirred at 135° C. for 2 hours. Residual chloroethanol was removed under vacuum and the residue chromatographed.
  • Compound 74 (13.3 mg) was the major product and 75 (9.2 mg) the minor product.
  • the cyclopropyl analog of intermediate 89 was prepared by a Stille coupling analogous to that used to synthesize 89. Acidic cleavage of the phenyloxazoline group resulted in the HCl-mediated opening of the cyclopropyl ring. This material was deprotected and dichloroacetylated to give 76.
  • Free amine 37 (4.7 mg, 0.0224 mmol) was dissolved in MeOH (1 mL) and the mixture cooled to 0° C. Chloroacetic anhydride (5 drops) and triethylamine (5 drops) were added and the mixture warmed to room temperature and stirred for 2 hours. The solvent was removed under vacuum and the product purified by silica gel chromatography (2:3 EtOAc/hexanes) to give 3.3 mg (0.011 mmol) of product.
  • the biaryl intermediate was prepared from boronic acid 12 and 2-iodopyrazine. Deprotection and dichloroacetylation were accomplished as in the synthesis of 29.
  • the biaryl intermediate was prepared by reaction of 23 and the appropriate bromide using Suzuki coupling A. Deprotection and dichloroacetylation were carried out as described above in the synthesis of 29.
  • the biaryl intermediate was prepared by reaction of 23 with 2-amino-4-cyclopropyl-1,3,4-thiadiazole (prepared as in the synthesis of 24) using Suzuki coupling B. Deprotection was accomplished by brief treatment of the protected biaryl intermediate with 90/10 TFA/H 2 O and dichloroacetylation was performed as in the synthesis of 29.
  • the mixture was warmed to room temperature and stirred an additional 30 minutes by which time it was clear yellow and TLC indicated a product had formed.
  • the mixture was quenched by addition of 10% (v/w) aqueous NH 4 Cl (5 drops), producing a cloudy yellow suspension.
  • the mixture was concentrated under vacuum and re-suspended in EtOAc (50 mL) and enough 10% aqueous citric acid to produce a biphasic mixture having a pH of 2.5.
  • the layers were separated and the EtOAc layer was washed with brine (1 ⁇ 10 mL).
  • the mixture was dried over Na 2 SO 4 , filtered and evaporated to give 105 mg of yellow oil.
  • the protected biaryl intermediate was prepared by Suzuki coupling method B from boronic acid 23 and the appropriate aryl bromide. This intermediate was then deprotected by brief treatment with 9:1 (v/v) TFA/H 2 O and dichloroacetylated as described for 29. LRMS (ESI + ) m/z: 380.0 (M ⁇ H + C 17 H 13 Cl 2 FN 3 O 2 requires 380.0).
  • the biaryl intermediate was prepared from boronic acid 23 using Suzuki coupling.
  • the phenyllithium intermediate was prepared by treatment of intermediate 19 with n-butyllithium in THF at ⁇ 78° C. The intermediate was reacted with pyridazine and the mixture of the resulting 2- and 3-position adducts was oxidized with DDQ. The desired 3-pyridazyl regioisomer was isolated by chromatography. LRMS (ESI + ) m/z: 326.0 (M ⁇ H + C 15 H 14 F 3 N 3 O 2 requires 326.0)
  • Example 108 The starting material in Example 108 was reacted with Lawesson's reagent and the product was cyclized to the biaryl intermediate with hydroxylamine-O-sulfonic acid in methanol in presence of pyridine.
  • LRMS (ESI + ) m/z: 363.0 (M ⁇ H + C 14 H 13 Cl 2 FN 2 O 2 S requires 363.0)
  • the starting acetylene was obtained as described in Example 118.
  • the 3-carboethoxy isoxazole intermediate was obtained by cycloaddition of the nitrile oxide generated in situ from ethyl nitroacetate, di-t-butyldicarbonate and 4-dimethylaminopyridine.
  • the amide was obtained from the 3-carboethoxy isoxazole intermediate by hydrolysis to the acid, conversion to the acyl chloride and reaction with ammonia.
  • LRMS (ESI + ) m/z: 358.0 (M ⁇ H + C 15 H 14 F 3 N 3 O 4 requires 358.0)
  • the starting acetylene was obtained as described in Example 118.
  • the 3-methyl isoxazole intermediate was obtained by cycloaddition of the nitrile oxide generated in situ from nitroethane, di-t-butyldicarbonate and 4-dimethylaminopyridine.
  • LRMS (ESI + ) m/z: 329.0 (M ⁇ H + C 15 H 15 F 3 N 2 O 3 requires 329.0)
  • the imidazole intermediate (2.77 g) was dissolved in THF (20 mL) and 4 N HCl (20 mL), and stirred at 80° C. for 2.5 hrs. The reaction mixture was evaporated to dryness under reduced pressure. The residue was co-evaporated with methanol twice and dried overnight under vacuum. The crude material was dissolved in methanol (20 mL) and triethylamine (5 mL) was added, followed by methyl dichloroacetate (5 mL). The mixture was stirred at room temperature for 20 hrs. The solvent was evaporated and the mixture was purified by flash column chromatography to give compound 169 (1.1 g) as white solid.
  • the present invention provides novel florfenicol-like compounds and methods for their use in the treatment or prevention of bacterial infection in animals or humans.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel florfenicol compounds having the chemical structure:
Figure US20060014743A1-20060119-C00001
 wherein the compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such as, without limitation, birds, fish, shellfish and mammals.

Description

    RELATED APPLICATIONS
  • This Application is a continuation-in-part of U.S. patent application Ser. No. 10/094,688, filed Mar. 8, 2002 and entitled “Novel Florfenicol-type Antibiotics.” The '688 application is incorporated as if fully set forth herein.
    • FIELD OF THE INVENTION
  • The present invention relates to the fields of organic chemistry, pharmaceutical chemistry, biochemistry and medicine. In particular, it relates to novel florfenicol-type antibiotics.
    • BACKGROUND OF THE INVENTION
  • Florfenicol is a broad spectrum antibiotic with activity against many gram-negative and gram-positive bacteria. Florfenicol is useful for the prevention and treatment of bacterial infections due to susceptible pathogens in birds, reptiles, fish, shellfish and mammals. One of its primary uses is in the treatment of pneumonia and associated respiratory infections in cattle (often referred to generically as Bovine Respiratory Disease or BRD) caused by Mannhemia haemolytica, Pasturella multocida and(or) Haemophilus somnus. It is also indicated in the treatment of pododermatitis in cattle caused by Fusobacterium necrophorum and Bacterioides melaninogenicus, swine respiratory disease caused by Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus suis, Salmonella cholerasuis and(or) Mycoplasma spp., colibacillosis in chickens caused by Escherichia coli, enteric septicemia in catfish caused by Edwardsiella ictaluri, and furunculosis in salmon caused by Aeromonas salmonicida. Other genera of bacteria that have exhibited susceptibility to florfenicol include. Enterobacter, Klebsiella, Staphylococcus, Enterococcus, Bordetella, Proteus, and Shigella. In particular, chloramphenicol resistant strains of organisms such as K. pneumoniae, E. cloacae, S. typhus and E. coli are susceptible to florfenicol.
  • Florfenicol is a structural analog of thiamphenicol, which in turn is a derivative of chloramphenicol in which the aromatic nitro group, which nitro group has been implicated in
    Figure US20060014743A1-20060119-C00002
    chloramphenicol-induced, non-dose related irreversible aplastic anemia in humans, is replaced with a methylsulfonyl group. Florfenicol has a fluorine atom in place of the primary hydroxyl group of chloramphenicol and thiamphenicol. This renders florfenicol less susceptible to deactivation by bacteria containing the plasmid-encoded enzyme, chloramphenicol acetyl transferase (CAT), which acetylates the primary hydroxyl group of chloramphenicol and thiamphenicol, thereby preventing them from binding to ribosomal subunits of susceptible bacteria. Ribosomal binding is the primary mechanism of action of the chloramphenicol antibiotics and results in inhibition of peptidyl transferase, which is responsible for the transfer of amino acids to growing peptide chains and subsequent protein formation in bacteria. Nonetheless, compounds having the primary hydroxyl group do have utility in the treatment of bacterial infections, as evidenced by the continuing use of chloramphenicol and thiampheniol throughout the world.
  • In recent years, a number of bacterial genera and species have begun to exhibit some resistance to florfenicol. For example, resistance has been observed in Salmonella species (Bolton, L. F., et al., Clin. Microbiol. 1999, 37, 1348), E. coli (Keyes, K., et al., Antimicrob. Agents Chemother., 2000, 44, 421.), Klebsiella pneumoniae (Cloeckaert, A., et al., Antimicrob. Agents Chemother., 2001, 45, 2381), and in the aquacultural pathogen, Photobacterium damselae subsp. piscicida (formerly Pasteurella piscicida) (Kim, E., et al., Microbiol. Immunol., 1996, 40, 665). This resistance has been traced to a highly conserved gene (flo) that produces an antibiotic efflux pump (Flo).
  • The emergence, and threatened spread, of resistance to florfenicol has fostered the need for new antibiotics that retain or exceed the activity of florfenicol, maintain its imperviousness to the CAT enzyme and, in addition, are not substrates for the Flo efflux pump. The compounds of the present invention are such antibiotics.
    • SUMMARY
  • Thus, an embodiment of this invention is a compound having the chemical formula:
    Figure US20060014743A1-20060119-C00003
    wherein:
    • R1 is selected from the group consisting of —OH and —F;
    • R2 and R3 are independently selected from the group consisting of hydrogen, (1C-4C)alkyl, halo, —CF3, —NH2, —CN and N3;
    • R4 is selected from the group consisting of: —C(═R5)R6,
      • wherein:
      • R5 is selected from the group consisting of oxygen, N—C≡N, and NOR7,
        • wherein:
        • R7 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alicyclic and heteroalicyclic;
      • R6 is selected from the group consisting of hydrogen, (1C-4C)alkyl, (3C-6C)cycloalkyl, (1C-4C)alkoxy, aryl, heteroaryl, alicyclic and heteroalicyclic;
        Figure US20060014743A1-20060119-C00004
        wherein:
    • A1 is carbon or nitrogen;
    • A2, A3, A4 and A5 are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur, provided that at least one of A1-A5 is not carbon, that the total number of nitrogen, oxygen and sulfur atom in the ring does not exceed 4 and that the ring is aromatic;
    • carbon atoms in the ring are independently substituted with an entity selected from the group consisting of hydrogen, (1C-4C)alkyl, (3C-6C)cycloalkyl, (1C-4C)alkylO—, —CF3, —OH, —CN, halo, (1C-4C)alkylS(O)—, (1C-4C)alkylS(O)2—, NH2SO2—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, —NH2, (1C-4C)alkylNH—, ((1C-4C)alkyl)2N—, (1C-4C)alkylSO2NH—, (1C-4C)alkylC(O)—, (3C-6C)cycloalkylC(O)—, (1C-4C)alkylOC(O)—, (1C-4C)alkylC(O)NH—, —C(O)NH2, (1C-4C)alkylNHC(O)— and ((1C-4C)alkyl)2NC(O)—, wherein any of the alkyl groups in any of the substituents may optionally be substituted with a group selected from halo and —OH;
    • if A1 is carbon and the ring does not contain oxygen or sulfur, one of the nitrogen atoms may optionally be substituted with an entity selected from the group consisting of (1C-4C)alkyl, (1C-4C)alkylS(O)2— and —NH2;
      Figure US20060014743A1-20060119-C00005
      wherein:
    • A6, A7, A8, A9 and A10 are independently selected from the group consisting of carbon, nitrogen and
      Figure US20060014743A1-20060119-C00006
      provided that only one of A6-A10 at a time can be
      Figure US20060014743A1-20060119-C00007
      carbon atoms in the ring are independently substituted with an entity selected from the group consisting of hydrogen, (1C-4C)alkyl, (3C-6C)cycloalkyl, (1C-4C)alkylO—, —CF3, —OH, —CN, halo, (1C-4C)alkylS(O)—, (1C-4C)alkylS(O)2—, NH2SO2—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, —NH2, (1C-4C)alkylNH—, ((1C-4C)alkyl)2N—, (1C-4C)alkylSO2NH—, (1C-4C)alkylC(O)—, (3C-6C)cycloalkylC(O)—, (1C-4C)alkylOC(O)—, (1C-4C)alkylC(O)NH—, —C(O)NH2, (1C-4C)alkylNHC(O)—, ((1C-4C)alkyl)2NC(O)— and —OCH2O—, the oxygen atoms in the —OCH2O— substituent being bonded to adjacent ring carbon atoms, wherein any of the alkyl groups in any of the substituents may optionally be substituted with a group selected from halo and —OH;
    • R8 is hydrogen in all compounds, except when R2 and R3 are both F, in which case R8is hydrogen or F; and,
    • the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
  • In an embodiment of this invention, R1 is —F.
  • In an embodiment of this invention, R2 and R3 are independently selected from the group consisting of Cl and F.
  • In an embodiment of this invention, R8 is hydrogen.
  • In an embodiment of this invention, R4 is —C(═R5)R6 wherein R5 and R6 are as defined above.
  • In an embodiment of this invention, R4 is CH3C(O)—.
  • In an embodiment of this invention, R4 is
    Figure US20060014743A1-20060119-C00008
    wherein:
    • A6, A7, A8, A9 and A10 are as defined above, and,
    • any of A6-A10 that is carbon is substituted with an entity selected from the group consisting of hydrogen, —NH2, halo-, —CN, (1C-4C)alkyl-, (1C-4C)alkylC(O)—, (1C-4C)alkylS(O)—, (1C-4C)alkylS(O)2—, NH2SO2—, (1C-4C)alkylSO2NH—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, wherein any of the alkyl groups in any of the substituents may optionally be substituted with halo or —OH.
  • In an embodiment of this invention, R4 is
    Figure US20060014743A1-20060119-C00009
    and one, two or three of A6-A10 is/are nitrogen; and,
    • one or two of the remaining carbon atoms in the ring is/are optionally substituted with —NH2, all other carbon atoms in the ring being unsubstituted.
  • In a presently preferred embodiment of this invention, R4 is selected from the group consisting of:
    Figure US20060014743A1-20060119-C00010
  • In an embodiment of this invention, R4 is
    Figure US20060014743A1-20060119-C00011
    as defined above.
  • In an embodiment of this invention, R4 is
    Figure US20060014743A1-20060119-C00012
    and all carbon atoms and nitrogen atoms are unsubstituted.
  • In an embodiment of this invention, R4 is
    Figure US20060014743A1-20060119-C00013
    and one of A2-A5 that is carbon is substituted with an —NH2 group, all other carbon and, if applicable, nitrogen atoms in the ring being unsubstituted.
  • In a presently preferred embodiment of this invention, R4 is selected from the group consisting of:
    Figure US20060014743A1-20060119-C00014
  • A presently preferred embodiment of this invention is a compound selected from the group consisting of:
    Figure US20060014743A1-20060119-C00015
    Figure US20060014743A1-20060119-C00016
    Figure US20060014743A1-20060119-C00017
    Figure US20060014743A1-20060119-C00018
    wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
  • A presently particularly preferred embodiment of this invention is a compound selected from the group consisting of:
    Figure US20060014743A1-20060119-C00019
    Figure US20060014743A1-20060119-C00020
    wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
  • In another particularly preferred embodiment of this invention, the compound herein is substantially enantiomerically pure and has a 1-(R)-2-(S) absolute configuration.
  • An embodiment of this invention is a method of treating or preventing a bacterial infection, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound hereof.
  • In an embodiment of this invention, the bacterial infection is caused by a bacteria of the genus Pasteurella, Haemophilus, Fusobacterium, Bacterioides, Aeromonas, Enterobacter, Escherichia, Klebsiella, Salmonella, Shigella, Actinobacillus, Streptococcus, Mycoplasma, Edwardsiella, Staphylococcus, Enterococcus, Bordetella, Proteus, or Mannheimia.
  • In an embodiment of this invention the bacterial infection is caused by Mannhemia haemolytica, Pasteurella multocida, Haemophilus somnus, Fusobacterium necrophorum, Bacterioides melaninogenicus, Actinobacillus pleuropneumoniae, Streptococcus suis, Salmonella cholerasuis, Mycoplasma bovis, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Mycoplasma gallisepticum, Edwardsiella ictaluri, Escherichia coli, Enterobacter cloacae, Staphylococcus aureus, Staphylococcus intermedius, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Proteus mirabilis, or Aeromonas salmonicida.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Brief Description of the Tables
  • Table 1 shows structures of representative compounds of this invention. The table and the compounds therein are not intended, nor should they be construed, to limit this invention in any manner whatsoever.
  • Table 2 is a list of the microorganisms against which the compounds of this invention were tested. The list is not intended, nor should it be construed, to limit the scope of this invention in any manner whatsoever.
    • DEFINITIONS
  • As used herein, “halo” refers to fluorine, chlorine, bromine or iodine.
  • As used herein, “alkyl” refers to a saturated (containing no multiple bonds) aliphatic (no delocalized π-electron system), hydrocarbon (containing, if unsubstituted, only carbon and hydrogen). The designation (n1C-n2C)alkyl, wherein n1 and n2 are integers from 1-6, refers to a straight chain or branched chain alkyl comprising from n1 to n2 carbon atoms. For example, (1C-4C)alkyl refers to CH3—, CH3CH2—, CH3CH2CH2—, CH3CH(CH3)—, CH3CH2CH2CH2—, CH3CH2CH(CH3)— or (CH3)3C—. The alkyl group may be unsubstituted or substituted with one or more moieties selected from the group consisting of halo, —OH, OCH3, and —C≡N.
  • As used herein, “cycloalkyl” refers to an all-carbon cyclic or fused multicyclic ring, which, although it may contain one or more double bonds, maintains an essentially aliphatic character; that is, the double bonds do not interact to form a delocalized π-electron system around the ring. For the purposes of this invention, the ring may contain up to 7 carbon atoms. The designation (3C-6C)cycloalkyl refers to 3, 4, 5, and 6-member all-carbon-atom rings. As used herein, “fused” means that two cycloalkyl groups share at least one ring atom between them. Thus, such compounds as spiro[4.4]nonane are considered “fused” for the purposes of this invention. More commonly, fused rings share two adjacent ring carbon atoms. An example of such a fused system is decalin. A cycloalkyl ring may be unsubstituted or substituted with a moiety selected from the group consisting of —OH, —OCH3, halo and —C≡N.
  • As used herein, “aryl” refers to an all-carbon 6-member ring or two fused six-member rings, the ring or fused rings having a delocalized π-electron system. By “fused” is meant that each ring of the system shares two adjacent ring carbon atoms with at least one other ring. An aryl ring may be unsubstituted or substituted with one or more moieties selected from the group consisting of —OH, —OCH3, halo and —C≡N.
  • As used herein, “heteroaryl” refers to a five-member or six-member ring or to two rings, i.e., two 5-member, two six-member or a five- and a six-member ring fused together wherein the ring or fused ring has a delocalized π-electron system. If a ring is six-membered, it must consist of carbon and nitrogen only and may contain from one to four nitrogen atoms. If a ring is five-membered, it must contain one nitrogen, oxygen or sulfur atom and may contain one, two or three additional nitrogen atoms. A five-member ring with a circle in the center indicates that the ring is heteroaromatic. The circle is used to emphasize the fact that the location of the double bonds that participate in making the ring heteroaromatic is not static, rather it is dependent on the nature of the atoms forming the ring, i.e., whether they are carbon, nitrogen, oxygen or sulfur and what groups, if any, are bonded to them. The actual structure of any five-member heteroaromatic will be immediately apparent to those skilled in the art once the ring atoms are designated. With regard to heteroaromatic groups, the term fused has the same meaning as in -the case of aryl groups. A heteroaryl group may be unsubstituted or substituted with any of the moieties described above with regard to aryl groups.
  • As used herein, “heteroalicyclic” refers to a cyclic or fused cyclic ring system containing atoms selected from the group consisting of carbon, nitrogen, oxygen and sulfur but no delocalized π-electron system. “Fused” has the same meaning set forth above with regard to cycloalkyl rings. Likewise, a heteroalicyclic ring may be unsubstituted or substituted with the same moieties described above for cycloalkyl rings.
  • Whenever a ring carbon atom is stated to be “unsubstituted,” it is understood that any unfilled valences are in fact occupied by hydrogen atoms. Likewise, if a ring nitrogen atom is capable of being further substituted and it is stated to be unsubstituted, it means that the nitrogen is bonded to a hydrogen atom.
  • As used herein, “relative stereochemistry” refers to the positioning in space of substituents relative to one another.
  • As used herein, “absolute stereochemistry” refers to the exact positioning of substitutents in three-dimensional space as determined by the Cahn-Ingold-Prelog rules, the application of which are well-known to those skilled in the art.
  • As used herein, an “enantiomer” refers to one of the two absolute stereochemical configurations of a molecule that rotates plane polarized light in one direction or the other (i.e.; counterclockwise from its original axis, conventionally called “left,” or clockwise, conventionally referred to as “right”). By “substantially enantiomerically pure” is meant that the compound consists of greater than 90% of the one enantiomer, preferably greater than 95%, and most preferably greater than 99%.
  • As used herein, a “racemate” refers to a 1:1 mixture of the two enantiomers of a compound. Racemic mixtures are designated by a (±) indicator. Substantially enantiomerically pure compounds are shown without the indicator.
  • As used herein, “patient” refers to birds, reptiles, fish, shellfish, and mammals. In particular it refers to birds such as, without limitation, chickens and turkeys, fish such as, without limitation, salmon, trout, catfish and yellowtail, mammals such as, without limitation, cats, dogs, rabbits, sheep, cattle, pigs, horses and goats and to human beings.
  • Discussion
  • The compounds of this invention are expected to be useful for the treatment of bacterial infections in patients.
  • Compounds
  • The compounds of the present invention are set forth generally in the Summary, above. Exemplary compounds of this invention are shown in Table 1. Neither the table nor the compounds shown therein are intended, or are to be construed, as limiting the scope of this invention in any manner whatsoever.
    TABLE 1
    Compound # Structure
    28
    Figure US20060014743A1-20060119-C00021
    29
    Figure US20060014743A1-20060119-C00022
    41
    Figure US20060014743A1-20060119-C00023
    47
    Figure US20060014743A1-20060119-C00024
    48
    Figure US20060014743A1-20060119-C00025
    49
    Figure US20060014743A1-20060119-C00026
    50
    Figure US20060014743A1-20060119-C00027
    51
    Figure US20060014743A1-20060119-C00028
    52
    Figure US20060014743A1-20060119-C00029
    53
    Figure US20060014743A1-20060119-C00030
    54
    Figure US20060014743A1-20060119-C00031
    55
    Figure US20060014743A1-20060119-C00032
    56
    Figure US20060014743A1-20060119-C00033
    57
    Figure US20060014743A1-20060119-C00034
    58
    Figure US20060014743A1-20060119-C00035
    59
    Figure US20060014743A1-20060119-C00036
    60
    Figure US20060014743A1-20060119-C00037
    61
    Figure US20060014743A1-20060119-C00038
    62
    Figure US20060014743A1-20060119-C00039
    63
    Figure US20060014743A1-20060119-C00040
    64
    Figure US20060014743A1-20060119-C00041
    65
    Figure US20060014743A1-20060119-C00042
    66
    Figure US20060014743A1-20060119-C00043
    67
    Figure US20060014743A1-20060119-C00044
    68
    Figure US20060014743A1-20060119-C00045
    69
    Figure US20060014743A1-20060119-C00046
    71
    Figure US20060014743A1-20060119-C00047
    72
    Figure US20060014743A1-20060119-C00048
    73
    Figure US20060014743A1-20060119-C00049
    74
    Figure US20060014743A1-20060119-C00050
    75
    Figure US20060014743A1-20060119-C00051
    76
    Figure US20060014743A1-20060119-C00052
    77
    Figure US20060014743A1-20060119-C00053
    78
    Figure US20060014743A1-20060119-C00054
    79
    Figure US20060014743A1-20060119-C00055
    80
    Figure US20060014743A1-20060119-C00056
    81
    Figure US20060014743A1-20060119-C00057
    82
    Figure US20060014743A1-20060119-C00058
    84
    Figure US20060014743A1-20060119-C00059
    85
    Figure US20060014743A1-20060119-C00060
    86
    Figure US20060014743A1-20060119-C00061
    91
    Figure US20060014743A1-20060119-C00062
    92
    Figure US20060014743A1-20060119-C00063
    93
    Figure US20060014743A1-20060119-C00064
    94
    Figure US20060014743A1-20060119-C00065
    95
    Figure US20060014743A1-20060119-C00066
    97
    Figure US20060014743A1-20060119-C00067
    98
    Figure US20060014743A1-20060119-C00068
    100
    Figure US20060014743A1-20060119-C00069
    101
    Figure US20060014743A1-20060119-C00070
    106
    Figure US20060014743A1-20060119-C00071
    107
    Figure US20060014743A1-20060119-C00072
    109
    Figure US20060014743A1-20060119-C00073
    110
    Figure US20060014743A1-20060119-C00074
    111
    Figure US20060014743A1-20060119-C00075
    112
    Figure US20060014743A1-20060119-C00076
    113
    Figure US20060014743A1-20060119-C00077
    114
    Figure US20060014743A1-20060119-C00078
    115
    Figure US20060014743A1-20060119-C00079
    116
    Figure US20060014743A1-20060119-C00080
    117
    Figure US20060014743A1-20060119-C00081
    118
    Figure US20060014743A1-20060119-C00082
    120
    Figure US20060014743A1-20060119-C00083
    121
    Figure US20060014743A1-20060119-C00084
    122
    Figure US20060014743A1-20060119-C00085
    123
    Figure US20060014743A1-20060119-C00086
    124
    Figure US20060014743A1-20060119-C00087
    125
    Figure US20060014743A1-20060119-C00088
    126
    Figure US20060014743A1-20060119-C00089
    127
    Figure US20060014743A1-20060119-C00090
    128
    Figure US20060014743A1-20060119-C00091
    129
    Figure US20060014743A1-20060119-C00092
    130
    Figure US20060014743A1-20060119-C00093
    131
    Figure US20060014743A1-20060119-C00094
    132
    Figure US20060014743A1-20060119-C00095
    133
    Figure US20060014743A1-20060119-C00096
    134
    Figure US20060014743A1-20060119-C00097
    135
    Figure US20060014743A1-20060119-C00098
    136
    Figure US20060014743A1-20060119-C00099
    137
    Figure US20060014743A1-20060119-C00100
    138
    Figure US20060014743A1-20060119-C00101
    139
    Figure US20060014743A1-20060119-C00102
    140
    Figure US20060014743A1-20060119-C00103
    141
    Figure US20060014743A1-20060119-C00104
    142
    Figure US20060014743A1-20060119-C00105
    143
    Figure US20060014743A1-20060119-C00106
    144
    Figure US20060014743A1-20060119-C00107
    145
    Figure US20060014743A1-20060119-C00108
    146
    Figure US20060014743A1-20060119-C00109
    147
    Figure US20060014743A1-20060119-C00110
    148
    Figure US20060014743A1-20060119-C00111
    149
    Figure US20060014743A1-20060119-C00112
    150
    Figure US20060014743A1-20060119-C00113
    151
    Figure US20060014743A1-20060119-C00114
    152
    Figure US20060014743A1-20060119-C00115
    153
    Figure US20060014743A1-20060119-C00116
    154
    Figure US20060014743A1-20060119-C00117
    155
    Figure US20060014743A1-20060119-C00118
    156
    Figure US20060014743A1-20060119-C00119
    157
    Figure US20060014743A1-20060119-C00120
    158
    Figure US20060014743A1-20060119-C00121
    159
    Figure US20060014743A1-20060119-C00122
    160
    Figure US20060014743A1-20060119-C00123
    161
    Figure US20060014743A1-20060119-C00124
    162
    Figure US20060014743A1-20060119-C00125
    163
    Figure US20060014743A1-20060119-C00126
    164
    Figure US20060014743A1-20060119-C00127
    165
    Figure US20060014743A1-20060119-C00128
    166
    Figure US20060014743A1-20060119-C00129
    167
    Figure US20060014743A1-20060119-C00130
    168
    Figure US20060014743A1-20060119-C00131
    169
    Figure US20060014743A1-20060119-C00132
    170
    Figure US20060014743A1-20060119-C00133
    171
    Figure US20060014743A1-20060119-C00134
    172
    Figure US20060014743A1-20060119-C00135
    173
    Figure US20060014743A1-20060119-C00136
    174
    Figure US20060014743A1-20060119-C00137
    175
    Figure US20060014743A1-20060119-C00138
    176
    Figure US20060014743A1-20060119-C00139
    177
    Figure US20060014743A1-20060119-C00140
    178
    Figure US20060014743A1-20060119-C00141
    179
    Figure US20060014743A1-20060119-C00142
    180
    Figure US20060014743A1-20060119-C00143

    Syntheses
  • Intermediates were prepared in enantiomerically pure form, starting with commercially available chloramphenicol base (1), or as racemic mixtures by condensation of ρ-bromobenzaldehyde with glycine under basic conditions. For the enantiomerically pure synthesis of intermediates such as 9, chloramphenicol base was converted to compound 3 (Rebstock, M. C., et al., J. Am, Chem. Soc., 1949, 71, 2458; Evans, D. D., et al., J. Chem. Soc., 1954, 1687; Morris, D. S. and Smith, S. D., J. Chem. Soc., 1954, 1680). Compound 3 was subjected to the Sandmeyer reaction after which the acetate protecting group was removed under acidic conditions to provide enantiomerically pure 9.
  • Alternatively, ρ-bromobenzaldehyde (5) can be converted to (d/l)-threo-p-bromophenylglycine (6, Scheme 1), (Bolhoffer, W. A. J. Am. Chem. Soc. 1954, 76, 1322; Herbert, R. B.; Wilkinson, B.; Ellames, G. J. Can. J. Chem. 1994, 72, 114), which can be protected as N-Boc derivative 7 and then reduced in two-steps: activation with DCC and N-hydroxysuccinimide followed by treatment with NaBH4 to provide 8. Compound 9 can be isolated as its TFA salt or as the free base. Regioselective introduction of fluoride is accomplished by protecting the amine and benzylic hydroxyl group as phenyl oxazoline 10 followed by fluorination with (diethylamino)sulfur trifluoride (DAST) or [bis(2-methoxyethyl)amino]sulfur trifluoride (Lal, G. S., J. Org. Chem., 1999, 64, 7048) to give 11. Compound 11 is used in the Suzuki cross-coupling reaction for the synthesis of biaryl derivatives. The other Suzuki partner, an aryl boronic acid such as 12, can be prepared as shown and reacted with aryl halides.
    Figure US20060014743A1-20060119-C00144
  • The conditions for removal of the phenyloxazoline protecting group proved to be incompatible with many functional groups at the p-position of the aromatic ring. Thus, a new protecting group motif was developed based on literature methods (Scheme 2; Jommi, G., et al., Gazz. Chim. Ital., 1986, 116:485). Phenylserine 6 was converted to methyl ester 13, which was protected as oxazolidinone 14, which, in turn, was reduced with NaBH4 to 15. Fluorination with either DAST or [bis(2-methoxyethyl)amino]sulfur trifluoride gave intermediate 16, which did not give consistently good Suzuki reaction yields. Thus, 16 was converted to 17. Cleavage of the oxazolidinone protecting group was facilitated by the introduction of a Boc group (Grehn, L., et al., Acta Chem. Scand. B, 1986, 40, 745) followed by base-catalyzed cleavage to give 18 (Ishizuka, T. and Kunieda, T., Tetrahedron Lett., 1987, 28, 4185; Jommi, G., et al., Gazz. Chim. Ital., 1988, 118:75).
    Figure US20060014743A1-20060119-C00145
    Figure US20060014743A1-20060119-C00146
  • Compound 18 was protected as isopropylidene derivative 19, which was converted to boronic acid 23 (Scheme 3). Compounds 18, 19, 22 and 23 were used in Suzuki cross-coupling reactions. Compound 23 provided the most versatility since it could be cross-coupled with any aryl bromide or iodide and the protecting groups could be easily removed under mild conditions. Compound 22 was attractive as a Suzuki cross-coupling partner in that the coupling reactions yielded the desired florfenicol analogs directly without the need for deprotection and dihaloacetylation. However, cross-coupling yields with 22 were lower than those with 23. Cross-couplings using 21 gave the desired products contaminated with acetate and monochloroacetate analogs.
  • Racemic compound 20 was identical spectroscopically to a sample synthesized from semi-synthetic 11 by hydrolytic cleavage and basic work-up. This provided unequivocal proof that the condensation of phenylserine 6 had proceeded with the appropriate relative threo or syn stereoselectivity.
    Figure US20060014743A1-20060119-C00147
  • Compounds 11 and 12 were used to prepare compounds 28 and 29 (Scheme 4). Compound 11 was cross-coupled with 3-pyridine boronic acid under standard biphasic Suzuki conditions to yield protected intermediate 26. The N—C cross-coupling product 27 was prepared according to the recently reported methods of Lam and coworkers (Lam, P. Y. S., et al., Synlett, 2000, 674; Lam, P. Y. S., Tetrahedron, Lett., 1998, 39, 2941; Lam, P. Y. S., Tetrahedron Lett., 2001, 42, 3415). Both 26 and 27 were deprotected and dichloroacetylated to give 28 and 29.
    Figure US20060014743A1-20060119-C00148
    Figure US20060014743A1-20060119-C00149
  • Compound 23 and 2-bromo-1,3,4-thiadiazole (24) were reacted to give 48 (Scheme 5). Suzuki cross-coupling produced the heterobiaryl 25. Compound 25 was deprotected with 9:1 TFA/H2O, which removed the Boc and isopropylidene groups simultaneously, and then was difluoroacetyated to give 48.
    Figure US20060014743A1-20060119-C00150
  • i) Cs2CO3, PdCl2(dppf), THF, DMF, H2O; ii) 9:1 TFA/H2O; iii) Et3N, methyl difluoroacetate, Δ
  • While ρ-bromo functional groups of derivatives such as 11 and the corresponding boronic acids such as 12 have substantial utility as synthetic intermediates to florfenicol analogs, ρ-cyano compounds have also served as important intermediates. Using literature methods (Morris, D. S.; Smith, S. D., above), intermediates such as 30 have been prepared in enantiomerically pure form (Scheme 6). Larger amounts of intermediate were prepared using racemic, totally synthetic intermediates such as 35. The aldol condensation used to produce 32 from ρ-cyanobenzaldehyde and glycine methyl ester was adapted from the literature (Pines, S. H. and Kazlowski, M. A., J. Org. Chem., 1972, 37, 292).
    Figure US20060014743A1-20060119-C00151
  • Compound 41 (Scheme 7) was prepared from intermediate 36, the preparation of which from 30 has been described (von Strandtmann, M., et al., J. Med. Chem., 1967, 10, 888). Compound 36 was deprotected with aqueous H2SO4 and then regioselectively protected as phenyloxazoline 38. Compound 39 was obtained on treatment with DAST and then was deprotected and dichloroacetylated to give 41.
    Figure US20060014743A1-20060119-C00152
    Figure US20060014743A1-20060119-C00153
  • Compound 47 was prepared from intermediate 35 by treatment with hydroxylamine hydrochloride followed by triethyl orthoformate to give 43, which was deprotected to give 46, which was then dichloroacetylated.
    Figure US20060014743A1-20060119-C00154
    Figure US20060014743A1-20060119-C00155
  • ρ-Acyl derivatives were obtained by Stille coupling reactions of the protected intermediates (Scheme 9, compounds 87 and 88) with acid chlorides. Trimethylstannyl groups were introduced by Pd-mediated reactions using hexamethylditin.
    Figure US20060014743A1-20060119-C00156
  • The cyclobutyl derivative 73 was prepared from 87 via a Stille coupling reaction that produced intermediate 89 (Scheme 10) which was deprotected and dichloro-acetylated.
  • Attempted deprotection of the cyclopropyl derivative corresponding to 89 led to HCl-mediated ring opening. Thus, to prepare 91, the boc/isopropylidene approach was employed since deprotection occurs under conditions that do not affect the cyclopropyl group.
    Figure US20060014743A1-20060119-C00157
    Figure US20060014743A1-20060119-C00158
  • When required, ρ-carboxyphenyl derivatives of protected phenicol intermediates could be prepared in two ways. For example, hydrolysis of the ρ-nitrile analog of 17 gives the corresponding carboxylic acid. However, nitrites generally could not be obtained as readily as the bromo derivatives. Thus, the preferred approach to carboxylation was replacement of the bromo group. For example, carboxylic acid derivative 102 (Scheme 11) was prepared by lithiation of 17 followed by treatment with CO2 and acid work-up. Compound 102 was converted to methyl ester 103, which was reacted with hydrazine to give 104. Cyclization of 104 with triethyl orthoformate gave oxadiazole 105, which was deprotected and dihaloacetylated to give 106 and 107.
    Figure US20060014743A1-20060119-C00159
    Figure US20060014743A1-20060119-C00160
  • The carboxylic acid derivative of 102 was also used to prepare compounds such as 109 (Scheme 12), by reduction to alcohol 108 followed by deprotection and dichloroacetylation
    Figure US20060014743A1-20060119-C00161
    Biological Evaluation
  • All of the compounds of this invention are expected to demonstrate antimicrobial activity against the same bacteria as the other members of the chloramphenicol family. In addition, they may be expected to be active against species of bacteria that are resistant to current chloramphenicol antibiotics, in particular florfenicol. It is also expected that the present compounds may exhibit activity against genera and species of bacteria against which current chloramphenicol-type antibiotics are not active.
  • It is also understood that, with regard to bioactivity, one enantiomer of a compound may be more active than the other. In such case, whether expressly stated or not, the more active isomer is considered the preferred embodiment of this invention. Particularly preferred is the most active enantiomer of the 1-(R)-2(S) absolute configuration of any compound herein.
  • To determine the range and level of activity of the compounds of this invention, the following protocols may be used. Other such protocols will become apparent to those skilled in the art based on the disclosures herein and are within the scope of this invention. Some compounds herein are expected to not only exhibit substantial antibacterial activity but to also be less susceptible to current chloramphenicol resistance mechanisms. The screening protocols herein may be used to determine such characteristics also.
  • Susceptibility Testing
  • Compounds were evaluated against a panel of bacterial strains using a broth microdilution assay performed as recommended by the NCCLS (National Committee for Clinical Laboratory Standards (NCCLS) 2000, Methods for Dilution of Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Fifth Edition, Approved Standard, NCCLS Document M7-A5, Vol 20, No. 2). The minimum inhibitory concentration (MIC) is defined as the lowest concentration of a compound that prevents the growth of the bacteria.
  • The following 10 organisms constituted the primary panel of evaluation:
    TABLE 2
    Efflux
    Bacteria Strain Pump Phenotype
    Escherichia coli ECM1194 AcrABa Wild type
    Escherichia coli ECM1694 None ΔacrAB::Tn903kmr
    Escherichia coli ECM 1642 AcrAB MarR
    Escherichia coli ECM 1888 MdfA tolC::Tn mdfR
    Escherichia coli ECM 1750 CmlA ΔacrAB::Tn903kmr/
    pLQ821
    Escherichia coli ECM 1958 Flo ΔacrAB::Tn903kmr/
    p1956
    Escherichia coli ECM 1970 AcrAB + marR/p1956
    Flo
    Escherichia coli ECM 1197 AcrABa EMR::Cm (cat)
    or ECM 2024 AcrABa ECM1197 acrAB::Kan
    Pasteurella ATCC43134 Wild type
    multocida
    Mannhemia ATCC33396 Wild type
    haemolytica

    aAcrAB efflux pump expressed at a low level
  • Assays were performed in Cation-Adjusted Mueller-Hinton Broth (CAMHB) at a bacterial inoculum of 5×105 CFU/ml and a final volume of 100 μl. Florfenicol and chloramphenicol controls and test compounds were prepared at four times the desired final concentration. Dilution to the desired concentration was accomplished directly on the plates by serial 2-fold dilution using a multi-channel pipette. After dilution, 25 μl of CAMHB was added to each well.
  • The bacterial inocula were prepared as follows. For each strain, one isolated colony was used to inoculate a volume of 5 ml of CAMHB. The cultures were incubated overnight (20 hours) at 35° C. in a shaking incubator. They were then diluted in sterile saline to a density equivalent to a 0.5 McFarland suspension (approx. 108 CFU/ml). The suspensions were further diluted in CAMHB to approximately 5×105 CFU/ml. A volume of 50 μl of the inoculum was added to each well. Positive and negative growth controls were included on each plate. The original inocula were determined by applying 10 μl of several 10-fold dilutions on TSA plates. Agar plates were incubated overnight at 35° C. and colony-forming units (CFU) counted. Microtiter plates were incubated for 20 hours at 35° C. and were read using a microtiterplate reader (Molecular Devices) at 650 nm and by visual observation using a microtiterplate reading mirror to determine the MIC.
  • Pharmaceutical Compositions
  • A compound of the present invention, a prodrug thereof or a physiologically acceptable salt of either the compound or its prodrug, can be administered as such to a patient or can be administered in pharmaceutical compositions in which the foregoing materials are mixed with suitable excipient(s). Techniques for formulation and administration of drugs may be found in Remington's Pharmacological Sciences, Mack Publishing Co., Easton, Pa., latest edition. The formulations and techniques discussed in Remington relate primarily to use with human patients; however, they may readily modified for use with non-human patients by techniques well-known to those skilled in the veterinary art.
  • Routes of Administration
  • As used herein, “administer” or “administration” refers to the delivery of a compound, salt or prodrug of the present invention or of a pharmaceutical composition containing a compound, salt or prodrug of this invention to an organism for the purpose of treating or preventing a microbial infection.
  • Suitable routes of administration may include, without limitation, oral, rectal, transmucosal, intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal, aural or intraocular. The preferred routes of administration are oral and parenteral.
  • Alternatively, one may administer the compound in a local rather than systemic manner, for example, by preparation as a salve that is applied directly to the infected area or by injection of the compound directly into infected tissue. In either case, a sustained release formulation may be used.
  • Composition/Formulation
  • Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., using a variety of well-known mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. The compositions may be formulated in conjunction with one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • For injection, including, without limitation, intravenous, intramusclular and subcutaneous injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, physiological saline buffer or polar solvents including, without limitation, N-methyl-2-pyrrolidone, 2-pyrrolidone, other pyrrolidones, N,N-dimethylacetamide, N,N-dimethylformamide, dimethylsulfoxide, acetone and glycerol formal. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well-known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, pastes, slurries, solutions, suspensions, concentrated solutions and suspensions for diluting in the drinking water of a patient, premixes for dilution in the feed of a patient, and the like, for oral ingestion by a patient. Pharmaceutical preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores. Useful excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, for example, maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydroxypropyl-methylcellulose, sodium carboxy-methylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.
  • Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Pharmaceutical compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers may be added in these formulations, also.
  • For administration by inhalation, the compounds of the present invention can conveniently be delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • The compounds may also be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Useful compositions include, without limitation, suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain adjuncts such as suspending, stabilizing and/or dispersing agents. Pharmaceutical compositions for parenteral administration include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
  • In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. A compound of this invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
  • Other delivery systems for relatively hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well-known examples of delivery vehicles or carriers for hydrophobic drugs. In addition, organic solvents such as dimethylsulfoxide may be used, although often at the risk of greater toxicity.
  • Additionally, the compounds may be delivered using a sustained-release system, such as semi-permeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the particular compound, additional stabilization strategies may be employed.
  • Pharmaceutical compositions useful herein also may comprise solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • Dosage
  • A therapeutically effective amount refers to an amount of compound effective to prevent, alleviate or ameliorate symptoms of a microbial infection. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the disclosure herein.
  • For any compound used in the methods of the invention, the therapeutically effective amount can be estimated initially from cell culture assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the MIC as determined in cell culture. Such information can then be used to more accurately determine dosages useful in patients.
  • Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. For example, the MIC and the LD50 for a particular compound can be determined by methods well-known in the art. The data obtained can be used to formulat a range of dosages useful in patients. The dosage, of course, may vary depending upon the dosage form and route of administration. The exact formulation, route of administration and dosage can be selected by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1). In general, however, the presently preferred dosage range for systemic delivery of a compound of this invention will be from about 1 to about 100 mg/Kg. The presently preferred dosage range for topical use will generally be from about 0.1 mg to about 1 gm.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the compound that are sufficient to maintain a concentration equal to the MIC or any other desired level. Such plasma levels are often referred to as minimum effective concentrations (MECs). The MEC will vary for each compound but can be estimated from in vitro data, e.g., the concentration necessary to achieve 80+% inhibition of a microbe, may be ascertained using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. HPLC assays or bioassays can be used to determine plasma concentrations.
  • Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
  • In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures known in the art may be employed to determine the correct dosage amount and interval.
  • The amount of a composition administered will, of course, be dependent on the patient being treated, the severity of the infection, the manner of administration, the judgment of the prescribing physician, etc.
  • Packaging
  • The compositions may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or of human or veterinary administration. Such notice, for example, may be of the labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
    • EXAMPLES
  • The following examples are provided to illustrate certain embodiments of this invention and are not intended, nor are they to be construed, to limit its scope in any manner whatsoever.
  • Starting materials were obtained from commercial suppliers and used without further purification unless otherwise noted. Chemical suppliers included Aldrich, Fluka, and Lancaster. Pd(PPh3)4 was obtained from Lancaster or Strem and immediately transferred into N2 flushed vials (between 10 and 100 mg each) in an N2 glove bag. The vials were wrapped in aluminum foil and stored in N2-flushed, zip-lock baggies at −20° C. PdCl2(dppf) was obtained from Aldrich and used from the bottle. Standard reagent grade solvents, which were not necessarily anhydrous, were used. Anhydrous solvents were purchased from chemical suppliers and used as is.
  • 1H NMR spectra were recorded on a 300 MHz Varian FT-NMR spectrometer and are reported in the format “chemical shift (multiplicity, integration, coupling constant).” Coupling constants are reported in Hz. Mass spectra were obtained on a Micromass Platform II single quadrupole mass spectrometer equipped with electrospray ionization (ESI).
  • The following three Suzuki cross-coupling methods were used:
  • Method A: the aryl boronic acid (0.167 mmol) and aryl bromide (0.334 mmol) were combined in a mixture of aqueous Na2CO3 (3 mL of a 10% (w/w) solution) and THF (5 mL). The mixture was purged briefly with N2. Pd(PPh3)4 (10 mol %, 0.0167 mmol) was added, the mixture purged with N2, and then refluxed for 16 hours. The reaction mixture was diluted with ethyl acetate (EtOAc), washed with a saturated brine solution, dried over anhydrous Na2SO4 and concentrated. The residue was then purified by chromatography.
  • Method B: the aryl boronic acid (0.301 mmol), the aryl bromide (0.602 mmol), and Cs2CO3 (0.903 mmol) were combined in THF (2.0 mL), DMF (2,0 mL), and H2O (0.5 mL) at room temperature. The mixture was purged with N2 for 5 min and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.0301 mmol) was added. The mixture was purged with N2 for 5 minutes and then stirred at 55° C. for 16 hours. The mixture was concentrated under vacuum, diluted with EtOAc and washed with brine. The EtOAc was dried over anhydrous Na2SO4 and concentrated. The residue was purified by chromatography.
  • Method C: the aryl boronic acid (0.934 mmol), the aryl bromide (2.34 mmol), and Cs2CO3 (2.80 mmol) were suspended in a mixture of toluene (4 mL), n-butanol (4 mL), and H2O (2 mL). The mixture was purged at room temperature with N2 after which Pd(PPh3)4 (0.280 mmol) was added. The mixture was purged with N2 for an additional 5 minutes and then heated to 75° C. After 12 hours, the mixture was cooled to room temperature and concentrated under vacuum. The residue was partitioned between H2O (75 mL) and EtOAc (75 mL). The EtOAc layer was washed with brine (2×50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The residue was purified by chromatography.
    • Example 1 Compound 3
  • Figure US20060014743A1-20060119-C00162
  • In 80 mL of methanol was dissolved 8.13 g (32.0 mmol) of chloramphenicol base as the N-acetate, prepared by literature methods (Rebstock, M. C., et al., supra, Crooks H. M. et al., supra; Evans, D. D.; Morris, D. S. et al., supra). After purging with N2, Pd/C was added and the mixture was stirred under H2(1 atm) for 16 hours. The Pd/C was then removed by filtration through Celite. The solution was concentrated under vacuum and the residue purified by silica gel chromatography, eluting with 15% MeOH in CH2Cl2 to give 3 (7.13 g, 31.7 mmol). 1H NMR (300 MHz, CD3OD): δ 1.92 (s, 3H), 3.40 (dd, 1H, J=11.1, 6.0), 3.61 (dd, 1H, J=1.1, 5.7), 4.01 (m, 1H), 4.73 (d, 1H, J=5.4), 6.69 (d, 2H, J=8.4), 7.11 (d,2H, J=8.4).
    • Example 2 Compound 4
  • Figure US20060014743A1-20060119-C00163
  • An aqueous solution of NaNO2 (1.27 g, 18.5 mmol, 50 mL H2O) was added dropwise to a solution of 3 (3.76 g, 16.8 mmol) in 35 mL of 48% aqueous HBr at 0° C. After addition was completed, the mixture was stirred for 30 min at 0° C. The mixture was then added dropwise to a solution of CuBr (2.65 g, 18.45 mmol) in 15 mL 48% aqueous HBr. The mixture was warmed to room temperature and stirred for an additional 16 hours. The reaction mixture was neutralized with 3 M aqueous NaOH, filtered through a pad of Celite, and extracted with EtOAc (3×100 mL). The combined organic fractions were dried over anhydrous Na2SO4 and concentrated under vacuum to give 1.2 g (4.1 mmol) of crude product that was used without further purification. 1H NMR (300 MHz, CD3OD): δ 1.87 (s, 3H), 3.48 (dd, 1H, J=11.0, 5.9), 3.69 (dd, 1H, J=11.0, 6.5), 4.01 (m, 1H), 4.91 (d, 1H, J=3.6), 7.30 (d, 2H, J=8.3), 7.45 (d, 2H, J=8.3).
    • Example 3 Compound 6
  • Figure US20060014743A1-20060119-C00164
  • 4-Bromobenzaldehyde (100 g, 0.540 mol) was dissolved in ethanol (EtOH) in a 2 L round-bottom flask. With rapid stirring, glycine (0.5 molar equivalents, 20.3 g, 0.270 mol) and then, in one portion, KOH (30.3 g, 0.540 mol) were added. It is essential to add the KOH all at once. Thus, an ice bath should be used when performing the reaction on a larger scale to control the exotherm. After addition of the KOH, the turbid suspension became yellow and homogeneous. After about 15 minutes, a thick white precipitate began to form. The mixture was stirred for 12 hours at room temperature under N2. Enough 2 N aqueous HCl was added (˜400 mL) to make the solution red to pH paper. The mixture was then stirred at approximately 60° C. until it again become a homogeneous yellow solution. The EtOH was removed under vacuum to give an aqueous suspension of white precipitate. The precipitate was filtered and the remaining aqueous solution washed three times with EtOAc. The aqueous solution was then basified to about pH 9 with concentrated aqueous NH3 and excess ammonia was removed under vacuum. As the NH3 was removed, the product, 6, began to precipitate. Evaporation continued to one-quarter the volume of solution where precipitation was first observed. The product was then collected on a vacuum filter and dried under vacuum to a constant weight (51.3 g). If NMR indicates the presence of the undesired trans stereoisomer, it can be removed by recrystallization from H2O/EtOH). 1H NMR (300 MHz, CD3OD): δ 3.64 (d, 1H, J=3.6), 5.25 (d, 1H, J=3.6), 7.41 (d, 2H, J=8.4), 7.53 (d, 2H, J=8.4).
    • Example 4 Compound 7
  • Figure US20060014743A1-20060119-C00165
  • Compound 6 (32.60 g, 12.53 mmol) was dissolved in 10% aqueous K2CO3 (10% w/v; 500 mL). Di-tert-butyl dicarbonate (34.2 g, 157 mmol) was dissolved in 1,4-dioxane (500 mL) and added to the aqueous solution, after which the mixture was stirred at room temperature for 72 hours. The mixture was concentrated under vacuum and taken up in 100 mL 1 N aqueous NaOH and washed with Et2O (2×100 mL). The aqueous layer was acidified with 1 N aqueous HCl and the product extracted into EtOAc (3×200 mL). The combined EtOAc extracts were dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The product (26.7 g, 74.0 mmol) was isolated and used without further purification. 1H NMR (300 MHz, CD3OD): δ 1.32 (s, 9H), 4.37 (d, 1H, J=2.7), 5.23 (d, 1H, J=2.7), 7.32 (d, 2H, 8.4), 7.46 (d, 2H, J=8.4).
    • Example 5 Compound 8
  • Figure US20060014743A1-20060119-C00166
  • Compound 7 (5.29 g, 14.7 mmol) and N-hydroxysuccinimide (1.69 g, 14.7 mol) were dissolved in EtOAc (200 mL) and the mixture cooled to 0° C. N,N′-dicyclohexyl-carbodiimide (3.04 g, 14.7 mmol) was added and the mixture stirred for 30 minutes, warmed to room temperature and stirred for 30 additional minutes. It was then cooled to 0° C. and filtered to remove the precipitated N,N′-dicyclohexylurea byproduct. The filtrate was concentrated under vacuum and the residue dissolved in THF (100 mL). The solution was cooled to 0° C., NaBH4 (5.6 g, 150 mmol) added, and the mixture stirred for two minutes. Water was then added to the mixture dropwise until bubbling ceased, then a volume of water equal to the volume of THF was added over 30 minutes, after which the mixture was warmed to room temperature and stirred for 5 hours. The dioxane was removed under vacuum and EtOAc (200 mL) was added, followed by gradual acidification of the aqueous layer with 1 N aqueous HCl. The EtOAc layer was washed with brine and dried over anhydrous Na2SO4. Filtration followed by concentration under vacuum gave 4.31 g (12.4 mmol) of 8, which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 1.32 (s, 9H), 3.46-3.51 (m, 1H), 3.63-3.73 (m, 2H), 4.88 (br s, 1H), 7.29 (d, 2H, J=8.3), 7.45 (d, 2H, J=8.3).
    • Example 6 Compound 9 (From 4)
  • Figure US20060014743A1-20060119-C00167
  • Compound 4 (1.0 g, 3.5 mmol) was dissolved in 10% aqueous H2SO4 (10% v/v, 15 mL total) and the solution refluxed for 10 h. The reaction mixture was basified with 3 M aqueous NaOH and extracted with EtOAc (3×50 mL). The combined EtOAc fractions were dried over anhydrous Na2SO4 and concentrated under vacuum to give 710 mg (2.9 mmol) of 4, which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 2.80-2.90 (br m, 1H), 3.30-3.39 (br m, 1H), 3.40-3.50 (br m,1H), 4.52-4.58 (m, 1H), 7.30 (d, 2H, J=8.1), 7.49 (d, 2H, J=8.1).
    • Example 7 Compound 9 (from 8)
  • Figure US20060014743A1-20060119-C00168
  • Compound 8 (4.31 g, 12.4 mmol) was dissolved in trifluoroacetic acid (TFA, 40 mL). The mixture was stirred for 3 hours at room temperature and concentrated under vacuum. The TFA salt was partitioned between 50 mL of 2 N aqueous NaOH and an equal volume of EtOAc. The layers were separated and the aqueous layer was washed with EtOAc (50 mL). The combined EtOAc fractions were washed with brine, dried over anhydrous Na2SO4 and concentrated under vacuum to give a waxy solid (2.72 g, 11.1 mmol), which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 2.83-2.90 (m, 1H), 3.30-3.35 (m, 1H), 3.46 (dd, 1H J=10.8, 4.8), 4.56 (d, 1H, J=6.6), 7.29 (d, 2H, J=8.6), 7.49 (d, 2H, J=8.6).
    • Example 8 Compound 10
  • Figure US20060014743A1-20060119-C00169
  • Compound 9 (710 mg, 2.89 mmol), ethyl benzimidate hydrochloride (533 mg, 2.89 mmol) and triethylamine (Et3N, 0.40 mL, 2.89 mmol) were combined in 25 mL 1,2-dichloroethane. The mixture was refluxed with stirring under N2 for 16 hours at which time TLC indicated one major product. After cooling to room temperature, the mixture was diluted with EtOAc, washed twice with saturated aqueous NH4Cl, twice with saturated aqueous NaHCO3 and then dried over anhydrous Na2SO4. The solution was filtered and the EtOAc removed under vacuum to give 885 mg (2.66 mmol) of 10, which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 3.74-3.89 (m, 2H), 4.13-4.18 (m, 1H), 5.59 (d, 1H, J=6.6), 7.30 (d, 2H, J=8.4), 7.46-7.57 (m, 5H), 7.99-8.02 (m, 2H).
    • Example 9 Compound 11
  • Figure US20060014743A1-20060119-C00170
  • Compound 10 (885 mg, 2.66 mmol) was suspended in CH2Cl2 (15 mL) and cooled to −78° C. Diethylaminosulfur trifluoride (DAST, 0.53 mL, 4.00 mmol) was added by syringe, the mixture warmed over 1 hour to room temperature and then stirred for 16 hours under N2. Excess DAST was quenched by slow addition of H2O after which the mixture was diluted with additional CH2Cl2. The organic layer was washed with H2O and saturated aqueous NaHCO3, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue (950 mg) was chromatographed on silica gel, eluting with 15:85 EtOAc/hexanes to give 11 as an oil (420 mg, 1.25 mmol). 1H NMR (300 MHz, CDCl3): δ 4.23-4.35 (m, 1H), 4.45-4.75 (m, 2H), 5.43 (d, 1H, J=6.9), 7.17(d, 2H, 8.3), 7.36-7.47 (m, 5H), 7.96 (d, 2H, J=8.3).
    • Example 10 Compound 12
  • Figure US20060014743A1-20060119-C00171
  • Compound 11 (807 mg, 2.41 mmol, enantiopure from chloramphenicol or racemic from (±)-threo-p-bromophenylserine), was dissolved in anhydrous THF (10 mL) in a flame-dried round bottom flask and cooled to −78° C. n-BuLi (1.6 M in hexanes, 3.02 mL, 4.83 mmol) was added with vigorous stirring. After 10 minutes, trimethyl borate (0.55 mL, 4.83 mmol) was added, the mixture warmed to room temperature over 1 hour and then stirred for 6 hours. The mixture was quenched with 1 N aqueous HCl and extracted three times with EtOAc. The combined EtOAc fractions were washed three times with brine and dried over anhydrous Na2SO4. The EtOAc was removed under vacuum to give 805 mg of material, which was purified by flash column chromatography, eluting initially with 1:1 hexanes/EtOAc to remove impurities followed by elution with 1:9 MeOH/CH2Cl2 to obtain the product as an oil (285 mg, 0.953 mmol). 1H NMR (300 MHz, CD3OD): δ 4.29-4.39 (m, 1H), 4.69 (dd, 2H, J=47.1, 4.2), 5.63 (d, 1H, J=6.6), 7.37 (d, 2H, J=8.1), 7.47-7.52 (m, 2H), 7.56-7.62 (m, 1H), 7.67 (d, 1H, J=7.5) 7.74-7.82 (m, 1H), 8.01 (d, 2H, J=7.2).). LRMS (ESI−) m/z: 298.0 (M−H+C16H14BFNO3 requires 298.1).
    • Example 11 Compound 13
  • Figure US20060014743A1-20060119-C00172
  • Compound 6 (20.6 g, 0.079 mol) was suspended in 400 mL of anhydrous MeOH. The mixture was stirred rapidly and cooled in an ice bath to 0° C. Anhydrous HCl gas was slowly bubbled in. After 10 minutes, all solids had dissolved. Acidification was continued for 10 minutes after the mixture became homogeneous, at which point the MeOH turned pH paper very red. The apparatus was fitted with a drying tube and the reaction mixture was refluxed for 8 hours followed by stirring at room temperature for 12 hours. The mixture was concentrated under vacuum and then suspended in a mixture of 300 mL of EtOAC and 100 mL of water. With rapid stirring, 3 N NaOH was added very slowly until the suspended material dissolved. Addition of base was continued until a pH of 10 was attained. The layers were separated and the EtOAc fraction was washed with brine (2×) and dried over anhydrous Na2SO4. Concentration under vacuum gave 13 as a white powder (15.3 g), which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 3.59 (d, 1H, J=4.5), 3.66 (s, 3H), 4.92 (d, 1H, J=4.5), 7.29 (d, 2H, J=8.3), 7.49 (d, 2H, J=8.3).
    • Example 12 Compound 14
  • Figure US20060014743A1-20060119-C00173
  • 1,1′-Carbonyldiimidazole (23.6 g, 0.146 mol) was dissolved in 250 mL of anhydrous 1,2-dichloroethane at room temperature followed by addition of triethylamine (Et3N, 12.2 g, 16.8 mL). In a separate flask, 13 (33.26 g, 0.121 mol) was dissolved in 125 mL of anhydrous tetrahydrofuran (THF) and an equivalent of triethylamine. The THF solution was diluted with 125 mL of 1,2-dichloroethane and then added, under N2, over 2 hours to the 1,1′-carbonyldiimidazole solution. After addition was complete, the mixture was stirred for 2 hours under N2 at room temperature. The reaction mixture was concentrated under vacuum and the residue diluted with 300 mL of EtOAc, which was washed with 5×200 mL of 2 N HCl, 3×300 mL of saturated NaHCO3, and 2×200 mL of brine. The EtOAc layer was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 34.27 g of 14, 80-90% pure by 1H NMR. Compound 14 was used without further purification. 1H NMR(300 MHz, CD3OD): δ 3.83 (s, 3H), 4.34 (d, 1H, J=5.0), 5.65 (d, 1H, J=5.0), 7.36 (d, 2H, J=8.7), 7.60 (d, 2H, J=8.7).
    • Example 13 Compound 15
  • Figure US20060014743A1-20060119-C00174
  • Compound 14 (55.3 g, 0.184 mmol) was dissolved in 375 mL MeOH. The solution was cooled to 0° C. and NaBH4 (2 equivalents, 13.9 g, 0.369 mol) was added in portions, care being taken to not let the temperature exceed 20° C. After the last portion was added, cooling was ceased and the mixture stirred for 2 hours. Glacial acetic acid was added slowly until a pH of 7 was achieved. The mixture was filtered through Celite and concentrated under vacuum. The residue was partitioned between EtOAc (375 mL) and 2 N HCl (500 mL). The organic layer was washed with 2 N HCl (2×300 mL), saturated aqueous NaHCO3 (2×250 mL) and brine (250 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The product was crystallized from hexanes/EtOAc to give 26.3 g of 15. 1H NMR(300 MHz, CD3OD): δ 3.64-3.72 (m, 3H), 5.38 (d, 1H, J=5.1), 7.32 (d, 2H, J=8.6), 7.57 (d, 2H, J=8.6).
    • Example 14 Compound 16
  • Figure US20060014743A1-20060119-C00175
  • Compound 15 (7.57 g, 0.0278 mol) was suspended in 275 mL of CH2Cl2. Under N2 and with rapid stirring, the biphasic mixture was cooled to −78° C. in a dry ice/acetone bath. DAST (5.51 mL, 6.72 g, 0.0417 mol) was added dropwise by syringe over 2-3 minutes. After 30 minutes the mixture was transferred to an ice water bath and stirred for 30 minutes, during which time the solids dissolved. Another 1 mL of DAST was added to ensure completion of the reaction. The mixture was stirred for 20 minutes at 0° C. and then warmed to room temperature. The mixture was stirred at room temperature for 20 minutes and then cooled to 0° C. Excess DAST was quenched by dropwise addition of saturated aqueous NaHCO3 over 30 minutes with very rapid stirring. After bubbling ceased, the aqueous layer was slightly basic (7<pH<9). The CH2Cl2 was diluted with enough EtOAc (˜600 mL) to bring the organic layer to the top during aqueous extraction. The organic layer was washed with saturated aqueous NaHCO3 (1×300 mL), 1 N HCl (2×200 mL), saturated aqueous NaHCO3 (3×200 mL) and brine (1×150 mL) and dried over anhydrous Na2SO4. After filtration, the mixture was concentrated under vacuum to give 8.13 g of brown oil. 1H NMR(300 MHz, CD3OD): δ 3.87-3.98 (dm, 1H, J=20 (F—CHN)), 4.54 (dd, 2H, J=46.7 (CH2—F), 4.2), 5.42 (d, 1H, J=5.1), 7.34 (d, 2H, J=8.4), 7.59 (d, 2H, J=8.4).
    • Example 15 Compound 17
  • Figure US20060014743A1-20060119-C00176
  • Compound 16 (8.13 g or 0.0297) was dissolved in 200 mL of CH3CN. Boc2O (9.71 g, 1.5 equivalents, 0.0445 mol) and DMAP (362 mg, 0.00297 mol, 0.1 equivalent) were then added. The mixture was stirred for 2 hours at room temperature under N2. Concentration of the mixture under vacuum was followed by partitioning between 200 mL of EtOAc and 200 mL of 1 N HCl. The EtOAc layer was washed with 2 N HCl (3×100 mL), saturated aqueous NaHCO3 (2×100 mL) and brine. The EtOAc layer was filtered, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue was recrystallized twice from hexanes/EtOAc. 1H NMR (300 MHz, CD3OD): δ 1.53 (s, 9H), 4.29-4.40 (dm, 1H, J=24.6), 4.63-4.98 (m, 2H), 5.53 (d, 1H, J=4.2), 7.34 (d, 2H, J=8.4), 7.61, (d, 2H, J=8.4).
    • Example 16 Compound 18
  • Figure US20060014743A1-20060119-C00177
  • Compound 17 (0.050 g, 0.134 mmol) was suspended in 5 mL of CH3OH. Cs2CO3 (8.7 mg, 20 mol %, 0.0267 mmol) was added with rapid stirring at room temperature. The solids dissolved in about 10 minutes after which stirring was continued for 10 minutes, at which time TLC (3:1 hexanes/EtOAc) indicated that the reaction was complete. The reaction mixture was concentrated under vacuum and the residue partitioned between 20 mL of EtOAc and 10 mL of H2O. The H2O layer was acidified slightly with 1N aqueous HCl, the mixture vigorously shaken and the layers separated. The EtOAc layer was washed with saturated aqueous NaHCO3 (1×20 mL) and brine (1×20 mL). The EtOAc was dried over anhydrous Na2SO4 and concentrated under vacuum to give 43.4 mg (0.124 mmol) of 18 as a white foam. 1H NMR (300 MHz, CD3OD): δ 1.33 (s, 9H), 3.90-4.57 (m, 4H), 7.29 (d, 2H, J=8.1), 7.46 (d, 2H, J=8.1)
    • Example 17 Compound 22
  • Figure US20060014743A1-20060119-C00178
  • Compound 18 (0.740 g, 2.13 mmol) was stirred in 10 mL TFA/H2O (9/1, v/v) at room temperature for one hour. The mixture was concentrated under vacuum and partitioned between 30 mL of EtOAc and 30 mL of 1N aqueous NaOH. The mixture was shaken vigorously and the layers allowed to separate. The organic layer was washed with brine (2×), dried over anhydrous Na2SO4 and concentrated under vacuum to give 0.484 g (1.95 mmol, 92%) of product, which was dissolved in 20 mL of CH2Cl2. To this was added 1 mL of Et3N and 1 mL of difluoroacetyl chloride, prepared according to literature procedure (Yu, K.-L., et al., J. Med. Chem., 1996, 39, 2411-2421.). After 1 hour, the mixture was concentrated under vacuum. The residue was placed in 10 mL of a 1:8:1 (v/v/v) solution of Et3N/MeOH/H2O and stirred for one hour at room temperature to cleave any difluoroacetyl groups on the benzylic oxygen. The mixture was then concentrated under vacuum, and partitioned between EtOAc (50 mL) and 1 N HCl (50 ml). The EtOAc layer was washed twice with 20 mL of 1 N HCl, twice with 20 mL saturated aqueous NaHCO3 and twice with 20 mL brine. The EtOAc was then dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. Compound 22 (584 mg, 1.79 mmol) was used without further purification. 1H NMR (300 MHz, CD3OD): δ 4.25-4.67 (m, 3H), 4.90 (d, 1H, J=3.9), 5.98 (t, 1H, J 53.9), 7.30 (d, 2H, J=8.6), 7.48 (d, 2H, J=8.6).
    • Example 18 Compound 19
  • Figure US20060014743A1-20060119-C00179
  • Compound 18 (1.03 g, 2.94 mmol) was dissolved in CH2Cl2 (30 mL) in a 50 mL round-bottom flask. 2-Methoxypropene (339 μL, 3.54 mmol) was added by syringe, followed by a single crystal of ρ-toluenesulfonic acid (ρ-TsOH) hydrate. After about 1 minute, the mixture turned yellow. TLC (4:1 hexanes/EtOAc) showed some 18 to still be present. An additional 5 drops of 2-methoxypropene were added followed two minutes later by another 5 drops, a which time TLC indicated the reaction was complete. The CH2Cl2 was removed under vacuum and the residue partitioned between EtOAc (75 mL) and saturated aqueous NaHCO3 (50 mL). The EtOAc layer was washed twice with 50 mL NaHCO3 and twice with brine. The EtOAc layer was dried over anhydrous Na2SO4, filtered and evaporated to give a yellow oil (1.08 g, 2.78 mmol) that solidified to a waxy solid, which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 1.49 (s, 9H), 1.55 (s, 3H), 1.67 (s, 3H), 3.70-3.85 (m, 1H), 4.34-4.53 (m, 2H), 5.08, (d, 1H, J=7.5), 7.37 (d, 2H, J=8.6), 7.54 (d, 2H, J=8.6).
    • Example 19 Compound 23
  • Figure US20060014743A1-20060119-C00180
  • Compound 19 (309 mg, 0.796 mmol) was placed in an oven-dried 50 mL round-bottom flask equipped with a magnetic stir bar. The flask was immediately capped with a rubber septum and flushed with dry N2. Anhydrous THF (15 mL) was added by syringe and a long cannula was used to flush the solvent with N2 for 10 minutes. The mixture was then cooled to −78° C. With vigorous stirring, n-BuLi (850 μL, 0.995 mmol) was added dropwise by syringe over 3 minutes to give a clear orange solution. After 20 minutes, B(OMe)3 (158 μL, 1.39 mmol), which had been stored over 4 Å activated molecular sieves for at least 48 hours, was added dropwise over one minute using an oven-dried, gas-tight syringe. The mixture was warmed to room temperature and stirred under N2for 16 hours. Approximately 20 mL of saturated aqueous NH4Cl was added with vigorous stirring, which resulted in a white precipitate dispersed in the two liquid phases. The mixture was stirred for an additional 90 minutes and then diluted with EtOAc and H2O until all the precipitate dissolved. The organic layer was separated, washed with brine and dried over anhydrous Na2SO4. After filtration, the EtOAc was removed under vacuum to give 328 mg of yellow oil. The product was purified by silica gel chromatography to give 23 (163 mg). 1H NMR (300 MHz, CD3OD): δ 1.49 (s, 9H), 1.56 (s, 3H), 1.67 (s, 3H), 3.74-3.88 (m, 1H), 4.33-1.52 (m, 2H), 5.10 (d, 1H, J=7.5), 7.43 (d, 2H, J=8.1), 7.64 (d, 2H, J=8.1). LRMS (ESI−) m/z: 352.2 (M−H+ C17H24BFNO5 requires 352.7).
    • Example 20 Compound 28
  • Figure US20060014743A1-20060119-C00181
  • This is an example of Suzuki coupling method A. Compound 11 (47 mg, 0.14 mmol) and pyridine-3-boronic acid (21 mg, 0.17 mmol) were dissolved in 5.0 mL of THF. Pd(PPh3)4 (11 mg, 0.0098 mmol) and 3.0 mL of 10% (w/v) aqueous Na2CO3 were added. The reaction mixture was refluxed for 16 hours, cooled, diluted with EtOAc and washed twice with 10% (w/v) aqueous Na2CO3 and twice with brine. The EtOAc layer was then dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. Silica gel chromatography (eluting with 1:1 hexanes/EtOAc) gave 47 mg (0.14 mmol) of 26. Intermediate 26 was heated to 105° C. in a sealed tube with 6M aqueous HCl and held at that temperature for 16 hours. The mixture was cooled to room temperature and basified to pH 10 with 3 N NaOH. The product was extracted into EtOAc, which was dried over Na2SO4, filtered, and concentrated under vacuum to give 42 mg of the deprotected free amine, contaminated with the expected benzoic acid-related by-product arising from cleavage of the protecting group. The crude residue was dichloroacetylated as in the synthesis of 29. Silica gel chromatography, eluting with 7.5% MeOH in CH2Cl2, gave 10 mg of product. 1H NMR (300 MHz, CD3OD): δ 4.31-4.74(m, 3H), 5.02 (d, 1H, J=3.6), 6.27 (s, 1H), 7.49-7.56 (m, 3H), 7.64 (d, 2H, J=8.4), 8.09 (ddd, 1H, J=8.0, 2.3, 1.5), 8.50 (br d, 1H, J=3.9), 8.78 (br s, 1H). LRMS (ESI+) m/z: 356.9 (calc. for M+H+: C16H16Cl2FN2O2 357.0).
    • Example 21 Compound 27
  • Figure US20060014743A1-20060119-C00182
  • Boronic acid 12 (43 mg, 0.144 mmol), imidazole (15 mg, 0.215 mmol) and 4 Å powdered molecular sieves (110 mg) were combined in CH2Cl2 (4.0 mL) and pyridine (23 μL). With rapid stirring, Cu(OAc)2 (26 mg, 0.144 mmol) was added and the mixture stirred, exposed to air, for 40 hours at room temperature. The mixture was quenched with 3 mL of 2 M NH3 in MeOH. The mixture was filtered through Celite and concentrated under vacuum. The product was purified by flash column chromatography (19:1 CH2Cl2/MeOH). Although 1H NMR indicated that a significant side-product had eluted with the desired product, the mixture was used without further purification. LRMS (ESI+) m/z: 321.9 (calc. for M+H+ C19H17FN3O 322.1).
    • Example 22 Compound 29
  • Figure US20060014743A1-20060119-C00183
  • Compound 27 (27 mg, 0.084 mmol) was heated with 6 N HCl (3.0 mL) to 100° C. in a sealed tube and held for 16 hours. The mixture was cooled to room temperature, basified with 3 N aqueous NaOH and extracted three times with EtOAc. The combined EtOAc fractions were dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 9 mg of residue. LRMS (ESI+) m/z: 236.1 (Calc. for M+H+ C12H15FN3O 236.1).
  • The residue was refluxed in MeOH (5.0 mL) containing Et3N (26 μL 0.189 mmol) and methyl dichloroacetate (13 μL, 0.126 mmol) for 3 hours. The mixture was concentrated under vacuum and purified by silica gel chromatography (7.5% MeOH in CH2Cl2) to give 29 (6.0 mg, 0.017 mmol). 1H NMR (300 MHz, CD3OD): δ 4.33-4.75 (m, 3H), 5.03 (d, 1H, J=3.3), 6.26 (s, 1H), 7.13 (s, 1H), 7.51-7.58 (m, 5H), 8.10 (s, 1H). LRMS (ESI+) m/z: 345.8 (calc. for M+H+ C14H15Cl2FN3O2 346.0).
    • Example 23 Compound 34
  • Figure US20060014743A1-20060119-C00184
  • Compound 32 was prepared by the procedure of Pines, et al., supra. In a 250-mL round-bottom flask was placed 1,1′-carbonyldiimidazole (CDI, 5.06 g, 31.2 mmol) and Et3N (2.17 mL, 15.6 mmol) in 1,2-dichloroethane (50 mL). Compound 32 (4.00 g, 15.6 mmol) was added to a beaker containing 1,2-dichloroethane (50 mL). Et3N (4.34 mL, 31.2 mmol) was added to the beaker upon which a thick suspension formed. Additional 1,2-dichloroethane (20 mL) and THF (50 mL) were added to thin the suspension. The mixture was added portion-wise to the CDI suspension over 30 min. The mixture, which became mostly homogenous and turned yellow was stirred for 12 hours. The solvent was removed under vacuum and the residue was partitioned between 2 N aqueous HCl and EtOAc. The EtOAc layer was washed with 2 N HCl (2×45 mL), saturated aqueous NaHCO3 (2×30 mL) and brine. It was dried over anhydrous Na2SO4, filtered, and evaporated to give 3.27 g of 33 as a fluffy yellow solid, which was used without further purification.
  • Compound 33 (1.00 g,4.06 mmol) was dissolved in MeOH (50 mL) and cooled to 0° C. in an ice bath. Over 5 minutes, NaBH4 (308 mg, 8.13 mmol) was added portion-wise. After bubbling ceased, TLC (5% MeOH in CH2Cl2) indicated that starting material remained so 100 mg additional NaBH4 was added. After bubbling ceased, the mixture was quenched with glacial HOAc until a pH of approximately 7 was achieved. The mixture was concentrated under vacuum and partitioned between EtOAc and 1 N HCl. The EtOAc layer was washed with saturated aqueous NacHCO3 (2×40 mL) and brine (40 mL) and dried over anhydrous Na2SO4. The product was isolated by silica gel chromatography (2% to 3% to 4% to 10% MeOH in CH2Cl2) to give 128 mg of 34 as an oil. Additional product was obtained by evaporation of the aqueous iayer followed by trituration with hot EtOAc (153 mg, 281 mg total). 1H NMR (300 MHz, CD3OD): δ 3.69 (br s, 3H), 5.50 (br s, 1H), 7.58 (d, 2H, J=7.8), 7.79 (d, 2H, J=7.8).
    • Example 24 Compound 35
  • Figure US20060014743A1-20060119-C00185
  • Fluorination was performed using DAST as in the synthesis of compound 11. 1H NMR (300 MHz, CD3OD): δ 3.89-3.97 (m, 1H), 4.49-4.66 (m, 2 H), 5.55 (d, 1H, J=4.8), 7.59 (d, 2H, J=8.1), 7.80 (d, 2H, J=8.4).
    • Example 25 Compound 38
  • Figure US20060014743A1-20060119-C00186
  • Compound 36 (2.12 g), was prepared by the procedure of von Strandtmann, supra. It was heated with 10% aqueous H2SO4 to 100° C. in a sealed tube and held for 4 hours. After cooling to room temperature, the mixture was basified with 1 M NaOH and extracted three times with n-butanol. The n-butanol fractions were combined and dried over anhydrous Na2SO4. The solvent was evaporated to give 1.61 g of 37.
  • Compound 37 (1.61 g, 7.70 mmol) was dissolved in 1,2-dichloroethane (100 mL), along with ethyl benzimidate hydrochloride (1.42 g, 7.70 mmol), and Et3N (1.06 mL, 7.70 mmol). The mixture was refluxed for 12 hours, cooled to room temperature and diluted with EtOAc. The solution was washed with saturated aqueous NH4Cl (3×) and saturated NaHCO3 (1×) and dried over anhydrous Na2SO4. The product precipitated from the EtOAc on cooling and addition of several drops of hexanes to give 0.62 g of 38 (2.1 mmol). 1H NMR (300 MHz, CD3OD): δ 2.60 (s, 3H), 3.79 (dd, 1H, J=11.3, 5.9), 3.89 (dd, 1H, J=11.3, 4.1), 4.14-4.20 (m, 1H), 5.70 (d, 1H, 6.3), 7.47-7.61 (m, 5H), 8.01-8.05 (m, 4H).
    • Example 26 Compound 39
  • Figure US20060014743A1-20060119-C00187
  • Compound 38 (0.62 g, 2.1 mmol) was suspended in CH2Cl2 (15 mL) and cooled to −78° C. DAST (0.42 mL, 3.1 mmol) was added by syringe and the solution stirred overnight, during which time it was allowed to come to room temperature as the cold bath warmed. The solvent was removed under vacuum and the product isolated by silica gel chromatography (1:4 EtOAc/hexanes) to give 0.17 g of 39. 1H NMR (300 MHz, CD3OD): δ 2.60 (s, 3H), 4.30-4.40 (m, 1H), 4.63-4.67 (m, 1H), 4.79-4.81 (m, 1H), 5.74 (d, 1H, 6.9), 7.48-7.63 (m, 5H), 8.01-8.07 (m, 4H).
    • Example 27 Compound 40
  • Figure US20060014743A1-20060119-C00188
  • Compound 39 (0.17 g, 0.58 mmol) was suspended in 6 N aqueous HCl (5 mL) in a sealed tube. The mixture was heated to 100° C. and held for 12 hours. After cooling to room temperature, the mixture was basified with 3 N NaOH and the product extracted into CH2Cl2 (3×). The combined CH2Cl2 fractions were dried over anhydrous Na2SO4, filtered and concentrated to give 40 (0.113 g, 0.541 mmol). 1H NMR (300 MHz, CD3OD): δ 2.60 (s, 3H), 3.04-3.15 (m, 1H), 4.09-4.48 (m, 3H), 4.71 (d, 1H, J=6.0), 7.52 (d, 2H, J=8.1), 7.90 (d, 2H, J=8.1).
    • Example 28 Compound 41
  • Figure US20060014743A1-20060119-C00189
  • Compound 40 was dichloroacetylated to give 41 in the same manner that 27 was converted to 29. 1H NMR (300 MHz, CD3OD): δ 2.57 (s, 3H), 4.31-4.78 (m, 3H,), 5.03 (d, 1H, J=3.3), 6.23 (s, 1H), 7.53 (d, 2H, J=8.6), 7.95 (d, 2H, J=8.6).
    • Example 29 Compound 43
  • Figure US20060014743A1-20060119-C00190
  • Compound 35 (100 mg, 0.454 mmol) was dissolved in 3 mL of EtOH and transferred to a 25 mL round-bottom flask. Hydroxylamine hydrochloride (38 mg, 0.545 mmol) was added followed by Et3N (127 μL, 0.909 mmol). The mixture was stirred at reflux for 3 hours, at which point TLC indicated complete consumption of starting material. The mixture was concentrated under vacuum to 232 mg of yellow oil, which was used without further purification. A portion of the oil (115 mg) was dissolved in 10 mL of triethylorthoformate. The mixture was stirred at 120° C. under N2 for 2 hours and then at room temperature for 48 hours. TLC (10% MeOH in CH2Cl2) a major new spot. The triethyl orthoformate was removed under vacuum and the residue partitioned between EtOAc and 1 N aqueous NaOH. The organic layer was washed with 1 N aqueous NaOH (2×) and brine (2×). The EtOAc layer was dried over anhydrous Na2SO4, filtered, and evaporated, to give 84 mg of oil. The product was purified by chromatotron (1 mm silica plate, 60:40 to 50:50 to 40:60 hexanes/EtOAc). Another purification by chromatotron (2% MeOH in CH2Cl2) gave 43 (20 mg) as a white solid. 1H NMR (300 MHz, CD3OD): δ 3.93-4.04 (m, 1H), 4.49-4.67 (m, 2 H), 5.53 (d, 1H, J=5.1), 7.59 (d, 2H, J=8.3), 8.17 (d, 2H, J=8.3), 9.28 (s, 1H).
    • Example 30 Compound 45
  • Figure US20060014743A1-20060119-C00191
  • Compound 43 (20 mg, 0.076 mmol) was dissolved in CH3CN (2 mL). Boc2O (25 mg, 0.114 mmol) was added followed by a single crystal of DMAP (approximately 1 mg, 0.008 mmol). After 2 hours, TLC (1:1 hexanes/EtOAc) indicated that the reaction was complete. The CH3CN was removed under vacuum and the resulting white solid dissolved in EtOAc, which was washed with 1 N aqueous HCl (2×), followed by NaHCO3 (2×) then brine. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 44 as a white solid (28 mg).
  • Compound 44 (0.026 mg, 0.072 mmol) was dissolved in MeOH (2 mL) and Cs2CO3 (5 mg, 0.014 mmol) was added in a single portion. After 1 hour, TLC (1:1 hexanes/EtOAc) showed a single product. The solvent was removed under vacuum, EtOAc added and the mixture stirred rapidly at room temperature. Then, H2O was added, followed by 0.5 M HCl dropwise until all solids dissolved. The organic phase was washed with 0.5 N HCl, followed by saturated aqueous NaHCO3 (2×) and brine. The organic layer was then dried over anhydrous Na2SO4, filtered and concentrated to give a yellow oil, which was purified by chromatotron (1 mm silica plate, 4:1 hexanes/EtOAc to 1:1 hexanes/EtOAc to give 45 (13 mg, 0.039 mmol). 1H NMR (300 MHz, CD3OD): δ 1.31 (s, 9H), 4.01-4.63 (m, 3 H), 4.94 (d, 1H, J=2.7), 7.55 (d, 2H, J=8.4), 8.05 (d, 2H, J=8.4), 9.24 (s, 1H).
    • Example 31 Compound 47
  • Figure US20060014743A1-20060119-C00192
  • Compound 45 was dissolved in 2.5 mL of 9:1 TFA/H2O in a 10 mL flask. The mixture was stirred at room temperature for 30 minutes, at which time TLC indicated completion of the reaction. The mixture was concentrated under vacuum and partitioned with rapid stirring between 1 N aqueous NaOH and EtOAc. The EtOAc layer was washed with brine (1×), dried over anhydrous Na2SO4, filtered and evaporated to give 11 mg of 46 as an oil.
  • To 6 mg (0.025 mmol) of 46 in a 10 mL round bottom flask was added MeOH (2 mL), followed by Et3N (3.5 μL, 0.025 mmol) and methyl dichloroacetate (13.1 μL, 0.025 mmol). The mixture was refluxed for 4 hours at which time TLC indicated no reaction had occurred. An additional 26.2 μL of methyl dichloroacetate was added followed by 7 μL of Et3N. The mixture was refluxed for 20 hours after which TLC indicated that the reaction was complete. The product was purified via chromatotron (1 mm silica gel plate, 99:1 CH2Cl2/MeOH) to give 5 mg 47. 1H NMR (300 MHz, CD3OD): δ 4.32-4.72 (m, 3H), 5.03 (d, 1H, J=2.7), 6.25 (s, 1H), 7.56 (d, 2H, J=8.3), 8.05 (d, 2H, J=8.3), 9.24 (s, 1H). LRMS (ESI−) m/z: 346.0 (M−H+ C13H11Cl2FN3O3 requires 346.0).
    • Example 32 Compound 24
  • Figure US20060014743A1-20060119-C00193
  • In a 200 mL round-bottom flask, 2-amino-1,3,4-thiadiazole (1.00 g, 9.89 mmol) was added to 10 mL of 48% aqueous HBr. Water (10 mL) was added to give a yellow solution in which most solids dissolved. The mixture was cooled to 0° C. and CuBr (142 mg, 0.989 mmol) was added to give an opaque brown solution with some precipitate. NaNO2 (682 mg, 9.89 mmol) was dissolved in 25 mL H2O and added dropwise over 45 minutes to the thiadiazole mixture. The mixture became dark green and opaque with the first drops of NaNO2 solution. Slowly, the solution became brownish yellow and brown gas evolved. The mixture was stirred for an additional 10 minutes at 0° C. from the time gas evolution began. The mixture was warmed to room temperature over 30 minutes. Saturated aqueous NaHCO3 was added dropwise until bubbling ceased and the pH was 8.5. To this was added 50 mL of EtOAc and the biphasic mixture stirred rapidly. The mixture was filtered through a pad of Celite to remove solids and then the layers were separated. The organics were washed with brine (2×). The aqueous layer was extracted with EtOAc and washed with brine (1×). The combined organic layers were dried over Na2SO4. The remaining aqueous material was extracted once more by vigorous stirring with EtOAc (50 mL) for 12 hours. This EtOAc layer was washed with brine and combined with the EtOAc that was already drying over Na2SO4. The solution was filtered and evaporated under vacuum to give 24 as a tan solid (1.22 g, 7.36 mmol), which was used without further purification.
    • Example 33 Compound 25
  • Figure US20060014743A1-20060119-C00194
  • This is an example of Suzuki coupling method B. Compound 23 (19 mg, 0.0538 mmol) was dissolved in THF (1 mL), DMF (1 mL), and H2O (0.5 mL). The mixture was stirred at room temperature until all material dissolved and then 2-bromo-1,3,4-thiadiazole (24, 5.0 mg, 0.027 mmol) was added. The solution was purged with N2 for 5 minutes by means of a long needle. PdCl2(dppf) was added and then the solution was again purged with N2 for 5 minutes. The mixture was then stirred at 55° C. for 18 hours under N2 and then at room temperature for an additional 30 hours. The resulting clear brown solution was concentrated under vacuum. Compound 25 (5.4 mg, 0.0137 mmol) was obtained as a yellow oil by chromatotron purification (silica gel, 1 mm plate, 1:9 EtOAc/hexanes to 1:4 EtOAc/hexanes).
  • It was found that the yield could be substantially improved by switching to coupling method C. Compounds 23 (0.330 g, 0.934 mmol) and 24 (0.385 g, 2.34 mmol) were dissolved in a mixture of toluene, n-butanol, and H2O (8 mL:8 mL:2 mL) and Cs2CO3 (0.912 g, 2.80 mmol) was added. The mixture was purged with N2 and Pd(PPh3)4 was added. The mixture was again purged with N2 for 5 minutes and then stirred rapidly at 70° C. under N2 for 12 hours. The mixture was concentrated under vacuum and the residue partitioned between H2O (75 mL) and EtOAc (75 mL. The layers were separated and the EtOAc was washed with brine (2×50 mL). The EtOAc was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 0.720 g of yellow oil. Compound 25 (0.220 g) was obtained by silica gel chromatography, eluting with 5:1 to 2:1 to 1:1 hexanes/EtOAc. 1H NMR (300 MHz, CD3OD): δ 1.50 (s, 9H), 1.58 (s, 3H), 1.70 (s, 3H), 3.80-3.94 (m, 1 H), 4.42-4.61 (m, 2H), 5.20, (d, 1H, J=7.5), 7.64 (d, 2H, J=8.3), 8.05 (d, 2H, J=8.3), 9.45 (s, 1H).
    • Example 34 Compound 48
  • Figure US20060014743A1-20060119-C00195
  • Compound 25 (5.4 mg, 0.014 mmol) was transferred to a 25 mL round-bottom flask and 2.5 mL of 9:1 TFA/H2O (v/v) were added. The resulting bright yellow mixture was stirred at room temperature for 18 hours. The solvent was removed under vacuum and the residue dissolved three times in a mixture of MeOH and toluene, which was evaporated to near dryness each time. The product was recovered as an oil (4.9 mg, 0.013 mmol), which was used without further purification. 1H NMR (300 MHz, CD3OD): δ 3.59-3.70 (m, 1H), 4.30-4.71 (m, 2H), 4.92 (d, 1H, J=8.1), 7.64 (d, 2H, J=8.3), 8.08 (d, 2H, J=8.3), 9.47 (s, 1H).
  • In a 10 mL round-bottom flask, the above product was dissolved in 2 mL of MeOH. To this was added Et3N (9.7 μL, 0.070 mmol) followed by methyl difluoroacetate (3.0 μL, 0.035 mmol). The mixture was refluxed for 16 hours, at which point TLC indicated that some starting material still remained. An additional 3 drops of Et3N was added followed by 2 drops of methyl difluoroacetate. After 3 hours, all starting material had been consumed. The mixture was cooled to room temperature and evaporated to dryness under vacuum. Compound 48 (4.1 mg, 012 mmol) was obtained by chromatotron purification (silica gel, 1 mm plate). 1H NMR (300 MHz, CD3OD): δ 4.31-4.72 (m, 3H), 5.03 (d, 1H, J=3.9), 5.98 (t, 1H, J=53.9), 7.58 (d, 2H, J=8.3), 7.99 (d, 2H, J=8.3), 9.43 (s, 1H). LRMS (ESI−) m/z: 330.1 (M−H+ C13H11F3N3O2S requires 330.1).
    • Example 35 Compound 49
  • Figure US20060014743A1-20060119-C00196
  • The biaryl intermediate was prepared from 18 and the appropriate boronic acid using Suzuki coupling method A. Removal of the Boc group was accomplished by brief treatment with 90/10 (v/v) TFA/H2O. Dichloroacetylation was performed as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.31-4.80 (m, 3H), 5.01 (d, 1H, J=3.6), 6.26 (s, 1H), 7.52 (d, 2H, 8.3), 7.65 (d, 2H, J=8.3), 7.79 (s, 4H). LRMS (ESI−) m/z: 379.0 (M−H+ C18H14C12FN2O2 379.0).
    • Example 36 Compound 50
  • Figure US20060014743A1-20060119-C00197
  • The biaryl intermediate was prepared from 22 and the appropriate boronic acid using Suzuki coupling method A. 1H NMR (300 MHz, CD3OD): δ 4.27-4.68 (m, 3H), 4.99 (d, 1H, J=4.5), 6.00 (t, 1H, J=53.9), 7.52 (d, 2H, J=8.1), 7.67 (d, 2H, J=8.1), 7.76-7.82 (m, 2H). LRMS (ESI−) m/z: 347.1 (M−H+ C18H14F3N2O2 requires 347.1).
    • Example 37 Compound 51
  • Figure US20060014743A1-20060119-C00198
  • The biaryl intermediate was prepared from 22 and the appropriate boronic acid using Suzuki coupling method A. 1H NMR (300 MHz, CD3OD): δ 3.14 (s, 3H), 4.30-4.68 (m, 3H), 5.00 (d, 1H, J=4.5), 6.00 (t, 1H, J=54), 7.53 (d, 2H, J=8.3), 7.70 (d, 2H, J=8.3), 7.88 (d, 2H, J=8.6), 8.00 (d, 2H, J=8.6). LRMS (ESI−) m/z: 400.1 (M−H+ C18H17F3NO4S requires 400.1).
    • Example 38 Compound 52
  • Figure US20060014743A1-20060119-C00199
  • The biaryl intermediate was prepared from 22 and the appropriate boronic acid using Suzuki coupling method B. 1H NMR (300 MHz, CD3OD): δ 4.26-4.64 (m, 3H), 4.93 (d, 1H, J=4.8), 6.01 (t, 1H, J=53.9), 7.40-7.45 (m, 4H), 7.60-7.66 (m, 3H). LRMS (ESI−) m/z: 328.1 (M−H+ C15H13F3NO2S requires 328.1).
    • Example 39 Compound 53
  • Figure US20060014743A1-20060119-C00200
  • The biaryl intermediate was prepared from 22 and the appropriate boronic acid using Suzuki coupling method B. 1H NMR (300 MHz, CD3OD): δ 4.25-4.65 (m, 3H), 4.92 (d, 1H, J=4.5), 6.01 (t, 1H, J=53.9), 7.06-7.08 (m, 1H), 7.36-7.42 (m, 4H), 7.61 (d, 2H, J=8.4). LRMS (ESI+) m/z: 352.0 (calc. for M+Na+ C15H14F3NNaO2S 352.1).
    • Example 40 Compound 54
  • Figure US20060014743A1-20060119-C00201
  • The biaryl intermediate was prepared from 18 and the boronic acid using Suzuki coupling method B. Removal of the Boc group was accomplished by brief treatment with 9/1 (v/v) TFA/H2O. Dichloroacetylation was performed as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.33-4.79 (m, 3H), 5.03 (d, 1H, J=3.3), 6.26 (s, 1H), 7.55 (d, 2H, J=8.4), 7.69-7.75 (m, 4H), 8.56 (d, 2H, J=5.7). LRMS (ESI+) m/z: 357.1 (calc. for M+H+ C16H16Cl2FN2O2 357.1).
    • Example 41 Compound 55
  • Figure US20060014743A1-20060119-C00202
  • The biaryl intermediate was prepared from boronic acid 23 and compound 24 using Suzuki coupling method B. Removal of the protecting groups was accomplished by brief treatment with 9/1 (v/v) TFANH2O. Dichloroacetylation was performed as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.34-4.76 (m, 3H), 5.04 (d, 1H, J=3.0), 6.24 (s, 1H), 7.58 (d, 2H, J=8.3), 7.97 (d, 2H, J=8.3), 9.42 (s, 1H). LRMS (ESI−) m/z: 362.0 (calc. for M−H+ C13H11Cl2FN3O2S 362.0).
    • Example 42 Compound 56
  • Figure US20060014743A1-20060119-C00203
  • Compound 54 (29.4 mg, 0.0824 mmol) was dissolved in 5 mL of CH2Cl2. The mixture was cooled to 0° C. and m-chloroperbenzoic acid (m-CPBA, 38 mg, 0.16 mmol) was added with stirring. After 5 minutes, the mixture was warmed to room temperature and stirred for 12 hours. The mixture was concentrated under vacuum and the product purified by silica gel chromatography eluting successively with 2%, 3%, 4%, 6%, and 10% MeOH in CH2Cl2. Compound 56 was obtained as a white solid (22.5 mg, 0.060 mmol). 1H NMR (300 MHz, CD3OD): δ 4.32-4.75 (m, 3H), 5.03 (d, 1H, J=3.3), 6.25 (s, 1H), 7.56 (d, 2H, J=8.4), 7.74 (d, 2H, J=8.4), 7.84 (d, 2H, J=7.2), 8.34 (d, 2H, J=7.2). LRMS (ESI−) m/z: 371.0 (calc. for M−H+ C16H14Cl2FN2O3 371.0).
    • Example 43 Compound 57
  • Figure US20060014743A1-20060119-C00204
  • The biaryl intermediate was prepared from 18 and the appropriate boronic acid using Suzuki coupling method B. Removal of the protecting group was accomplished by brief treatment with 9/1 (v/v) TFA/H2O. Difluoroacetylation was performed as in the synthesis of 48. 1H NMR (300 MHz, CD3OD): δ 4.28-4.68 (m, 3H), 5.00 (d, 1H, J=4.2), 5.99 (t, 1H, J=53.9), 7.55 (d, 2H, J=8.1), 7.70-7.77 (m, 4H), 7.84 (d, 2H, J=7.2), 8.56 (d, 2H, J=6.3). LRMS (ESI+) m/z: 325.2 (calc. for M+H+ C16H16F3N2O2 325.1).
    • Example 44 Compound 58
  • Figure US20060014743A1-20060119-C00205
  • Compound 58 was prepared from 68 as 56 was from 54. 1H NMR (300 MHz, CD3OD): δ 4.30-4.75 (m, 3H), 5.02 (d, 1H, J=3.3), 6.25 (s, 1H), 7.55-7.67 (m, 5H), 7.87 (d, 1H, J=8.1), 8.30 (d, 1H, J=7.2), 8.58 (br s, 1H). LRMS (ESI−) m/z: 371.0 (calc. for M−H+ C16H14Cl2FN2O3 371.0).
    • Example 45 Compound 59
  • Figure US20060014743A1-20060119-C00206
  • The biaryl intermediate was prepared from 11 and the appropriate boronic acid using Suzuki coupling method A. The phenyloxazoline protecting group was removed and the dichloroacetate group introduced as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.30-4.75 (m, 3H), 5.02 (d, 1H, J=3.6), 6.26 (s, 1H), 7.54-8.70 (m, 8H). LRMS (ESI−) m/z: 354.8 (calc. for M−H+ C16H14Cl2FN2O2 355.0).
    • Example 46 Compound 60
  • Figure US20060014743A1-20060119-C00207
  • Compound 60 was prepared from compound 59 in the same manner that other pyridine N-oxides in these examples were formed from the corresponding pyridine. 1H NMR (300 MHz, CD3OD): δ 4.33-4.78 (m, 3H), 5.03 (d, 1H, J=3.3), 6.25 (s, 1H), 7.57 (d, 2H, J=8.4), 7.75 (d, 2H, J=8.4), 7.87 (d, 2H, J=7.5), 8.38 (d, 2H, J=7.5). LRMS (ESI−) m/z: 370.8 (calc. for M−H+ C16H14Cl2FN2O3 371.0).
    • Example 47 Compound 61
  • Figure US20060014743A1-20060119-C00208
  • The biaryl intermediate was prepared from 11 and the appropriate boronic acid using Suzuki coupling method A. The phenyl oxazoline protecting group was cleaved and dichloroacetate introduced as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 3.14 (s, 3H), 4.36-4.75 (m, 3H), 5.02 (d, 1H, J=3.6), 6.27 (s, 1H), 7.54 (d, 2H, J=8.3), 7.68 (d, 2H, J=8.3), 7.87 (d, 2H, J=8.7), 8.01 (d, 2H, J=8.7). LRMS (ESI−) m/z: 431.8 (calc. for M−H+ C18H17Cl2FNO4S 432.0).
    • Example 48 Compound 62
  • Figure US20060014743A1-20060119-C00209
  • The free amine intermediate was prepared as in the synthesis of 28. The nitrogen was monochloroacetylated using chloroacetyl chloride. 1H NMR (300 MHz, CD3OD): δ 4.00-4.03 (m, 2H), 4.27-4.70 (m, 3H), 5.00 (d, 1H, J=3.9), 7.49-7.55 (m, 3H), 7.66 (d, 2H, J=8.4), 8.09 (d app t, 1H, J=7.8, 2.4), 8.50 (dd, 1H, J=4.8, 1.5), 8.78 (br d, 1H, J=2.4). LRMS (ESI+) m/z: 321.0 (calc. for M+H+ C16H15CIFN2O2 357.1).
    • Example 49 Compound 63
  • Figure US20060014743A1-20060119-C00210
  • Prepared in the same manner as 28 using ethyl chlorofluoroacetate. 1H NMR (300 MHz, CD3OD): δ 4.31-4.70 (m, 3H), 5.01 (d, 1H, J=3.9), major diastereomer 6.49 (d, 1H, J=49.8), minor diastereomer 6.51 (d, 1H, J=49.8), 7.49-7.56 (m, 3H), 7.63-7.67 (m, 2H), 8.07-8.11 (m, 1H), 8.49-8.51 (m, 1H), 8.78 (br d, 1H, J=1.5). LRMS (ESI) m/z: 338.9 (calc. for M−H+ C16H14CIF2N2O2 339.1).
    • Example 50 Compound 64
  • Figure US20060014743A1-20060119-C00211
  • The biaryl intermediate was prepared from 12 and 2-bromopyridine using Suzuki coupling method A. 1H NMR (300 MHz, CD3OD): δ 4.28-4.74 (m, 3H), 5.02 (d, 1H, J=3.6), 6.27 (s, 1H), 7.33-7.37 (m, 1H), 7.53 (d, 2H, J=8.1), 7.18-7.93 (m, 4H), 8.58-8.60 (m, 1H). LRMS (ESI−) m/z: 354.8 (calc. for M−H+ C16H14Cl2FN2O2 355.0)
    • Example 51 Compound 65
  • Figure US20060014743A1-20060119-C00212
  • Compound 65 was prepared in the same manner as 59 using ethyl chlorofluoroacetate. 1H NMR (300 MHz, CD3OD): δ 4.32-4.70 (m, 3H), 5.02 (d, 1H, J=3.6), major diastereomer 6.48 (d, 1H, J=49.8), minor diastereomer 6.50 (d, 1H, J=50.1), 7.55-7.58 (m, 2H), 7.73-7.78 (m, 4H) 8.57 (br d, 2H, J=5.7). LRMS (ESI−) m/z: 338.8 (calc. for M−H+ C16H14CIF2N2O2 339.1).
    • Example 52 Compound 66
  • Figure US20060014743A1-20060119-C00213
  • The biaryl intermediate was prepared from 12 and the appropriate bromide using Suzuki coupling method A. Removal of the protecting group and dichloroacetylation was accomplished as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.34-4.72 (m, 3H), 5.01 (d, 1 H, J=2.4), 6.25 (s, 1H), 7.52 (d, 2H, J=6.3), 7.57 (d, 1H, J=2.6) 7.84 (d, 1H, J=2.6), 7.90 (d, 2H, J=6.3). LRMS (ESI−) m/z: 360.7 (calc. for M−H+ C14H12Cl2FN2O2S 361.0).
    • Example 53 Compound 67
  • Figure US20060014743A1-20060119-C00214
  • The biaryl intermediate was prepared from 12 and the appropriate bromide using Suzuki coupling method A. Removal of the protecting group and dichloroacetylation was accomplished as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.32-4.75 (m, 3H), 5.04 (d, 1H, J=3.6), 6.26 (s, 1H), 7.59 (d, 2H, J=8.3), 7.70 (d, 2H, J=8.3) 9.06 (s, 2H,), 9.13 (s, 1H). LRMS (ESI+) m/z: 357.8 (calc. for M+H+ C15H15Cl2FN3O2 358.0).
    • Example 54 Compound 68
  • Figure US20060014743A1-20060119-C00215
  • The biaryl intermediate was prepared from bromide 11 and the appropriate boronic acid using Suzuki coupling method A. Removal of the protecting group and dichloroacetylation was accomplished as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.31-4.74 (m, 3H), 5.02 (d, 1H, J=3.6), 6.27 (s, 1H), 7.48-7.51 (m, 1H), 7.54 (d, 2H, J=8.3), 7.64 (d, 2H, J=8.3) 8.08 (ddd, 1H, J=8.0, 2.4, 1.8), 8.50 (dd, 1H, 4.8, 1.5), 8.77 (dd, 1H, J=2.4, 0.9). LRMS (ESI−) m/z: 354.8 (calc. for M−H+ C16H14Cl2FN2O2 355.0).
    • Example 55 Compound 69
  • Figure US20060014743A1-20060119-C00216
  • The biaryl intermediate was prepared from bromide 11 and the appropriate boronic acid using Suzuki coupling method A. Removal of the protecting group and dichloroacetylation was performed as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 2.63 (s, 3H), 4.31-4.74 (m, 3H), 5.01 (d, 1H, J=3.9), 6.27 (s, 1H), 7.51 (d, 2H, J=8.3), 7.67 (d, 2H, J=8.3), 7.75 (d, 2H, J=8.6) 8.06 (d, 2H, J=8.6).
    • Example 56 Compound 71
  • Figure US20060014743A1-20060119-C00217
  • This compound was prepared in analogous fashion to 41 using ethyl chlorofluoroacetate in place of methyl dichloroacetate. 1H NMR (300 MHz, CD3OD): δ 2.58 (s, 3H), 4.31-4.71 (m, 3H), 5.03 (br d, 1H, J=3.9), major diastereomer 6.46 (d, 1H, J=49.8), minor diastereomer (d, 1H, J=50.1), major diastereomer 7.53 (d, 2H, J=8.1), minor diastereomer 7.51 (d, 2H, J=8.1), 7.94-7.96 (m, 2H). LRMS (ESI−) m/z: 304.1 (calc. for M−H+ C13H13CIF2NO3 304.1).
    • Example 57 Compound 72
  • Figure US20060014743A1-20060119-C00218
  • Initially, the ρ-cyano analog of compound 11 had been prepared by methods analogous to those used to prepare 11 itself. Attempts to remove the phenyloxazoline protecting group (as described in the synthesis of 29) led to some of the desired deprotected nitrile intermediate. However, much of the mass recovered was the deprotected ρ-carboxylic acid corresponding to acidic hydrolysis of the nitrile functional group. This material was dichloroacetylated using the same procedure as that employed in the synthesis of 29 and the product was converted to its methyl ester with CH2N2. 1 NMR (300 MHz, CD3OD): δ 3.83 (s, 3H), 4.25-4.66 (m, 3H), 4.98 (d, 1H, J=3), 6.17 (s, 1H), 7.46 (d, 2H, J=8.3), 7.91 (d, 2H, J=8.3).
    • Example 58 Compound 73
  • Figure US20060014743A1-20060119-C00219
  • Compound 87 (36.5 mg, 0.0873 mmol) was dissolved in THF (5 mL anhydrous) under N2. After addition of anhydrous powdered K2CO3 (24 mg, 0.175 mmol), the mixture was purged with N2. Et3N (31 mL, 0.218 mmol) and cyclobutanecarbonyl chloride (13 mL, 0.113 mmol) were added and the mixture purged gently with N2 for another 5 min. Pd2dba3 was added and the mixture purged again with N2. The mixture was then stirred under N2 for 3 hours after which it was diluted with EtOAc and H2O and filtered through a cotton plug. The EtOAc layer was washed with 1N aqueous HCl (×2), brine (×2), and dried over anhydrous Na2SO4. The mixture was filtered and the solvent removed to give 16.9 mg, 0.0501 mmol of material that was purified by chromatotron (1 mm plate, eluting with 4:1 hexanes/EtOAc). The protected intermediate obtained was subjected to phenyloxazoline cleavage and dichloroacetylation as in the synthesis of 29 to give 73. 1H NMR (300 MHz, CD3OD): δ 1.73-1.85 (m, 1H), 1.99-2.11 (m, 1H), 2.20-2.27 (m, 4H), 3.97-4.09 (m, 1H), 4.23-4.67 (m, 3H), 4.95 (d, 1H, J=3.3), 6.16 (s, 1H), 7.45 (d, 2H, J=8.4), 7.81 (d, 2H, J=8.4). LRMS (ESI−) m/z: 360.0 (calc. for M−H+ C16H17Cl2FNO3 360.0).
    • Example 59 Compound 74
  • Figure US20060014743A1-20060119-C00220
  • The carboxylic acid intermediate from the synthesis of 72 was dichloroacetylated as in the synthesis of 29. The resulting intermediate (95.8 mg, 0.297 mmol) was dissolved in 2 mL of MeOH, several drops of H2O were added and then a 20% (w/v) aqueous Cs2CO3 solution was added dropwise until the solution reached pH 7. The mixture was concentrated under vacuum. One drop of Et3N and 10 mL of 2-chloroethanol were added and the mixture stirred at 135° C. for 2 hours. Residual chloroethanol was removed under vacuum and the residue chromatographed. Compound 74 (13.3 mg) was the major product and 75 (9.2 mg) the minor product. 1H NMR (300 MHz, CD3OD): δ 3.78-3.82 (m, 2H), 4.23-4.68 (m, 5H), 4.97 (d, 1H, J=3.0), 6.17 (s, 1H), 7.46 (d, 2H, J=8.3), 7.93 (d, 2H, J=8.3). LRMS (ESI+) m/z: 407.9 (calc. for M+Na+ C14H15Cl3FNNaO4 408.0).
    • Example 60 Compound 75
  • Figure US20060014743A1-20060119-C00221
  • 1H NMR (300 MHz, CD3OD): δ 3.83-3.39 (m, 2H), 4.31-4.74 (m, 5H), 5.02 (d, 1H, J=3.3), 6.23 (s, 1H), 7.52 (d, 2H, J=8.4), 8.02 (d, 2H, J=8.4). LRMS (ESI31 ) m/z: 366.0 (calc. for M−H+ C14H15Cl2FNO5 366.0).
    • Example 61 Compound 76
  • Figure US20060014743A1-20060119-C00222
  • The cyclopropyl analog of intermediate 89 was prepared by a Stille coupling analogous to that used to synthesize 89. Acidic cleavage of the phenyloxazoline group resulted in the HCl-mediated opening of the cyclopropyl ring. This material was deprotected and dichloroacetylated to give 76. 1H NMR (300 MHz, CD3OD): δ 2.10-2.19 (m, 2H), 3.19 (t, 2H, J=7.1), 3.66 (t, 2H, J=6.6), 4.31-4.74 (m, 3H), 5.03 (d, 1H, J=3.3), 6.23 (s, 1H), 7.53 (d, 2H, J=8.3), 7.96 (d, J=8.3). LRMS (ESI−) m/z: 381.9 (calc. for M−H+ C15H16Cl3FNO3 382.0).
    • Example 62 Compound 77
  • Figure US20060014743A1-20060119-C00223
  • The thiazole ring of this analog was formed by conversion of the protected nitrile intermediate to the corresponding thioamide by reaction with H2S in pyridine. The thioamide was then reacted with the appropriate protected α-halocarbonyl compound to form the substituted thiazole shown. Deprotection and dichloroacetylation was performed as for other compounds of this invention. 1H NMR (300 MHz, CD3OD): δ 4.32-4.75 (m, 5H), 5.01 (d, 1H, J=3.3), 6.27 (s, 1H), 7.38 (s, 1H), 7.51 (d, 2H, J=8.3), 7.91 (d, 2H, J=8.3). LRMS (ESI−) m/z: 390.9 (calc. for M−H+ C15H14Cl2FN2O3S 391.0).
    • Example 63 Compound 79
  • Figure US20060014743A1-20060119-C00224
  • This compound was formed by Suzuki coupling method A from an intermediate in which the primary hydroxyl group was not converted to a fluoride. Deprotection and dichloroacetylation were performed as with other compounds of this invention. 1H NMR (300 MHz, CD3OD): δ 3.55 (dd, 1H, J=11.0, 5.9), 3.77 (dd, 1H, J=11.0, 6.5), 4.07-4.11 (m, 1H), 5.02 (d, 1H, J=3.6), 5.96 (s, 2H), 6.29 (s, 1H), 6.86 (d, 1H, J=8.4), 7.05-7.07 (m, 2H), 7.40-7.50 (m, 4H). LRMS (ESI−) m/z: 395.9 (calc. for M−H+ C18H16Cl2NO5 396.0).
    • Example 64 Compound 80
  • Figure US20060014743A1-20060119-C00225
  • Compound 41 (11.5 mg, 0.0346 mmol) and hydroxylamine hydrochloride (2.8 mg, 0.0415 mmol) were stirred in EtOH (3 mL) for 12 hours and then refluxed for an additional 12 hours. The solvent was removed under vacuum and the product isolated as a single isomer (it was not determined whether the isomer was the cis or trans oxime). 1H NMR (300 MHz, CD3OD): δ 2.21 (s, 3H), 4.26-4.68 (m, 3H,), 4.95 (d, 1H, J=3.9), 6.27 (s, 1H), 7.39 (d, 2H, J=8.3), 7.61 (d, 2H, J=8.3).
    • Example 65 Compound 81
  • Figure US20060014743A1-20060119-C00226
  • Free amine 37 (4.7 mg, 0.0224 mmol) was dissolved in MeOH (1 mL) and the mixture cooled to 0° C. Chloroacetic anhydride (5 drops) and triethylamine (5 drops) were added and the mixture warmed to room temperature and stirred for 2 hours. The solvent was removed under vacuum and the product purified by silica gel chromatography (2:3 EtOAc/hexanes) to give 3.3 mg (0.011 mmol) of product. 1H NMR (300 MHz, CD3OD): δ 2.59 (s, 3H), 3.92-4.03 (m, 2H,), 4.29-4.68 (m, 3H), 5.02 (d, 1H, J=3.3), 7.53 (d, 2H, J=8.4), 7.96 (d, 2H, J=8.4).
    • Example 66 Compound 82
  • Figure US20060014743A1-20060119-C00227
  • The biaryl intermediate was formed by Suzuki coupling method A using 22 and the appropriate boronic acid. 1H NMR (300 MHz, CD3OD): δ 4.28-4.68 (m, 3H), 5.00 (d, 1H, J=4.2), 6.01 (t, 1H, J=54), 7.49-7.60 (m, 3H), 7.66 (d, 2H, J=8.4), 8.07-8.11 (m, 1H), 8.50 (dd, 1H, J=4.8, 1.5), 8.79-8.79 (m, 1H). LRMS (ESI−) m/z: 322.9 (M−H+ C16H14F3N2O2 requires 323.1).
    • Example 67 Compound 84
  • Figure US20060014743A1-20060119-C00228
  • This compound was prepared by procedures analogous to those described in Schemes 2 and 3. The 4-(1,2,4-triazol-1-yl)phenylserine analog of 6 was synthesized by the same methods used to make 6. The required 4-(1,2,4-triazol-1-yl)benzaldehyde was prepared as described in the literature (Tanaka, A., et al., J. Med. Chem.1998; 41, 2390-2410). 1H NMR (300 MHz, CD3OD): δ 4.33-4.76 (m, 3H), 5.04 (d, 1H, J=3.3), 6.26 (s, 1H), 7.59 (d, 2H, J=8.6), 7.78 (d, 2H, J=8.6), 8.14 (s, 1H), 9.05 (s, 1H). LRMS (ESI−) m/z: 345.0 (calc. for M−H+ C13H12Cl2FN4O2 345.0).
    • Example 68 Compound 85
  • Figure US20060014743A1-20060119-C00229
  • The biaryl intermediate was prepared from boronic acid 12 and 2-iodopyrazine. Deprotection and dichloroacetylation were accomplished as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 4.32-4.75 (m, 3H), 5.04 (d, 1H, J=3.3), 6.27 (s, 1H), 7.57 (d, 2H, J=8.4), 8.05 (d, 2H, J=8.4), 8.51 (d, 1H, J=2.7), 8.65-8.66 (m, 1H), 9.08 (d, 1H, J=1.8). LRMS (ESI−) m/z: 355.8 (calc. for M−H+ C15H13Cl2FN3O2 356.0).
    • Example 69 Compound 86
  • Figure US20060014743A1-20060119-C00230
  • Same procedure as that for the synthesis of 68. 1H NMR (300 MHz, CD3OD): δ 4.29-4.73 (m, 3H), 5.01 (br d, 1H, J=3.9), major diastereomer 6.49 (d, 1H, J=49.8), minor diastereomer 6.51 (d, 1H, J=49.8), 7.48-7.56 (m, 3H), 7.64-7.67 (m, 2H), 8.06-8.10 (m, 1H), 8.49-8.51 (m, 1H), 8.78-8.79 (m, 1H). LRMS (ESI−) m/z: 338.9 (calc. for M−H+ C16H14CIF2N2O2 339.1).
    • Example 70 Compound 87
  • Figure US20060014743A1-20060119-C00231
  • Compound 11 (0.496 g, 1.48 mmol) was dissolved in anhydrous benzene (15 mL) under N2. The flask was fitted with a reflux condenser and a long needle was dropped through the condenser and the solution purged with a gentle stream of dry N2 for 5 minutes. Hexamethylditin (0.58 g, 1.78 mmol) was added and the mixture purged for another 5 minutes. Pd(PPh3)4 (0.171 g, 0.148 mmol) was added and purging with N2 continued. After 5 minutes, the needle was removed and a N2 inlet was placed at the top of the reflux condenser. The mixture was refluxed for approximately 2 hours under N2. Over the course of the reaction, the mixture turned from orange to yellow to black. The solvent was removed under vacuum and the product purified by chromatotron (silica gel, 1 mm plate) to give 440 mg of product as a clear oil. 1H NMR (300 MHz, CD3OD): δ 0.27 (s, 9H—this resonance contains significant satellite peaks, which are due to NMR-active isotopes of tin), 4.27-4.41 (m, 1H), 4.59-4.76 (m, 2H), 5.60 (d, 1H, J=6.9), 7.33 (d, 2H, J=8.1), 7.45-7.31 (m, 5H), 7.99-8.02 (m, 2H).
    • Example 71 Compound 88
  • Figure US20060014743A1-20060119-C00232
  • This compound was prepared in the same manner as 87. 1H NMR (300 MHz, CD3OD): δ 0.027 (s, 9H, with significant satellite peaks caused by NMR-active tin isotopes), 1.49 (s, 9H), 1.55 (s, 3H), 1.67 (s, 3H), 3.73-3.83 (m, 1H), 4.30-4.49 (m, 2H), 5.06 (d, 2H, J=7.5), 7.36-7.51 (m, 4H).
    • Example 72 Compound 89
  • Figure US20060014743A1-20060119-C00233
  • Compound 87 (36.5 mg, 0.0873 mmol) was dissolved in anhydrous THF under N2. With stirring, K2CO3 (24 mg, 0.16 mmol) was added. The mixture was purged with a gentle stream of N2 for 5 minutes. Et3N (31 μL, 0.22 mmol) and cyclobutanecarbonyl chloride (13 μL, 0.11 mmol) were added and the mixture purged with N2 for 5 minutes. Pd2dba3 was added, the mixture purged for 5 min and then stirred under N2 for 3 hours. The mixture was diluted with EtOAc (25 mL) and H2O (25 mL) and filtered through a cotton plug to remove solids. The EtOAc was washed with 1 N HCl (2×) and brine (2×), dried over Na2SO4 and concentrated under vacuum. The product was purified by chromatotron (silica plate, 1 mm, 1:4 EtOAc/hexanes) to give 16.9 mg (0.050 mmol) of product. LRMS (ESI+) m/z: 338.2 (M+H+ C21H21FNO2 requires 338.2).
    • Example 73 Compound 90
  • Figure US20060014743A1-20060119-C00234
  • Same procedure as in the synthesis of 89. 1H NMR (300 MHz, CD3OD): δ 0.027 (s, 9H, with significant satellite peaks caused by NMR-active tin isotopes), 1.49 (s, 9H), 1.55 (s, 3H), 1.67 (s, 3H), 3.73-3.83 (m, 1H), 4.30-4.49 (m, 2H), 5.06 (d, 2H, J=7.5), 7.36-7.51 (m, 4H).
    • Example 74 Compound 91
  • Figure US20060014743A1-20060119-C00235
  • Compound 91 was deprotected by brief treatment of 90 with 9/1 TFA/H2O. The dichloroacetyl group was introduced as in the synthesis of 29. LRMS (ESI−) m/z: 345.8 (calc. for M−H+ C15H16Cl2FNO3 346.0).
    • Example 75 Compound 92
  • Figure US20060014743A1-20060119-C00236
  • The same procedure as that used in the synthesis of 56 was employed. 1H NMR (300 MHz, CD3OD): δ 4.28-4.74 (m, 3H), 5.01 (d, 1H, J=3.9), 5.98 (t, 1H, J=53.8), 7.55 (d, 2H, J=8.4). 7.76 (d, 2H, J=8.4), 7.86 (d, 2H, J=7.1), 8.35 (d, 2H, J=7.1).
    • Example 76 Compound 93
  • Figure US20060014743A1-20060119-C00237
  • The biaryl intermediate was prepared by reaction of 23 and the appropriate bromide using Suzuki coupling A. Deprotection and dichloroacetylation were carried out as described above in the synthesis of 29. LRMS (ESI−) m/z: 433.0 (M−H+ C17H16Cl2FN2O4S requires 433.0).
    • Example 77 Compound 94
  • Figure US20060014743A1-20060119-C00238
  • The biaryl intermediate was prepared by reaction of 23 with 2-amino-4-cyclopropyl-1,3,4-thiadiazole (prepared as in the synthesis of 24) using Suzuki coupling B. Deprotection was accomplished by brief treatment of the protected biaryl intermediate with 90/10 TFA/H2O and dichloroacetylation was performed as in the synthesis of 29. 1H NMR (300 MHz, CD3OD): δ 1.12-1.31 (m, 4H), 2.46-2.52 (m, 1H), 4.30-4.75 (m, 3H), 5.02 (d, 1H, J=3.3), 6.24 (s, 1H), 7.54 (d, 2H, J=8.4), 7.87 (d, 2H, J=8.4).
    • Example 78 Compound 95
  • Figure US20060014743A1-20060119-C00239
  • Same procedure as in the synthesis of 94 using methyl difluoroacetate in place of methyl dichloroacetate. 1H NMR (300 MHz, CD3OD): δ 1.13-1.15 (m, 2H), 1.28-1.32 (m, 2H), 2.47-2.52 (m, 1H), 4.29-4.70 (m, 3H), 5.01 (d, 1H, J=4.2); 5.98 (t, 1H, J=53.7), 7.54 (d, 2H, J=8.7), 7.88 (d, 2H, J=8.7). LRMS (ESI−) m/z: 370.0 (M−H+ C16H15F3N3O2S requires 370.1).
    • Example 79 Compound 97
  • Figure US20060014743A1-20060119-C00240
  • Compound 96 was prepared in analogous fashion to 24. Compound 97 was prepared in analogous fashion to 48. Suzuki coupling method B was used, followed by deprotection and difluoroacetylation. LRMS (ESI−) m/z: 376.0 (M−H+ C14H13F3N3O2S2 requires 376.0)
    • Example 80 Compound 98
  • Figure US20060014743A1-20060119-C00241
  • Compound 97 (11.1 mg or 0.0294 mmol) was dissolved in 5 mL of CH2Cl2, with stirring at room temperature. To this was added m-CPBA (36 mg, 0.147 mmol). The mixture was stirred for 23 hours. Attempted Chromatotron (1 mm plate) purification, eluting with 80:20 then 70:30 then 50:50 hexanes/EtOAc; failed to remove m-CPBA-related materials. Thus, material from the Chromotron was subjected to C-8 reversed-phase HPLC, which gave 8.8 mg (0.021 mmol) of 98. 1H NMR (300 MHz, CD3OD): δ 3.52 (s, 3H), 4.34-4.72 (m, 3H), 5.05 (d, 1H, J=3.6), 5.97 (t, 1H, J=53.9), 7.61 (d, 2H, J=7.61), 8.05 (d, 2H, J=8.1).
    • Example 81 Compound 100
  • Figure US20060014743A1-20060119-C00242
  • Compound 99 was prepared in analogous fashion to 24 and 100 was prepared in analagous fashion to 48. Suzuki coupling method B was used followed by deprotection and difluoroacetylation. 1H NMR (300 MHz, CD3OD): δ 2.80 (s, 3H), 4.30-4.70 (m, 3H), 5.01 (d, 1H, J=3.6), 5.98 (t, 1H, J=53.9), 7.55 (d, 2H, J=8.4), 7.91 (d, 2H, J=8.3).
    • Example 82 Compound 101
  • Figure US20060014743A1-20060119-C00243
  • Compound 101 was prepared using the same procedure as in the synthesis of 100 but with methyldichloroacetate in place of methyidifluoroacetate. 1H NMR (300 MHz, CD3OD): δ 2.79 (s, 3H), 4.31-4.75 (m, 3H), 5.03 (d, 1H, J=3.0), 6.24 (s, 1H), 7.55 (d, 2H, J=8.4), 7.89 (d, 2H, J=8.4).
    • Example 83 Compound 102
  • Figure US20060014743A1-20060119-C00244
  • Compound 17 (100 mg, 0.258 mmol) was placed in a dry round-bottom flask equipped with a stir bar. The flask was charged with 5 mL of dry THF and the contents cooled to −78° C. under N2. With rapid stirring, n-BuLi (1.30 M in hexanes, 0.322 mmol, 0.248 mL) was added, which produced a clear brown/yellow solution. The mixture was stirred for an additional 10 minutes. Excess CO2, generated by sublimation of dry ice, was passed though a drying tube charged with Drierite and bubbled directly into the −78° C. mixture, now equipped with a venting needle in the septum to prevent buildup of CO2 pressure. The mixture was warmed to room temperature and stirred an additional 30 minutes by which time it was clear yellow and TLC indicated a product had formed. The mixture was quenched by addition of 10% (v/w) aqueous NH4Cl (5 drops), producing a cloudy yellow suspension. The mixture was concentrated under vacuum and re-suspended in EtOAc (50 mL) and enough 10% aqueous citric acid to produce a biphasic mixture having a pH of 2.5. The layers were separated and the EtOAc layer was washed with brine (1×10 mL). The mixture was dried over Na2SO4, filtered and evaporated to give 105 mg of yellow oil. The product was isolated by chromatotron (1 mm plate eluting with 4:1 hexanes/EtOAc to 65:35 hexanes/EtOAc to 1:1 hexanes/EtOAc to 2% MeOH in CH2Cl2 to 5% MeOH in CH2Cl2 and, finally, 10% MeOH in CH2Cl2 to which several drops of acetic acid had been added). The appropriate fractions were combined, diluted with toluene and evaporated to give 67.5 mg (0.191 mmol) of 102. 1H NMR (300 MHz, CD3OD): δ 1.49 (s, 9H), 1.57 (S, 3H), 1.69 (s, 3H), 3.77-3.90 (m, 1H), 4.39-4.57 (m, 1H), 4.90-5.10 (br s, 1H), 5.18 (d, 1H, J=7.2), 7.56 (d, 2H, J=8.1), 8.04 (d, 2H, J=8.1). LRMS (ESI−) m/z: 352 (M−H+ C18H23FNO5 requires 352).
    • Example 84 Compound 106
  • Figure US20060014743A1-20060119-C00245
  • Compound 102 (106 mg, 0.299 mmol) was dissolved in EtOAc and diazomethane, generated using an Aldrich Chemical Company diazomethane kit, was added dropwise until a slight yellow color persisted. Excess of diazomethane was allowed to evaporate overnight in a well-ventilated fume hood, and the remaining EtOAc solution was concentrated under vacuum. The residue was dissolved in Et2O and washed with aqueous NaHCO3 and then brine. The layers were separated and the organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give 0.087 g (0.24 mmol, 79%) of methyl ester 103, which was used without further purification or characterization.
  • Compound 103 (0.037 g, 0.136 mmol) was dissolved in 1 mL of EtOH. To this was added hydrazine hydrate (0.007 g, 0.177 mmol). The mixture was refluxed for 12 hours. The solvent was removed under vacuum and the product purified by chromatotron (1 mm plate, 10% MeOH in CH2Cl2). Compound 104 was isolated (40:0 mg, 0.109 mmol) and was used without further characterization. LRMS (ESI−) m/z: 366 (M−H+ C18H25FN3O4 requires 366).
  • Compound 104 (0.050 g, 0.133 mmol) was dissolved in 5 mL of triethyl orthoformate and stirred at 120° C. for 24 hours. The mixture was evaporated to give 26 mg of crude 105, which was used without further characterization or purification.
  • Compound 105 (0.0051 g, 0.014 mmol) was stirred at room temperature with 10 mL of 9:1 TFA/H2O for 10 minutes. The mixture was concentrated under vacuum, dissolved three times in a MeOH/toluene mixture, the solvents being evaporated each time, and dried to a constant weight to give 0.5 mg of deprotected material. The residue was dissolved in 1 mL of MeOH in an open container and 5 drops of methyl difluoroacetate and 15 drops of Et3N were added. The mixture was stirred at room temperature for 12 hours. After 12 hours, TLC indicated a single product. The mixture was concentrated under vacuum and the product isolated by silica gel chromatography eluting with 20:1 CH2Cl2/CH3OH to give 2.3 mg of 106. 1H NMR (300 MHz, CD3OD): δ 4.31-4.74 (m, 3H), 5.04 (d, 1H, J=3.9), 5.96 (t, 1H, J=53.9), 7.61 (d, 2H, J=8.4), 8.05 (d, 2H, J=8.4), 8.99 (d, 1H). LRMS (ESI−) m/z: 314 (M−H+ C13H11F3N3O3 requires 314).
    • Example 85 Compound 107
  • Figure US20060014743A1-20060119-C00246
  • Compound 107 was prepared in analogous manner to 106 using methyl dichloroacetate in place methyl difluoroacetate. 1H NMR (300 MHz, CD3OD): δ 4.32-4.80 (m, 3H), 5.06 (d, 1H, J=3.0), 6.23 (S, 1H), 7.62 (d, 2H, J8.4), 8.03 (d, 2H, J=8,4), 8.98 (s. 1H). LRMS (ESI−) m/z: 346 (M−H+ C13H11Cl2FN3O3 requires 346).
    • Example 86 Compound 108
  • Figure US20060014743A1-20060119-C00247
  • Compound 102 (32.7 mg, 0.0925 mmol) was dissolved in EtOAc (8 mL) and cooled with stirring to 0° C. Pentafluorophenol (17 mg, 0.093 mmol) was added. Once all solids had dissolved, DCC (19 mg, 0.093 mmol) was added and the mixture stirred at 0° C. for 1.25 hours. The mixture was evaporated to one-quarter the original volume at which time a DCU precipitate formed. The DCU was removed by filtration and the pentafluorophenyl ester was isolated by evaporation. The residue was dissolved in 4 mL of MeOH and cooled to 0° C. with stirring. NaBH4 (18 mg, 0.46 mmol) was added portionwise. When bubbling ceased, the mixture was warmed to room temperature. After 2 hour, excess NaBH4 was quenched by addition of 4 drops of glacial HOAc. The mixture was evaporated to dryness and the residue partitioned between 1N aq. HCl and EtOAc. The EtOAc was separated and washed with 1 N aqueous HCl (2×15 mL), saturated aqueous NaHCO3 (2×10 mL) and finally brine (1×25 mL). The EtOAc layer was dried over anhydrous Na2SO4, filtered, and evaporated to give 50 mg of yellow oil. Chromatotron purification (1 mm plate, eluting with 5% EtOAc in hexanes to 10% EtOAc in hexanes) gave 108 (10.3 mg, 0.030 mmol). 1H NMR (300 MHz, CD3OD): δ 1.49 (s, 9H), 1.57 (s, 3H), 1.68 (s. 3H), 3.75-3.89 (m, 1H), 3.90 (s, 2H), 4.39-4.58 (m, 1H), 4.90-5.05 (br s, 1H), 5.19 (d, 1H, J=7.2), 7.57 (d, 2H, J=8.3), 8.04 (d, 2H, J=8.3).
    • Example 87 Compound 109
  • Figure US20060014743A1-20060119-C00248
  • Compound 108 (10 mg, 0.30 mmol) was dissolved in 5 mL of 9:1 TFA/H2O and stirred at room temperature for 1 hour. The mixture was then concentrated under vacuum to give approximately 9 mg of deprotected material as the TFA salt. 1H NMR (300 MHz, CD3OD): δ 3.54-3.68 (m, 1H), 3.91 (s, 2H), 4.24-4.67 (m, 2H), 4.90 (d, 1H, solvent obscured), 7.57 (d, 2H, J=8.4), 8.07 (d, 2H, J=8.4).
  • The 9 mg of material (0.03 mmol) were dissolved in 2 mL of MeOH in an open container. To this was added 15 drops of Et3N and 15 drops of methyl dichloroacetate. The mixture was stirred for 56 hour at room temperature. By the end of the reaction the solvent had completely evaporated. The residue was loaded onto a chromatotron (1 mm plate, eluting with 2% MeOH in CH2Cl2 to 4% MeOH in CH2Cl2, providing 7.5 mg of 109. 1H NMR (300 MHz, CD3OD): δ 3.88 (s, 2H), 4.28-4.73 (m, 3H), 5.02 (d, 1H, J=3.3), 6.22 (s, 1H), 7.51 (d, 2H, J=8.4), 7.97 (d, 2H, J=8.4).
    • Example 88 Compound 110
  • Figure US20060014743A1-20060119-C00249
  • Prepared in analogous fashion to other pyridine-containing biaryl compounds herein. 1H NMR (300 MHz, CD3OD): δ 2.54 (s, 3H), 4.30-4.68 (m, 3H), 4.99 (d, J=3.3), 5.98 (t, 1H, J=40.5), 7.35 (d, 1H, J=6.0), 7.49 (d, 2H, J=6.2), 7.61 (d, 2H, J=6.2), 7.95 (dd 1H, J=6.0, 1.7), 8.61 (d, 1H, J=1.7). LRMS (ESI−) m/z: 336.9 (M−H+ C17H16F3N2O2 requires 337.1).
    • Example 89 Compound 111
  • Figure US20060014743A1-20060119-C00250
  • Prepared in analogous fashion to other pyridine-containing biaryl compounds herein. 1H NMR (300 MHz, CD3OD): δ 2.56 (s, 3H), 4.30-4.74 (m, 3H), 5.01 (d, 1H, J=3.9), 6.27 (s, 1H), 7.36 (d, 1H, J=8.1), 7.56 (d, 2H, J=8.4), 7.61 (d, 2H, J=8.4), 7.96 (1H, dd, J=8.1, 2.3), 8.62 (d, 1H, J=2.31).
    • Example 90 Compound 112
  • Figure US20060014743A1-20060119-C00251
  • Compound 111 (0.0185 g, 0.0499 mmol) was dissolved in 10 mL CH2Cl2 at 0° C. To this was added m-CPBA (0.246 g, 0.0997 mmol). The mixture was stirred until the ice bath melted and the mixture came to room temperature, approximately 12 hours. The mixture was concentrated under vacuum and 112 was isolated by preparative plate silica gel chromatography (15% MeOH in CH2Cl2) followed by a silica gel plug (3% MeOH in CH2Cl2). LRMS (ESI−) m/z: 385 (M−H+ C17H16Cl2FN2O3 requires 385.1).
    • Example 91 Compound 113
  • Figure US20060014743A1-20060119-C00252
  • Compound 113 was synthesized from compound 110 in the same manner 112 was synthesized from 111. LRMS (ESI−) m/z: 353 (M−H+ C17H16Cl2FN2O3 requires 353.1).
    • Example 92 Compound 114
  • Figure US20060014743A1-20060119-C00253
  • This compound was prepared in the same manner as other biaryls herein. LRMS (ESI−) m/z: 324 (M−H+ C15H13F3N3O2 requires 324.1).
    • Example 93 Compound 115
  • Figure US20060014743A1-20060119-C00254
  • Prepared in same manner as compound 48. The required aryl bromide was prepared in two steps from 2-amino-1,3,4-thiadiazole by bromination with Br2 followed by acetylation. LRMS (ESI−) m/z: 419 (M−H+ C15H14Cl2FN4O3S requires 419.0).
    • Example 94 Compound 116
  • Figure US20060014743A1-20060119-C00255
  • Compound 116 was synthesized as set forth in Schemes 2 and 3. The phenylserine analog was obtained by condensation of 4-bromo-2-fluorobenzaldehyde with glycine. Suzuki coupling method B was used to couple the bromide intermediate with m-pyridineboronic acid. Deprotection and difluoroacetylation were carried out as described previously herein. LRMS (ESI+) m/z: 343 (M+H+ C16H15F4N2O2 requires 343.1).
    • Example 95 Compound 117
  • Figure US20060014743A1-20060119-C00256
  • Same procedure as that used for the synthesis of 116. LRMS (ESI+) m/z: 375 (M+H+ C16H15F4N2O2 requires 375.1).
    • Example 96 Compound 118
  • Figure US20060014743A1-20060119-C00257
  • Compound 19 (100 mg, 0.258 mmol), potassium acetate (38 mg, 0.386 mmol), and 2 mL of N,N′-dimethylacetamide (DMAC) were combined in a glass pressure tube. Thiazole (112 mg, 1.31 mmol) was added by syringe, and the syringe rinsed with an additional 1 mL of DMAC, which was added to the pressure tube. The mixture was stirred at room temperature while purging with N2 for 10 minutes. Pd(PPh3)4 (15 mg, 0.013 mmol) was added, the mixture purged with N2 for 5 minutes, the tube sealed and heated to 150° C. behind a blast shield and held at that temperature for 12 hours. The mixture became dark brown. After cooling to room temperature, the contents of the tube were filtered through a pad of Celite and the filtrate evaporated to dryness. The residue was dissolved in 40 mL of 3:1 EtOAc/hexanes and washed with H2O (2×15 mL) and brine (2×15 mL) and then dried over anhydrous Na2SO4. The dried organic layer was filtered to remove the drying agent and concentrated under vacuum to give 109 mg of brown oil. Compound 119 was purified by silica gel chromatography eluting with 80:20 to 50:50 hexanes/EtOAc (54 mg, 0.14 mmol). LRMS (ESI+) m/z: 393.1 (M+H+ C20H26FN2O3S requires 393.2).
  • All of compound 119 was dissolved in 9:1 (v/v) TFA/H2O (7.5 mL) and stirred at room temperature for 30 minutes. The mixture was then concentrated under vacuum and the residue dissolved twice in a mixture of toluene and methanol, the solvents being evaporated each time. A portion of the product (9.7 mg, 0.027 mmol) was dissolved in 2 mL of MeOH and 10 drops of Et3N and 12 drops of methyl difluoroacetate were added. The mixture was left open to the air and stirred rapidly for 16 hours. The mixture was evaporated to dryness and the residue purified by chromatotron (1 mm plate) eluting with 3% MeOH in CH2Cl2 to give 118 (6.0 mg, 0.018 mmol. 1H NMR (300 MHz, CD3OD): δ 4.27-4.69 (m, 3H), 4.97(d, 1H, J=4.2), 5.99 (t, 1H, J=53.9), 7.47 (d, 2H, J=8.3), 7.65 (d, 2H, J=8.3), 8.16 (s, 1H), 8.94 (s, 1H), LRMS (ESI+) m/z: 331.1 (M+H+ C14H14F3N2O2S requires 331.1).
    • Example 97 Compound 120
  • Figure US20060014743A1-20060119-C00258
  • Compound 120 was prepared in a manner analogous to that used to prepare 118 using dichloroacetylation instead of difluoroacetylation. LRMS (ESI+) m/z: 363.0 (M+H+ C14H14Cl2FN2O2S requires 363.0).
    • Example 98 Compound 121
  • Figure US20060014743A1-20060119-C00259
  • The protected biaryl intermediate was synthesized by Suzuki coupling method B from 23 and 3-chloro-6-methylpyridazine. Deprotection and dichloroacetylation Were performed as for other compounds of this invention. LRMS (ESI+) m/z: 372.0 (M+H+ C16H17Cl2FN3O2 requires 372.1).
    • Example 99 Compound 122
  • Figure US20060014743A1-20060119-C00260
  • Prepared in analogous fashion to 121. LRMS (ESI+) m/z: 340.1 (M+H+ C16H17F3N3O2 requires 340.1).
    • Example 100 Compound 123
  • Figure US20060014743A1-20060119-C00261
  • The protected biaryl intermediate was prepared by Suzuki coupling method B from boronic acid 23 and the appropriate aryl bromide. This intermediate was then deprotected by brief treatment with 9:1 (v/v) TFA/H2O and dichloroacetylated as described for 29. LRMS (ESI+) m/z: 380.0 (M−H+ C17H13Cl2FN3O2 requires 380.0).
    • Example 101 Compound 124
  • Figure US20060014743A1-20060119-C00262
  • Prepared in analogous fashion to 123. Difluoroacetylation was performed as with other compounds of this invention. LRMS (ESI+) m/z: 348.0 (M+H+ C17H13F3N3O2 requires 348.1).
    • Example 102 Compound 125
  • Figure US20060014743A1-20060119-C00263
  • The biaryl intermediate was prepared from boronic acid 23 using Suzuki coupling. LRMS (ESI+) m/z: 392.0 (M−H+ C15H13Cl3FN3O2 requires 392.0).
    • Example 103 Compound 126
  • Figure US20060014743A1-20060119-C00264
  • The starting nitrile was prepared from 35 by analogy to the preparation of bromo intermediate 19. Treatment with Ph2P(S)SH gave the thiobenzamide which was converted to the thiobenzamidine intermediate by reaction with dimethylformamide dimethylacetal. Cyclization with hydroxylamine-O-sulfonic acid in methanol/pyridine gave the biaryl intermediate. LRMS (ESI+) m/z: 364.0 (M−H+ C13H12Cl2FN3O2S requires 364.0)
    • Example 104 Compound 127
  • Figure US20060014743A1-20060119-C00265
  • The phenyllithium intermediate was prepared by treatment of intermediate 19 with n-butyllithium in THF at −78° C. The intermediate was reacted with pyridazine and the mixture of the resulting 2- and 3-position adducts was oxidized with DDQ. The desired 3-pyridazyl regioisomer was isolated by chromatography. LRMS (ESI+) m/z: 326.0 (M−H+ C15H14F3N3O2 requires 326.0)
    • Example 105 Compound 128
  • Figure US20060014743A1-20060119-C00266
  • Compound 128 was synthesized using the procedure in Example 104. LRMS (ESI+) m/z: 358.0 (M−H+ C15H14Cl2FN3O2 requires 358.0)
    • Example 106 Compound 129
  • Figure US20060014743A1-20060119-C00267
  • The procedure discussed in Example 104 was used. LRMS (ESI+) m/z: 358.0 (M−H+ C15H14Cl2FN3O2 requires 358.0)
    • Example 107 Compound 130
  • Figure US20060014743A1-20060119-C00268
  • The procedure of Example 104 was used. LRMS (ESI+) m/z: 326.0 (M−H+ C15H14F3N3O2 requires 326.0)
    • Example 108 Compound 131
  • Figure US20060014743A1-20060119-C00269
  • The phenyllithium intermediate was reacted with N-methoxy-N-methylacetamide and the resulting acetophenone was reacted with dimethylformamide dimethylacetal and hydroxylamine-O-sulfonic acid in methanol in presence of pyridine to give the isoxazole. LRMS (ESI+) m/z: 347.0 (M−H+ C14H13Cl2N2O3 requires 347.0)
    • Example 109 Compound 132
  • Figure US20060014743A1-20060119-C00270
  • Compound 132 was synthesized using the procedure in Example 108. LRMS (ESI+) m/z: 315.0 (M−H+ C14H13F3N2O3 requires 315.0.
    • Example 110 Compound 133
  • Figure US20060014743A1-20060119-C00271
  • The phenyllithium intermediate was reacted with dimethylformamide to give the formyl intermediate which was then reacted with the ylide generated from methoxymethyltriphenyl phosphonium bromide. The resulting enol ether was brominated with bromine to give the bromoaldehyde. Cyclization with thiourea gave the aminothiazole. LRMS (ESI+) m/z: 378.0 (M−H+ C14H14Cl2FN3O2S requires 378.0)
    • Example 111 Compound 134
  • Figure US20060014743A1-20060119-C00272
  • Compound 134 was synthesized using the procedure in Example 110. LRMS (ESI+) m/z: 346.0 (M−H+ C14H14F3N3O2S requires 346.0)
    • Example 112 Compound 135 (Mixture of Diastereoisomers)
  • Figure US20060014743A1-20060119-C00273
  • Compound 135 was synthesized using the procedure in Example 108. LRMS (ESI+) m/z: 331.0 (M−H+ C14H13F2N2O3 requires 331.0)
    • Example 113 Compound 136
  • Figure US20060014743A1-20060119-C00274
  • The starting material in Example 108 was reacted with Lawesson's reagent and the product was cyclized to the biaryl intermediate with hydroxylamine-O-sulfonic acid in methanol in presence of pyridine. LRMS (ESI+) m/z: 363.0 (M−H+ C14H13Cl2FN2O2S requires 363.0)
    • Example 114 Compound 137
  • Figure US20060014743A1-20060119-C00275
  • Compound 137 was synthesized using the procedure in Example 113. LRMS (ESI+) m/z: 331.0 (M−H+ C14H13F3N2O2S requires 331.0)
    • Example 115 Compound 138 (Mixture of Diastereoisomers)
  • Figure US20060014743A1-20060119-C00276
  • Compound 138 was synthesized using the procedure in Example 113. LRMS (ESI+) m/z: 347.0 (M−H+ C14H13CIF2N2O2S requires 347.0)
    • Example 116 Compound 139
  • Figure US20060014743A1-20060119-C00277
  • Compound 139 was synthesized using the procedure in Example 96 starting from the desired enantiomer of intermediate 19. LRMS (ESI+) m/z: 331.0 (M−H+ C14H13F3N2O2S requires 331.0)
    • Example 117 Compound 140 (Mixture of Diastereoisomers)
  • Figure US20060014743A1-20060119-C00278
  • Compound 140 was synthesized using the procedure in Example 41. LRMS (ESI+) m/z: 348.0 (M−H+ C13H12CIF2N3O2S requires 348.0)
    • Example 118 Compound 141
  • Figure US20060014743A1-20060119-C00279
  • Intermediate 19 was reacted with trimethylsilylacetylene in presence of copper iodide and PdCl2(PPh3)2. The product was desilylated by treatment with potassium carbonate in methanol. The cyanoacetylene intermediate was reacting acetylene with n-butyllithium, which was then reacted with tosylcyanide. Cyclization to the 3-aminoisoxazole was performed by treatment of the cyanoacetylene with hydroxylamine in ethanol. LRMS (ESI+) m/z: 330.0 (M−H+ C14H14F3N3O3 requires 330.0)
    • Example 119 Compound 142
  • Figure US20060014743A1-20060119-C00280
  • Compound 142 was synthesized using the procedure in Example 118. LRMS (ESI+) m/z: 362.0 (M−H+ C14H14Cl2FN3O3 requires 362.0)
    • Example 120 Compound 143
  • Figure US20060014743A1-20060119-C00281
  • The desired enantiomer of intermediate 19 was reacted with bis(pinacolato)diboron in presence of 1,1′-bis(diphenylphosphino)ferrocenepalladium (II) dichloride dichloromethane. The pinacolboronate ester was coupled with 5-bromo-2-cyanopyridine using the Suzuki reaction. LRMS (ESI+) m/z: 350.0 (M−H+ C17H14F3N3O2 requires 350.0)
    • Example 121 Compound 144
  • Figure US20060014743A1-20060119-C00282
  • Compound 144 was synthesized using the procedure in Example 120. LRMS (ESI+) m/z: 382.0 (M−H+ C17H14Cl2FN3O2 requires 382.0)
    • Example 122 Compound 145 (Mixture of Diastereoisomers)
  • Figure US20060014743A1-20060119-C00283
  • Intermediate 19 was reacted with n-butyllithium and then with dimethylformamide. The formyl intermediate was reacted with methylmagnesium bromide to give the benzylic alcohol as a mixture of diastereisomers. LRMS (ESI+) m/z: 324.0 (M−H+ C13H16Cl2FNO3 requires 324.0)
    • Example 123 Compound 146
  • Figure US20060014743A1-20060119-C00284
  • The starting acetylene, prepared as described in Example 118, was reacted with n-butyllithium followed by addition of carbon dioxide and the resulting acid was esterified with diazomethane in ethyl acetate/diethyl ether. The 3-hydroxyisoxazole was obtained by reacting the ester with hydroxylamine and was then methylated with diazomethane in ethyl acetate/diethyl ether. LRMS (ESI+) m/z: 377.0 (M−H+ C15H15Cl2FN2O4 requires 377.0)
    • Example 124 Compound 147
  • Figure US20060014743A1-20060119-C00285
  • Compound 147 was synthesized by the method of Example 120 using 2-bromo-1,3,4-thiadiazole in a Suzuki coupling. LRMS (ESI+) m/z: 364.0 (M−H+ C13H12Cl2FN3O2S requires 364.0)
    • Example 125 Compound 148
  • Figure US20060014743A1-20060119-C00286
  • The starting acetylene was obtained as described in Example 118. The 3-carboethoxy isoxazole intermediate was obtained by cycloaddition of the nitrile oxide generated in situ from ethyl nitroacetate, di-t-butyldicarbonate and 4-dimethylaminopyridine. The amide was obtained from the 3-carboethoxy isoxazole intermediate by hydrolysis to the acid, conversion to the acyl chloride and reaction with ammonia. LRMS (ESI+) m/z: 358.0 (M−H+ C15H14F3N3O4 requires 358.0)
    • Example 126 Compound 149
  • Figure US20060014743A1-20060119-C00287
  • Compound 149 was synthesized using the procedure in Example 108 starting from the desired enantiomer of intermediate 19. LRMS (ESI+) m/z: 347.0 (M−H+ C14H13Cl2FN2O3 requires 347.0)
    • Example 127 Compound 150
  • Figure US20060014743A1-20060119-C00288
  • The 3-carboxyisoxazole intermediate obtained as described in Example 125 was converted into the acid chloride using Vilsmeyer reagent in dimethylformamide. The crude product was reduced to the 3-hydroxymethyl isoxazole intermediate with tetrabutylammonium borohydride in THF. LRMS (ESI+) m/z: 377.0 (M−H+ C15H15Cl2FN2O4 requires 377.0)
    • Example 128 Compound 151
  • Figure US20060014743A1-20060119-C00289
  • Compound 151 was synthesized using the procedure in Example 127. LRMS (ESI+) m/z: 345.0 (M−H+ C15H15F3N2O4 requires 345.0)
    • Example 129 Compound 152
  • Figure US20060014743A1-20060119-C00290
  • Compound 152 was synthesized using the procedure in Example 125. LRMS (ESI+) m/z: 390.0 (M−H+ C15H14Cl2FN3O4 requires 390.0)
    • Example 130 Compound 153
  • Figure US20060014743A1-20060119-C00291
  • Compound 153 was synthesized using the procedure in Example 40. EDC/HOBT was used to acylate the amino intermediate with cyanoacetic acid. LRMS (ESI+) m/z: 314.0 (M−H+ C17H16FN3O2 requires 314.0)
    • Example 131 Compound 154
  • Figure US20060014743A1-20060119-C00292
  • Compound 154 was synthesized using the procedure in Example 130. LRMS (ESI+) m/z: 330.0 (M−H+ C16H16FN5O2 requires 330.0)
    • Example 132 Compound 155
  • Figure US20060014743A1-20060119-C00293
  • The starting acetylene was obtained as described in Example 118. The 3-methyl isoxazole intermediate was obtained by cycloaddition of the nitrile oxide generated in situ from nitroethane, di-t-butyldicarbonate and 4-dimethylaminopyridine. LRMS (ESI+) m/z: 329.0 (M−H+ C15H15F3N2O3 requires 329.0)
    • Example 133 Compound 156
  • Figure US20060014743A1-20060119-C00294
  • Compound 156 was synthesized using the procedure in Example 132. LRMS (ESI+) m/z: 361.0 (M−H+ C15H15Cl2FN2O3 requires 361.0)
    • Example 134 Compound 157
  • Figure US20060014743A1-20060119-C00295
  • Intermediate 19 was reacted with 4-methylimidazole in refluxing dimethylformamide in the presence of copper powder. LRMS (ESI+) m/z: 3460.0 (M−H+ C14H14Cl2FN3O2 requires 346.0)
    • Example 135 Compound 158
  • Figure US20060014743A1-20060119-C00296
  • Compound 158 was synthesized using the procedure in Example 134. LRMS (ESI+) m/z: 328.0 (M−H+ C15H16F3N3O2 requires 328.0)
    • Example 136 Compound 159
  • Figure US20060014743A1-20060119-C00297
  • Compound 159 was synthesized using the procedure in Example 126. LRMS (ESI+) m/z: 315.0 (M−H+ C14H13F3N2O3 requires 315.0)
    • Example 137 Compound 160
  • Figure US20060014743A1-20060119-C00298
  • A mixture of the desired enantiomer of intermediate 19 (1 g, 2.5 mmol), potassium carbonate (712 mg, 5 mmol), and propiolamide (1.07 g, 15 mmol) in N,N-dimethylacetamide (4 mL) was stirred at room temperature while purging with N2 for 10 minutes. Pd(PPh3)4 catalyst (15 mg, 0.013 mmol) was added and the mixture was purged with N2 for another 5 minutes. The resulting mixture was stirred at 100° C. for 9 hrs. After cooling to room temperature, the crude was flash silica gel chromatographed to give the coupling product (601 mg). 1H NMR (300 MHz, CDCl3): δ 1.49 (s, 9H), 1.59 (s, 3H), 1.70 (s, 3H), 3.75-3.90 (m, 1H), 4.35-4.60 (m, 2H), 5.15 (d, 1H, J=7.5), 5.65 (s, 1H), 5.85 (s, 1H), 7.45 (d, 2H, J=8.4), and 7.55 (d, 2H, J=8.4).
    Figure US20060014743A1-20060119-C00299
  • To dimethylformamamide (2 mL) was slowly added thionyl chloride (2 mL) at 0° C. and the reaction mixture was stirred at that temperature for 30 min. The solution was then cannulated to a solution of the propiolamide intermediate (600 mg) in DMF (4 mL) at 0° C. After stirring at room temperature for 30 min, the mixture was poured into ice/water (50 mL). The pH was adjusted to 7 with saturated sodium bicarbonate. The solution was extracted with ethyl acetate three times. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and purified by column chromatography to give propiolonitrile intermediate (326 mg). 1H NMR (300 MHz, CDCl3): δ 1.49 (s, 9H), 1.59 (s, 3H), 1.70 (s, 3H), 3.75-3.90 (m, 1H), 4.35-4.60 (m, 2H), 5.15 (d, 1H, J=7.5), 7.49 (d, 2H, J=8.4), and 7.63 (d, 2H, J=8.4).
    Figure US20060014743A1-20060119-C00300
  • To a solution of sodium hydroxide (206 mg, 7 eq.) in water (2 mL), was added hydroxylamine hydrochloride (256 mg, 5 eq.). The solution was added to the propiolonitrile intermediate (263 mg) dissolved in ethanol (7 mL). The resulting mixture was stirred at room temperature for 6 hrs. Ethyl acetate was added, the organic layer was separated, washed with water, and dried with anhydrous sodium sulfate. The crude material was purified by column chromatography to give the protected 3-aminoisoxazole which was then dissolved in THF (6 mL) and 4 N HCl (6 mL), and stirred at 80° C. for 2.5 hrs. The reaction mixture was evaporated to dryness under reduced pressure. The residue was co-evaporated with methanol twice and dried overnight under vacuum. To the crude material dissolved in methanol (2 mL) was added triethylamine (2 mL), followed by methyl dichloroacetate (1 mL). The mixture was stirred at room temperature for 24 hrs. The solvent was evaporated and the mixture was purified by flash column chromatography to give compound 160 (167 mg). 1H NMR (300 MHz, CDCl3+CD3OD): δ 4.35-4.70 (m, 3H), 5.05 (m, 1H), 5.85 (s, 1H), 6.16 (s, 1H), 7.44 (d, 2H, J=8.1), and 7.65 (d, 2H, J=8.1). LRMS (ESI+) m/z: 362.0 (M−H+ C14H14Cl2FN3O3 requires 362.0)
    • Example 138 Compound 161
  • Figure US20060014743A1-20060119-C00301
  • Compound 161 was synthesized using the procedure in Example 132 starting from the desired enantiomer of intermediate 19. LRMS (ESI+) m/z: 361.0 (M−H+ C15H15Cl2FN2O3 requires 361.0)
    • Example 139 Compound 162
  • Figure US20060014743A1-20060119-C00302
  • Compound 162 was synthesized using the procedure in Example 138. LRMS (ESI+) m/z: 329.0 (M−H+ C15H15F3N2O3 requires 329.0)
    • Example 140 Compound 163
  • Figure US20060014743A1-20060119-C00303
  • Compound 163 was synthesized using the procedure in Example 120. Dipyclohexylcarbodiimide was used to acylate the amino intermediate with cyanoacetic acid. LRMS (ESI+) m/z: 339.0 (M−H+ C18H15FN4O2 requires 339.0)
    • Example 141 Compound 164
  • Figure US20060014743A1-20060119-C00304
  • Compound 164 was synthesized using the procedure in Example 120. Dicyclohexylcarbodiimide was used to acylate the amino intermediate with azidoacetic acid. LRMS (ESI+) m/z: 355.0 (M−H+ C17H15FN6O2 requires 355.0)
    • Example 142 Compound 165
  • Figure US20060014743A1-20060119-C00305
  • Compound 165 was synthesized using the procedure in Example 120. The amino intermediate was acetylated with acetic anhydride. LRMS (ESI+) m/z: 314.0 (M−H+ C17H16FN3O2 requires 314.0)
    • Example 143 Compound 166
  • Figure US20060014743A1-20060119-C00306
  • Compound 166 was synthesized using the procedure in Example 120. LRMS (ESI+) m/z: 350.0 (M−H+ C13H11F4N3O2S requires 350.0)
    • Example 144 Compound 167
  • Figure US20060014743A1-20060119-C00307
  • Compound 167 was synthesized using the procedure in Example 120. Dicyclohexylcarbodiimide was used to acylate the amino intermediate with N-Boc-glycine and the resulting glycinamide was deprotected with hydrochloric acid in methanol. LRMS (ESI+) m/z: 329.0 (M−H+ C17H17FN4O2 requires 329.0)
    • Example 145 Compound 168
  • Figure US20060014743A1-20060119-C00308
  • Compound 168 was synthesized using the procedure in Example 144. LRMS (ESI+) m/z: 343.0 (M−H+ C18H19FN4O2 requires 343.0)
    • Example 146 Compound 169
  • Figure US20060014743A1-20060119-C00309
  • The desired enantiomer of intermediate 19 (1.16 g, 3 mmol), potassium carbonate (1.659 g, 12 mmol), imidazole (1.225 g, 18 mmol), and copper powder (191 mg, 3 mmol) in 20 mL of DMF were stirred vigorously at reflux for 4 hrs. The reaction mixture was cooled to room temperature and poured into water (100 mL). After extraction with ethyl acetate and washing of the organic extract with water (3×), the organic layer was passed through a silica gel and anhydrous sodium sulfate plug. Evaporation of solvent gave the imidazole (1.06 g). 1H NMR (300 MHz, CDCl3): δ 1.45 (s, 9H), 1.60 (s, 3H), 1.75 (s, 3H), 3.75-3.85 (m, 1H), 4.35-4.55 (m, 2H), 5.20 (d, 1H, J=7.5), 7.22 (s, 1H), 7.28 (s, 1H), 7.41 (d, 2H, J=8.4), 7.58 (d, 2H, J=8.4), and 7.89 (s, 1H).
    Figure US20060014743A1-20060119-C00310
  • The imidazole intermediate (2.77 g) was dissolved in THF (20 mL) and 4 N HCl (20 mL), and stirred at 80° C. for 2.5 hrs. The reaction mixture was evaporated to dryness under reduced pressure. The residue was co-evaporated with methanol twice and dried overnight under vacuum. The crude material was dissolved in methanol (20 mL) and triethylamine (5 mL) was added, followed by methyl dichloroacetate (5 mL). The mixture was stirred at room temperature for 20 hrs. The solvent was evaporated and the mixture was purified by flash column chromatography to give compound 169 (1.1 g) as white solid. 1H NMR (300 MHz, CDCl3): δ 4.30-4.75 (m, 3H), 5.21 (d, 1H, J=7.5), 5.86 (s, 1H), 7.05 (d, 1H, J=7.5), 7.10 (s, 1H), 7.28 (s, 1H), 7.39 (d, 2H, J=8.4), 7.52 (d, 2H, J=8.4 Hz), and 7.81 (s, 1H). LRMS (ESI+) m/z: 360.0 (M−H+ C15H16C12FN3O2 requires 360.0)
    • Example 147 Compound 170
  • Figure US20060014743A1-20060119-C00311
  • Compound 170 was synthesized by the method of Example 106 using the desired enantiomer of intermediate 19. LRMS (ES+) m/z: 358.0 (M−H+ C15H14Cl2FN3O2 requires 358.0)
    • Example 148 Compound 171
  • Figure US20060014743A1-20060119-C00312
  • Compound 171 was synthesized using the procedure in Example 147. LRMS (ESI+) m/z: 326.0 (M−H+ C15H14F3N3O2 requires 326.0)
    • Example 149 Compound 172
  • Figure US20060014743A1-20060119-C00313
  • Compound 172 was synthesized by the method of Example 110 using the desired enantiomer of intermediate 19. LRMS (ESI+) m/z: 346.0 (M−H+ C14H14F3N3O2S requires 346.0)
    • Example 150 Compound 173
  • Figure US20060014743A1-20060119-C00314
  • Compound 173 was synthesized using the procedure in. Example 137. LRMS (ESI+) m/z: 330.0 (M−H+ C14H14F3N3O3 requires 330.0)
    • Example 151 Compound 174
  • Figure US20060014743A1-20060119-C00315
  • Compound 174 was synthesized using the procedure in Example 146. LRMS (ESI+) m/z: 314.0 (M−H+ C14H14F3N3O2 requires 314.0)
    • Example 152 Compound 175
  • Figure US20060014743A1-20060119-C00316
  • Compound 175 was synthesized using the procedure in Example 28. LRMS (ESI+) m/z: 290.0 (M−H+ C13H14F3NO3 requires 290.0)
    • Example 153 Compound 176
  • Figure US20060014743A1-20060119-C00317
  • Compound 176 was synthesized using the procedure in Example 149. LRMS (ESI+) m/z: 378.0 (M−H+ C14H14C12FN3O2S requires 378.0)
    • Example 154 Compound 177
  • Figure US20060014743A1-20060119-C00318
  • Compound 177 was synthesized by the method of Example 33 using the bromopyridine derivative and boronic acid 23. LRMS (ESI+) m/z: 372.0 (M−H+ C16H16C12FN3O2 requires 372.0)
    • Example 155 Compound 178
  • Figure US20060014743A1-20060119-C00319
  • Compound 178 was synthesized by the method of Example 33 using a bromopyrimidine derivative and boronic acid 23. LRMS (ESI+) m/z: 373.0 (M−H+ C15H15Cl2FN4O2 requires 373.0)
    • Example 156 Compound 179
  • Figure US20060014743A1-20060119-C00320
  • Compound 179 was synthesized by the method of Example 33 using the bromopyrimidine derivative and boronic acid 23. Standard conditions were used for the removal of protecting groups and the introduction of dichloroacetamide functionality. LRMS (ESI+) m/z: 373.0 (M−H+ C15H15Cl2FN4O2 requires 373.0)
    • Example 157 Compound 180
  • Figure US20060014743A1-20060119-C00321
  • Compound 180 was synthesized by the method of Example 33 using the requisite chloropyridazine derivative and boronic acid 23. Standard conditions were used for the removal of protecting groups and the introduction of dichloroacetamide functionality. LRMS (ESI+) m/z: 373.0 (M−H+ C15H15Cl2FN4O2 requires 373.0)
    • Conclusion
  • Thus, it will be appreciated that the present invention provides novel florfenicol-like compounds and methods for their use in the treatment or prevention of bacterial infection in animals or humans.
  • Although certain embodiments and examples have been used to describe the present invention, it will be apparent to those skilled in the art that changes in the embodiments and examples shown may be made without departing from the scope of this invention.

Claims (24)

1-25. (canceled)
26. A method of preventing a bacterial infection in a nonhuman patient comprising administering to the nonhuman patient a pharmaceutically effective amount of a compound having the chemical formula:
Figure US20060014743A1-20060119-C00322
wherein R2 and R3 are independently selected from the group consisting of hydrogen, (1C-4C)alkyl, halo, —CF3, —NH2, —CN and N3;
wherein R4 is selected from the group consisting of:
Figure US20060014743A1-20060119-C00323
wherein A1 is carbon or nitrogen, and carbon atoms in the ring are independently substituted with an entity selected from the group consisting of hydrogen, (1C-4C)alkyl, (3C-6C)cycloalkyl, (1C-4C)alkylO—, —CF3, —OH, —CN, halo, (1C-4C)alkylSO—, (1C-4C)alkylSO2—, NH2SO2—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, —NH2, (1C-4C)alkylNH—, ((1C-4C)alkyl)2N—, (1C-4C)alkylSO2NH—, (1C-4C)alkylC(O)—, (3C-6C)cycloalkylC(O)—, (1C-4C)alkylOC(O)—, (1C-4C)alkylC(O)NH—, —C(O)NH2, (1C-4C)alkylNHC(O)— and ((1C-4C)alkyl)2NC(O)—, wherein any of the alkyl groups within the substituents may be unsubstituted or substituted with a group selected from halo and hydroxy;
wherein A2, A3, A4, and A5 are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur, provided that at least one of A1-A5 is not carbon, that the total number of nitrogen, oxygen and sulfur atoms in the ring does not exceed 4 and that the ring is aromatic; and wherein if A1 is carbon and the ring does not contain oxygen or sulfur, one of the nitrogen atoms may optionally be substituted with an entity selected from the group consisting of (1C-4C)alkyl, (1C-4C)alkylSO2— and —NH2; and
wherein A6, A7, A8, A9 and A10 are independently selected from the group consisting of carbon, nitrogen and
Figure US20060014743A1-20060119-C00324
provided that only one of A6-A10 at a time can be
Figure US20060014743A1-20060119-C00325
and that one, two, or three of the A6-A10 atoms are nitrogen; and wherein the carbon atoms in the ring are independently substituted with an entity selected from the group consisting of hydrogen, (1C-4C)alkyl, (3C-6C)cycloalkyl, (1C-4C)alkylO—, —CF3, —OH, —CN, halo, (1C-4C)alkylSO—, (1C-4C)alkylSO2—, NH2SO2—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, —NH2, (1C-4C)alkylNH—, ((1C-4C)alkyl)2N—, (1C-4C)alkylSO2NH—, (1C-4C)alkylC(O)—, (3C-6C)cycloalkylC(O)—, (1C-4C)alkylOC(O)—, (1C-4C)alkylC(O)NH—, —C(O)NH2, (1C-4C)alkylNHC(O)—, ((1C-4C)alkyl)2NC(O)— and —OCH2O—, wherein the oxygen atoms with the —OCH2O— substituent being bonded to adjacent ring carbon atoms, and wherein any of the alkyl groups within any of the substituents may be unsubstituted or substituted with a group selected from halo and hydroxy; and
wherein R8 is hydrogen in all compounds, except when R2 and R3 are both F, in which case R8 is hydrogen or F; and, the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
27. The method of claim 26, wherein R2 and R3 are independently selected from the group consisting of Cl and F; and wherein R8 is hydrogen.
28. The method of claim 27, wherein:
R4 is
Figure US20060014743A1-20060119-C00326
and,
wherein any of A6-A10 that is a carbon atom is substituted with an entity selected from the group consisting of hydrogen, —NH2, halo-, —CN, (1C-4C)alkyl-, (1C-4C)alkylC(O)—, (1C-4C)alkylSO—, (1C-4C)alkylSO2, NH2SO2—, (1C-4C)alkylSO2NH—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, wherein any of the alkyl groups within any of the substituents may be unsubstituted or substituted with halo or hydroxy.
29. The method of claim 27, wherein R4 is selected from the group consisting of:
Figure US20060014743A1-20060119-C00327
30. The method of claim 27 wherein R4 is
Figure US20060014743A1-20060119-C00328
31. The method of claim 30, wherein all carbon atoms and nitrogen atoms are unsubstituted.
32. The method of claim 30, wherein one of the A2-A5 atoms that is carbon is substituted with an —NH2 group, and all other carbon and nitrogen atoms in the ring are unsubstituted.
33. The method of claim 30, wherein R4 is selected from the group consisting of:
Figure US20060014743A1-20060119-C00329
34. The method of claim 27 selected from the group consisting of:
Figure US20060014743A1-20060119-C00330
Figure US20060014743A1-20060119-C00331
Figure US20060014743A1-20060119-C00332
Figure US20060014743A1-20060119-C00333
wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
35. The method of claim 34 selected from the group consisting of:
Figure US20060014743A1-20060119-C00334
Figure US20060014743A1-20060119-C00335
wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
36. The method of claim 26, wherein:
R4 is
Figure US20060014743A1-20060119-C00336
and, wherein any of A6-A10 that is a carbon atom is substituted with an entity selected from the group consisting of hydrogen, —NH2, halo-, —CN, (1C-4C)alkyl-, (1C-4C)alkylC(O)—, (1C-4C)alkylSO—, (1C-4C)alkylSO2, NH2SO2—, (1C-4C)alkylSO2NH—, (1C-4C)alkylNHSO2—, ((1C-4C)alkyl)2NSO2—, wherein any of the alkyl groups within any of the substituents may be unsubstituted or substituted with halo or hydroxy.
37. The method of claim 26, wherein:
R4 is
Figure US20060014743A1-20060119-C00337
wherein any of A6-A10 that are carbon atoms are optionally substituted with —NH2, and wherein all remaining A6-A10 carbon atoms are unsubstituted.
38. The method of claim 26, wherein R4 is selected from the group consisting of:
Figure US20060014743A1-20060119-C00338
39. The method of claim 26, wherein R4 is
Figure US20060014743A1-20060119-C00339
40. The method of claim 39, wherein all carbon atoms and nitrogen atoms are unsubstituted.
41. The method of claim 39, wherein one of the A2-A5 atoms that is carbon is substituted with an —NH2 group, and all other carbon and nitrogen atoms in the ring are unsubstituted.
42. The method of claim 39, wherein R4 is selected from the group consisting of:
Figure US20060014743A1-20060119-C00340
43. The method of claim 26, selected from the group consisting of:
Figure US20060014743A1-20060119-C00341
wherein the compound is either a racemate having the relative stereochemistry shown or is substantially enantiomerically pure and has the absolute stereochemistry shown.
44. A method of preventing a bacterial infection in a nonhuman patient comprising administering to the nonhuman patient a pharmaceutically effective amount of a compound having the chemical formula:
Figure US20060014743A1-20060119-C00342
45. The method of claim 44, wherein the compound is a racemate having the relative stereochemistry shown.
46. The method of claim 44, wherein the compound is substantially enantiomerically pure and has a 1-(R)-2-(S) absolute configuration.
47. The method of claim 26, wherein the bacterial infection is caused by a bacteria of the genus Pasteurella, Haemophilus, Fusobacterium, Bacterioides, Aeromonas, Enterobacter, Escherichia, Klebsiella, Salmonella, Shigella, Actinobacillus, Streptococcus, Mycoplasma, Edwardsiella, Staphylococcus, Enterococcus, Bordetella, Proteus, or Mannheimia.
48. The method of claim 47, wherein the bacterial infection is caused by Mannhemia haemolytica, Pasteurella multocida, Haemophilus somnus, Fusobacterium necrophorum, Bacterioides melaninogenicus, Actinobacillus pleuropneumoniae, Streptococcus suis, Salmonella cholerasuis, Mycoplasma bovis, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Mycoplasma gallisepticum, Edwardsiella ictaluri, Escherichia coli, Enterobacter cloacae, Staphylococcus aureus, Staphylococcus intermedius, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Proteus mirabilis, or Aeromonas salmonicida.
US11/211,919 2002-03-08 2005-08-25 Methods of preventing bacterial infections with florfenicol-type antibiotics Abandoned US20060014743A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/211,919 US20060014743A1 (en) 2002-03-08 2005-08-25 Methods of preventing bacterial infections with florfenicol-type antibiotics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9468802A 2002-03-08 2002-03-08
US10/410,330 US7041670B2 (en) 2002-03-08 2003-04-08 Florfenicol-type antibiotics
US11/211,919 US20060014743A1 (en) 2002-03-08 2005-08-25 Methods of preventing bacterial infections with florfenicol-type antibiotics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/410,330 Continuation US7041670B2 (en) 2002-03-08 2003-04-08 Florfenicol-type antibiotics

Publications (1)

Publication Number Publication Date
US20060014743A1 true US20060014743A1 (en) 2006-01-19

Family

ID=28038831

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/410,330 Expired - Lifetime US7041670B2 (en) 2002-03-08 2003-04-08 Florfenicol-type antibiotics
US11/211,919 Abandoned US20060014743A1 (en) 2002-03-08 2005-08-25 Methods of preventing bacterial infections with florfenicol-type antibiotics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/410,330 Expired - Lifetime US7041670B2 (en) 2002-03-08 2003-04-08 Florfenicol-type antibiotics

Country Status (16)

Country Link
US (2) US7041670B2 (en)
EP (1) EP1487785A2 (en)
JP (1) JP2005538937A (en)
KR (1) KR20040091698A (en)
CN (1) CN1649829A (en)
AU (1) AU2003249503A1 (en)
BR (1) BR0308289A (en)
CA (1) CA2478048A1 (en)
EC (1) ECSP045284A (en)
IL (1) IL163749A0 (en)
MX (1) MXPA04008677A (en)
NO (1) NO20044257L (en)
TW (1) TW200406372A (en)
UA (1) UA78026C2 (en)
WO (1) WO2003077828A2 (en)
ZA (1) ZA200406938B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070142468A1 (en) * 2003-07-18 2007-06-21 Murthy Yerramilli V Compositions containing prodrugs of florfenicol and methods of use
US20090105337A1 (en) * 2007-10-19 2009-04-23 Idexx Laboratories, Inc. Esters of Florfenicol
WO2012125832A2 (en) * 2011-03-15 2012-09-20 Rib-X Pharmaceuticals, Inc. Antimicrobial agents
US9573962B2 (en) 2009-10-16 2017-02-21 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US9845297B2 (en) 2009-10-16 2017-12-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US9937183B2 (en) 2013-09-09 2018-04-10 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US10106543B2 (en) 2013-09-09 2018-10-23 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US10947237B2 (en) 2015-03-11 2021-03-16 BioVersys AG Antimicrobial compounds and methods of making and using the same
US11999739B2 (en) 2016-05-06 2024-06-04 BioVersys AG Antimicrobials methods of making and using the same

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044437A1 (en) 2003-05-29 2005-09-14 Schering Plough Ltd COMPOSITIONS AND METHOD FOR TREATMENT OF INFECTIONS IN VACCINE AND PORCINE LIVESTOCK
TWI262181B (en) 2003-12-23 2006-09-21 Schering Plough Ltd Florfenicol prodrug having improved water solubility
WO2005066119A2 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Antibacterial 1-(4-mono-and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoropropanols and preparation thereof
EP1836162A2 (en) 2004-09-02 2007-09-26 IDEXX Laboratories Inc Antibacterial agents
PE20060693A1 (en) 2004-09-23 2006-09-01 Schering Plough Ltd NEW DERIVATIVES OF TRIFLUOROMETANSULFONANILIDE OXAMIDE ETER
EP1811841B1 (en) 2004-11-19 2009-10-28 Schering-Plough Ltd. Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitrile derivatives
US20060281695A1 (en) * 2005-06-09 2006-12-14 Schering-Plough Animal Health Corporation Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
RU2008112952A (en) * 2005-09-07 2009-10-20 Шеринг-Плоу Лтд. (CH) METHOD FOR PRODUCING COMPOUNDS OF OXYZOLIDINE ETHER AND THEIR TRANSFORMATION TO FLORPHENICOL
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8068991B2 (en) * 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8119667B2 (en) 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
WO2008005338A1 (en) * 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
CA2672586A1 (en) 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of florfenicol and its analogs
CA2672795A1 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof
JP2010529016A (en) * 2007-05-30 2010-08-26 シェーリング−プラウ リミテッド Process for preparing oxazoline protected aminodiol compounds useful as intermediates to florfenicol
TWI430995B (en) 2007-06-26 2014-03-21 Du Pont Naphthalene isoxazoline invertebrate pest control agents
BRPI0810929B8 (en) 2007-06-27 2022-12-06 Du Pont use of a compound of formula 1
TWI468407B (en) 2008-02-06 2015-01-11 Du Pont Mesoionic pesticides
CN102131772B (en) 2008-07-30 2015-03-11 英特威国际有限公司 Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
IN2012DN00709A (en) 2009-08-05 2015-06-19 Du Pont
JP2013501063A (en) 2009-08-05 2013-01-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Mesoionic insecticide
UA107804C2 (en) 2009-08-05 2015-02-25 Du Pont Mixtures of pesticides mezoionnyh
UA110924C2 (en) 2009-08-05 2016-03-10 Е. І. Дю Пон Де Немур Енд Компані Mesoionic pesticides
HUE028501T2 (en) 2010-05-27 2016-12-28 Du Pont Crystalline form of 4-[5 - [3 -chloro-5 -(trifluoromethyl)phenyl] -4,5 -dihydro-5 -(trifluoromethyl)-3 - isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1- naphthalenecarboxamide
WO2012087630A1 (en) 2010-12-20 2012-06-28 E.I. Du Pont De Nemours And Company Pyridine and pyrimidine compounds for controlling invertebrate
CN103649097A (en) 2011-05-02 2014-03-19 佐蒂斯有限责任公司 Novel cephalosporins used as antibacterial agents
AU2012273133A1 (en) 2011-06-20 2013-11-07 E. I. Du Pont De Nemours And Company Heterocyclic compounds for treating helminth infections
BR112014009217A2 (en) 2011-10-17 2017-04-18 Zoetis Llc fenicol-based antibacterials
CN103958476A (en) 2011-11-28 2014-07-30 纳幕尔杜邦公司 N- (4-quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
UA110436C2 (en) * 2012-03-06 2015-12-25 Zoetis Llc Antibacterial phenol compounds
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
CN103169780B (en) * 2012-06-12 2014-11-26 北京伟嘉人生物技术有限公司 Medicine for treating bacterial gill-rot disease of grass carp
ES2662801T3 (en) * 2012-06-27 2018-04-09 Merial, Inc. Vaccines attenuated against Streptoccocus suis and their manufacturing and use procedures
AU2013324198C1 (en) * 2012-09-26 2017-08-10 Zoetis Services Llc Phenicol antibacterial agents
WO2014099837A1 (en) 2012-12-18 2014-06-26 E. I. Du Pont De Nemours And Company Sulfonamide anthelmintics
PL2986592T3 (en) * 2013-04-17 2018-07-31 Zoetis Services Llc Novel phenicol antibacterial agents
CN109851534B (en) * 2017-11-30 2021-04-27 上海医药工业研究院 Synthetic method of florfenicol intermediate
CN115745823B (en) * 2022-11-03 2024-02-23 武夷学院 Preparation method and application of compound

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183265A (en) * 1962-10-16 1965-05-11 Warner Lambert Pharmaceutical Acylphenylacylamido-1, 3-propanediols and preparation therefor
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
US4582918A (en) * 1984-09-19 1986-04-15 Schering Corporation Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4743700A (en) * 1984-02-03 1988-05-10 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds
US4876352A (en) * 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US4918095A (en) * 1986-12-23 1990-04-17 Zambon S.P.A. Compositions with antibiotic activity and their use
US4973750A (en) * 1984-09-19 1990-11-27 Schering Corporation Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5105009A (en) * 1983-06-02 1992-04-14 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives
US5153328A (en) * 1984-02-03 1992-10-06 Zambon S.P.A. 2 Hydrocarbyl-4 substituted methyl 5 (4 substituted phenyl)-oxazolines
US5227494A (en) * 1988-09-14 1993-07-13 Schering Corporation Process for preparing oxazoline compounds
US5243056A (en) * 1983-06-02 1993-09-07 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives
US5332835A (en) * 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US5382673A (en) * 1990-10-25 1995-01-17 Schering Corporation Process for preparing florfenicol, its analogs and oxazoline intermediates thereto
US5621111A (en) * 1994-10-24 1997-04-15 Bayer Aktiengesellschaft Process for the preparation of side chain-fluorinated alkyloxazoles, and new side chain-fluorinated alkyloxazoles
US5663361A (en) * 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
US5789599A (en) * 1994-05-06 1998-08-04 Drexel University Aziridine compounds, methods of preparation and reactions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294818A (en) * 1964-04-06 1966-12-27 Warner Lambert Pharmaceutical Substituted dioxolanes and process for their production
GB1117617A (en) * 1964-09-23 1968-06-19 Warner Lambert Pharmaceutical Threo-phenylserine ester derivatives

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183265A (en) * 1962-10-16 1965-05-11 Warner Lambert Pharmaceutical Acylphenylacylamido-1, 3-propanediols and preparation therefor
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
US5243056A (en) * 1983-06-02 1993-09-07 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives
US5908937A (en) * 1983-06-02 1999-06-01 Jommi; Giancarlo Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoro propane derivatives
US5105009A (en) * 1983-06-02 1992-04-14 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives
US5153328A (en) * 1984-02-03 1992-10-06 Zambon S.P.A. 2 Hydrocarbyl-4 substituted methyl 5 (4 substituted phenyl)-oxazolines
US5332835A (en) * 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
US4743700A (en) * 1984-02-03 1988-05-10 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds
US5567844A (en) * 1984-02-03 1996-10-22 Zambon S.P.A. Process for preparing 1-phenyl-2-amino-3-fluoro-1-propanols
US4582918A (en) * 1984-09-19 1986-04-15 Schering Corporation Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4973750A (en) * 1984-09-19 1990-11-27 Schering Corporation Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4918095A (en) * 1986-12-23 1990-04-17 Zambon S.P.A. Compositions with antibiotic activity and their use
US4876352A (en) * 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5227494A (en) * 1988-09-14 1993-07-13 Schering Corporation Process for preparing oxazoline compounds
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5382673A (en) * 1990-10-25 1995-01-17 Schering Corporation Process for preparing florfenicol, its analogs and oxazoline intermediates thereto
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US5789599A (en) * 1994-05-06 1998-08-04 Drexel University Aziridine compounds, methods of preparation and reactions thereof
US5621111A (en) * 1994-10-24 1997-04-15 Bayer Aktiengesellschaft Process for the preparation of side chain-fluorinated alkyloxazoles, and new side chain-fluorinated alkyloxazoles
US5663361A (en) * 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090912A1 (en) * 2003-07-18 2008-04-17 Murthy Yerramilli V Compositions containing prodrugs of florfenicol and methods of use
US20080306152A1 (en) * 2003-07-18 2008-12-11 Idexx Lboratories, Inc. Compositions containing prodrugs of florfenicol and methods of use
US7662861B2 (en) 2003-07-18 2010-02-16 Idexx Laboratories, Inc. Compositions containing prodrugs of florfenicol and methods of use
US7786167B2 (en) 2003-07-18 2010-08-31 Idexx Laboratories, Inc. Compositions containing prodrugs of florfenicol and methods of use
US20070142468A1 (en) * 2003-07-18 2007-06-21 Murthy Yerramilli V Compositions containing prodrugs of florfenicol and methods of use
US20090105337A1 (en) * 2007-10-19 2009-04-23 Idexx Laboratories, Inc. Esters of Florfenicol
US7550625B2 (en) 2007-10-19 2009-06-23 Idexx Laboratories Esters of florfenicol
US9845297B2 (en) 2009-10-16 2017-12-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US10259825B2 (en) 2009-10-16 2019-04-16 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US9573962B2 (en) 2009-10-16 2017-02-21 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2012125832A3 (en) * 2011-03-15 2012-11-08 Rib-X Pharmaceuticals, Inc. Antimicrobial agents
WO2012125832A2 (en) * 2011-03-15 2012-09-20 Rib-X Pharmaceuticals, Inc. Antimicrobial agents
US9937183B2 (en) 2013-09-09 2018-04-10 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US10106543B2 (en) 2013-09-09 2018-10-23 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US10947237B2 (en) 2015-03-11 2021-03-16 BioVersys AG Antimicrobial compounds and methods of making and using the same
US11999739B2 (en) 2016-05-06 2024-06-04 BioVersys AG Antimicrobials methods of making and using the same

Also Published As

Publication number Publication date
US20040082553A1 (en) 2004-04-29
UA78026C2 (en) 2007-02-15
US7041670B2 (en) 2006-05-09
WO2003077828A2 (en) 2003-09-25
CA2478048A1 (en) 2003-09-25
AU2003249503A1 (en) 2003-09-29
ZA200406938B (en) 2005-09-27
EP1487785A2 (en) 2004-12-22
CN1649829A (en) 2005-08-03
TW200406372A (en) 2004-05-01
NO20044257L (en) 2004-12-06
MXPA04008677A (en) 2004-12-06
KR20040091698A (en) 2004-10-28
IL163749A0 (en) 2005-12-18
JP2005538937A (en) 2005-12-22
ECSP045284A (en) 2004-11-26
WO2003077828A3 (en) 2004-01-08
BR0308289A (en) 2005-01-11

Similar Documents

Publication Publication Date Title
US7041670B2 (en) Florfenicol-type antibiotics
US8415383B2 (en) Substituted benzamidines as antibacterial agents
US8492414B2 (en) Antibacterial agents
US8252782B2 (en) Monocarbams
JPH05509089A (en) Cephalosporins and congeners, manufacturing processes and pharmaceutical compositions
DK161082B (en) ANALOGY PROCEDURE FOR PREPARING SYN-ISOMER OXIMER DERIVATIVES OF 7-AMINOTHIAZOLYLACETAMIDOCEPHALOSPORANIC ACID
KR100455544B1 (en) Cephalosporin Antibiotics
US20230133667A1 (en) Macrocyclic broad spectrum antibiotics
KR19990063676A (en) Novel Cyclic Defepeptides PF1022 Derivatives
US6465456B2 (en) Isoxazolinone antibacterial agents
US20090137553A1 (en) Thiazepine Oxazolidinones as Antibacterial Agents
US4018921A (en) Substituted phenylglycylcephalosporins
SE448238B (en) NEW 1-OXADETHYACPHALOSPORINE DERIVATIVES, PROCEDURES FOR PREPARING THEREOF, ANTIBACTERIAL COMPOSITION CONTAINING THEM AND USING THEM TO INHIBIT BACTERY GROWTH IN VITRO
JP3238209B2 (en) Thiomethylthiocarbacephalosporin derivative
JPH08151386A (en) Heterocyclic ethylthiocephem compound, its production and antimicrobial composition
US3985740A (en) 7-[D-(α-amino-α-phenyl-, 2-thienyl- and 3-thienylacetamido)]-3-(5-methylthiazol-2-yl)carbonylthiomethyl-3-cephem-4-carboxylic acids
JP2004137185A (en) Antimicrobial agent containing thiophene skeleton
JPH0331285A (en) 2-isocephem and 2-oxa- isocephem, their preparation their use as chemicals and and in chemicals
JP3743680B2 (en) Novel cephem compound, production method thereof and antibacterial agent
US4022895A (en) Substituted phenylglycylcephalosporins
TW201930314A (en) Tricyclic compounds having sulfinyl and pharmaceutical compositions containing them
JP2005532358A (en) Peptide deformylase inhibitor
TW201833119A (en) Tricyclic compounds having sulfinyl or sulfonyl and pharmaceutical compositions containing them
JPH0631260B2 (en) Novel cephalosporin compound
GB2086375A (en) Thiazolidine derivatives with antibiotic activity

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION